var title_f35_9_35984="Avulsion fracture with ulnar collateral ligament injury";
var content_f35_9_35984=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RADIOL%2F86892&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RADIOL%2F86892&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 548px\">",
"   <div class=\"ttl\">",
"    Avulsion fracture associated with ulnar collateral ligament injury of the thumb",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 528px; height: 540px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Magnified view of lateral hand radiograph demonstrates the avulsion fracture at the base of the first proximal phalanx (white arrow).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Robert Ward, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_9_35984=[""].join("\n");
var outline_f35_9_35984=null;
var title_f35_9_35985="Stool sample 5 with answer";
var content_f35_9_35985=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F78000&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F78000&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Taenia ovum",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 348px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Wet mount of stool (x400) showing Taenia ovum. The ova of T. solium and T. saginata are indistinguishable in stool; exact identification depends upon examination of proglottids passed per rectum.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Harriet Provine.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_9_35985=[""].join("\n");
var outline_f35_9_35985=null;
var title_f35_9_35986="Acute cholangitis MRCP";
var content_f35_9_35986=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F57884&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F57884&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Acute cholangitis MRCP",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 396px; height: 398px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A 64-year-old man presented to the emergency department complaining of severe right upper quadrant abdominal pain, nausea, vomiting, and fevers. Laboratory data revealed an elevated white blood cell count with a left shift, elevated liver function tests including bilirubin, and elevated pancreatic enzymes. A right upper quadrant ultrasound revealed a dilated bile duct with possible stones in the bile duct and gallbladder. Magnetic resonance cholangiopancreatography (MRCP) was performed and revealed multiple filling defects in the common bile duct and cystic duct (arrows).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Andres Gelrud, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_9_35986=[""].join("\n");
var outline_f35_9_35986=null;
var title_f35_9_35987="Patient information: Urinary incontinence in men (The Basics)";
var content_f35_9_35987=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"11\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div id=\"basics-graphics\">",
"      <span class=\"basics-box-top\">",
"      </span>",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-graphics-title.png\"/>",
"       <span class=\"openRelatedGraphics\" id=\"PI/17043\" rel=\"graphic_box\">",
"        <a href=\"#\" title=\"View All Related Graphics\">",
"         View All",
"        </a>",
"       </span>",
"      </h4>",
"      <ul>",
"       <li>",
"        <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?26/28/27072\">",
"         Anatomy of the urinary tract",
"        </a>",
"       </li>",
"      </ul>",
"      <a href=\"#\" id=\"basics-seeall\">",
"       See All Graphics",
"      </a>",
"     </div>",
"     <script type=\"text/javascript\">",
"      if ($(\"#basics-graphics li\").length &lt;= 4) {",
"				$(\"#basics-seeall\").remove();",
"			} else {",
"				$(\"#basics-graphics li:gt(3)\").addClass(\"hidden\");",
"				$(\"#basics-seeall\").click(function(){",
"					$(\"#basics-graphics li.hidden\").removeClass(\"hidden\");",
"					$(this).remove();",
"					return false;",
"				});",
"			}",
"     </script>",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"mobipreview.htm?15/21/15698\">",
"         Patient information: Benign prostatic hyperplasia (enlarged prostate) (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?10/60/11202\">",
"         Patient information: Pelvic muscle (Kegel) exercises (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?34/56/35714\">",
"         Patient information: Surgery to treat stress urinary incontinence in women (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?42/36/43586\">",
"         Patient information: Treatments for urge incontinence in women (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"mobipreview.htm?27/51/28467\">",
"         Patient information: Benign prostatic hyperplasia (BPH) (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?19/0/19456\">",
"         Patient information: Pelvic floor muscle exercises (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?9/16/9474\">",
"         Patient information: Urinary incontinence in women (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?19/19/19764\">",
"         Patient information: Urinary incontinence treatments for women (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Urinary incontinence in men (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/urinary-incontinence-in-men-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H12993433\">",
"      <span class=\"h1\">",
"       What is urinary incontinence?",
"      </span>",
"      &nbsp;&mdash;&nbsp;&ldquo;Urinary incontinence&rdquo; is the term doctors use when a person leaks urine or loses bladder control. Incontinence is a very common problem, but it is not a normal part of aging. If you have urinary incontinence, you do not have to &ldquo;just live with it.&rdquo; There are treatments and things you can do on your own to stop or reduce urine leaks.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H12993448\">",
"      <span class=\"h1\">",
"       What are the symptoms of urinary incontinence?",
"      </span>",
"      &nbsp;&mdash;&nbsp;There are different types of urinary incontinence. Each causes different symptoms. In men, the 4 main types are:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Stress incontinence -- Men with stress incontinence leak urine when they laugh, cough, sneeze or do anything that &ldquo;stresses&rdquo; the belly. Some men get this type of incontinence after having surgery for prostate disease.",
"       </li>",
"       <li>",
"        Urge incontinence -- Men with urge incontinence feel a strong need to urinate all of a sudden. Often the &ldquo;urge&rdquo; is so strong that they can&rsquo;t make it to the bathroom in time. (If you have these sudden urges but do not leak urine, you might have an &ldquo;overactive bladder.&rdquo; That can also be treated.)",
"       </li>",
"       <li>",
"        Mixed incontinence -- Men with mixed incontinence have symptoms of both stress and urge incontinence.",
"       </li>",
"       <li>",
"        Incontinence caused by incomplete bladder emptying -- Some men cannot fully empty their bladder when they urinate. This can happen if they have a condition called &ldquo;benign prostatic hyperplasia,&rdquo; which makes the prostate grow larger than normal. An enlarged prostate can block the flow of urine. &nbsp; &nbsp;",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H12993463\">",
"      <span class=\"h1\">",
"       Is there anything I can do on my own to feel better?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. Here are some steps that can help reduce urine leaks:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Reduce the amount of liquid you drink, especially a few hours before bed.",
"       </li>",
"       <li>",
"        Cut down on any foods or drinks that make your symptoms worse. Some people find that alcohol, caffeine, or spicy or acidic foods irritate the bladder.",
"       </li>",
"       <li>",
"        Lose weight, if you are overweight.",
"       </li>",
"       <li>",
"        If you have diabetes, keep your blood sugar as close to normal as possible.",
"       </li>",
"       <li>",
"        If you take medicines called diuretics, keep in mind that these medicines increase the need to urinate. Try to plan ahead and take them when you know you will be near a bathroom for a few hours. If you keep having problems with leaking because of diuretics, ask your doctor if you can take a lower dose or switch to a different medicine.",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      These techniques can also help with bladder control:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Bladder retraining -",
"        <strong>",
"        </strong>",
"        During bladder retraining, you &ldquo;train&rdquo; yourself to go to the bathroom only at scheduled times. For instance, you might decide that you will go every hour. In that case, you would make yourself go every hour, even if you didn&rsquo;t feel the need to go. You would also try to wait until a whole hour had passed even if you needed to go sooner. Then, once you got used to going every hour, you would try to wait longer than an hour between bathroom visits. Over time, you might be able to &ldquo;retrain&rdquo; your bladder to wait 3 or 4 hours between bathroom visits.",
"       </li>",
"       <li>",
"        Pelvic muscle exercises - Pelvic muscle exercises strengthen the muscles that control the flow of urine. When done right, these exercises can help. But people often do them wrong. Ask your doctor or nurse how to do them right.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H12993480\">",
"      <span class=\"h1\">",
"       Should I see my doctor or nurse?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. Your doctor or nurse can find out what might be causing your incontinence. He or she can also suggest ways to help the problem.",
"     </p>",
"     <p>",
"      Ask your doctor or nurse if any of the medicines you take could be causing your symptoms. Some medicines can cause incontinence or make symptoms worse.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H12993495\">",
"      <span class=\"h1\">",
"       How is incontinence treated?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Your treatment options depend on what type of incontinence you have. Some of the treatment options include:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Medicines to relax the bladder-- These medicines can help with urge incontinence.",
"       </li>",
"       <li>",
"        Medicines to improve urine flow--These medicines can help with incontinence related to an enlarged prostate.",
"       </li>",
"       <li>",
"        Surgery to (",
"        <a class=\"graphic graphic_figure graphicRef79864 \" href=\"mobipreview.htm?26/28/27072\">",
"         figure 1",
"        </a>",
"        ):",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      <ul class=\"hyphen-block\">",
"       <li>",
"        Repair the tissues that support the bladder or hold it in place",
"       </li>",
"       <li>",
"        Improve the flow of urine, for example by removing part of the prostate gland",
"       </li>",
"       <li>",
"        Repair the muscles that control urine flow",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Electrical stimulation of the nerves that relax the bladder",
"       </li>",
"       <li>",
"        Devices, such as:",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      <ul class=\"hyphen-block\">",
"       <li>",
"        A &ldquo;condom catheter,&rdquo; which fits over the penis like a condom and collects urine into a bag that is strapped to the leg",
"       </li>",
"       <li>",
"        A penis clamp, which squeezes the penis to keep urine from leaking out (this can be used only for a certain amount of time)",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H12993510\">",
"      <span class=\"h1\">",
"       What will my life be like?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Many men with incontinence can recover bladder control or at least reduce the amount of leakage they have. The key is to speak up about it to your doctor or nurse. Then work with him or her to find a treatment or therapy that helps you. Sometimes it takes a few tries before you find a solution, but the effort is worth it.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H12993525\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?15/21/15698?source=see_link\">",
"       Patient information: Benign prostatic hyperplasia (enlarged prostate) (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?10/60/11202?source=see_link\">",
"       Patient information: Pelvic muscle (Kegel) exercises (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?34/56/35714?source=see_link\">",
"       Patient information: Surgery to treat stress urinary incontinence in women (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?42/36/43586?source=see_link\">",
"       Patient information: Treatments for urge incontinence in women (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?27/51/28467?source=see_link\">",
"       Patient information: Benign prostatic hyperplasia (BPH) (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?19/19/19764?source=see_link\">",
"       Patient information: Urinary incontinence treatments for women (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?9/16/9474?source=see_link\">",
"       Patient information: Urinary incontinence in women (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?19/0/19456?source=see_link\">",
"       Patient information: Pelvic floor muscle exercises (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"mobipreview.htm?35/9/35987?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 17043 Version 2.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-58.240.98.179-5450C57513-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_9_35987=[""].join("\n");
var outline_f35_9_35987=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12993433\">",
"      What is urinary incontinence?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12993448\">",
"      What are the symptoms of urinary incontinence?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12993463\">",
"      Is there anything I can do on my own to feel better?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12993480\">",
"      Should I see my doctor or nurse?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12993495\">",
"      How is incontinence treated?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12993510\">",
"      What will my life be like?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12993525\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PI/17043\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li>",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?26/28/27072\">",
"      Anatomy of the urinary tract",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?27/51/28467?source=related_link\">",
"      Patient information: Benign prostatic hyperplasia (BPH) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?15/21/15698?source=related_link\">",
"      Patient information: Benign prostatic hyperplasia (enlarged prostate) (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?19/0/19456?source=related_link\">",
"      Patient information: Pelvic floor muscle exercises (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?10/60/11202?source=related_link\">",
"      Patient information: Pelvic muscle (Kegel) exercises (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?34/56/35714?source=related_link\">",
"      Patient information: Surgery to treat stress urinary incontinence in women (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?42/36/43586?source=related_link\">",
"      Patient information: Treatments for urge incontinence in women (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?9/16/9474?source=related_link\">",
"      Patient information: Urinary incontinence in women (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?19/19/19764?source=related_link\">",
"      Patient information: Urinary incontinence treatments for women (Beyond the Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f35_9_35988="Ergotamine and caffeine: Patient drug information";
var content_f35_9_35988=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Ergotamine and caffeine: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?41/56/42885?source=see_link\">",
"     see \"Ergotamine and caffeine: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?8/26/8613?source=see_link\">",
"     see \"Ergotamine and caffeine: Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F166388\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Cafergot&reg;;",
"     </li>",
"     <li>",
"      Migergot&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F166389\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Cafergor&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10021428\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10021430\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691956",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat migraine headaches.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10021429\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702043",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to ergotamine, caffeine, or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703401",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any of these health problems: Blood clots, heart disease, high blood pressure, kidney disease, liver disease, poor blood flow to the legs, Raynaud's disease, very bad infection, or thromboangiitis obliterans.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703847",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have taken almotriptan, frovatriptan, naratriptan, rizatriptan, sumatriptan, or zolmitriptan in the last 24 hours.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701080",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are pregnant or may be pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701047",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are breast-feeding.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10021434\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697693",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug may be habit-forming with long-term use.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696633",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid use of caffeine (for example, tea, coffee, cola) and chocolate.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s4128402",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you drink grapefruit juice or eat grapefruit often, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697740",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use birth control that you can trust to stop pregnancy while taking this drug.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10021435\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698051",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling dizzy. Rise slowly over a few minutes when sitting or lying down. Be careful climbing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10021437\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698623",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Chest pain or pressure or a fast heartbeat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698988",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Numbness or tingling in your hands or feet.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699023",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad dizziness or passing out.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698640",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Trouble breathing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699031",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699118",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Weakness.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10021432\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705490",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Oral:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695927",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take 2 tablets at the first sign of attack.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695779",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take 1 tablet 30 minutes after the first dose, if needed. Space doses by at least 30 minutes.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694767",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take more than 6 tablets per attack or more than 10 tablets a week.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705519",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Rectal:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696199",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use suppository rectally.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694794",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not use more than 2 suppositories per attack or more than 5 suppositories a week.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10021433\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696572",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug is taken on an as needed basis.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10021438\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10021439\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11723 Version 36.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-122.72.76.133-EE7AE732F8-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_9_35988=[""].join("\n");
var outline_f35_9_35988=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F166388\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F166389\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10021428\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10021430\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10021429\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10021434\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10021435\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10021437\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10021432\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10021433\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10021438\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10021439\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?41/56/42885?source=related_link\">",
"      Ergotamine and caffeine: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?8/26/8613?source=related_link\">",
"      Ergotamine and caffeine: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f35_9_35989="Chlorambucil: Pediatric drug information";
var content_f35_9_35989=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Chlorambucil: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"mobipreview.htm?34/52/35654?source=see_link\">",
"    see \"Chlorambucil: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?25/16/25861?source=see_link\">",
"    see \"Chlorambucil: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F5708649\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F149339\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Leukeran&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F149340\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Leukeran&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1046195\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antineoplastic Agent, Alkylating Agent (Nitrogen Mustard)",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1046189\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?34/52/35654?source=see_link\">",
"      see \"Chlorambucil: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral (refer to individual protocols):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Children:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     General short courses: 0.1-0.2 mg/kg/day or 4.5 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /day once daily for 3-6 weeks for remission induction (usual: 4-10 mg/day); maintenance therapy: 0.03-0.1 mg/kg/day (usual: 2-4 mg/day)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Relapsing steroid-sensitive nephrotic syndrome: 0.2 mg/kg/day once daily for 8 weeks",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     CLL:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Biweekly regimen: Initial: 0.4 mg/kg/dose every 2 weeks; increase dose by 0.1 mg/kg every 2 weeks until a response occurs and/or myelosuppression occurs",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Monthly regimen: Initial: 0.4 mg/kg every 4 weeks, increase dose by 0.2 mg/kg every 4 weeks until a response occurs and/or myelosuppression occurs",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Malignant lymphomas:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Non-Hodgkin's lymphoma: 0.1 mg/kg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Hodgkin's: 0.2 mg/kg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Adults: 0.1-0.2 mg/kg/day or 3-6 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /day once daily for 3-6 weeks, then adjust dose on basis of blood counts",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F149314\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Leukeran&reg;: 2 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F149299\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1046199\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hazardous agent; use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (NIOSH, 2012)",
"     </a>",
"     .",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Oral: Administer 30-60 minutes before food; do not administer with acidic foods, hot foods, and spices",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F1615447\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Store in refrigerator; protect from light",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1046198\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of chronic lymphocytic leukemia (CLL), Hodgkin's and non-Hodgkin's lymphoma (FDA approved in adults); has also been used in the treatment of nephrotic syndrome (unresponsive to conventional therapy) and Waldenstr&ouml;m's macroglobulinemia",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F149390\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Chlorambucil may be confused with Chloromycetin&reg;",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Leukeran&reg; may be confused with Alkeran&reg;, leucovorin, Leukine&reg;, Myleran&reg;",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      High alert medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       This medication is in a class the Institute for Safe Medication Practices (ISMP) includes among its list of drug classes which have a heightened risk of causing significant patient harm when used in error.",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F149387\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     Central nervous system: Agitation (rare), ataxia (rare), confusion (rare), drug fever, fever, focal/generalized seizure (rare), hallucinations (rare)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     Dermatologic: Angioneurotic edema, erythema multiforme (rare), rash, skin hypersensitivity, Stevens-Johnson syndrome (rare), toxic epidermal necrolysis (rare), urticaria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Amenorrhea, infertility, SIADH (rare)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     Gastrointestinal: Diarrhea (infrequent), nausea (infrequent), oral ulceration (infrequent), vomiting (infrequent)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     Genitourinary: Azoospermia, cystitis (sterile)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     Hematologic: Neutropenia (onset: 3 weeks; recovery: 10 days after last dose), bone marrow failure (irreversible), bone marrow suppression, anemia, leukemia (secondary), leukopenia, lymphopenia, pancytopenia, thrombocytopenia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     Hepatic: Hepatotoxicity, jaundice",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Flaccid paresis (rare), muscular twitching (rare), myoclonia (rare), peripheral neuropathy, tremor (rare)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     Respiratory: Interstitial pneumonia, pulmonary fibrosis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     Miscellaneous: Allergic reactions, malignancies (secondary)",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1046203\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to chlorambucil or any component; cross hypersensitivity (skin rash) may occur with other alkylating agents; previous resistance",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F1046188\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with caution in patients with seizure disorder, head trauma, patients receiving epileptogenic drugs, and in patients with bone marrow suppression; avoid administration of live vaccines to immunocompromised patients; children with nephrotic syndrome may have an increased risk of seizures.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1046187\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hazardous agent; use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (NIOSH, 2012)",
"     </a>",
"     . Chlorambucil can severely suppress bone marrow function",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     ; neutropenia  may be severe. Reduce initial dosage if patient has received myelosuppressive or radiation therapy within the previous 4 weeks, or has a depressed baseline leukocyte or platelet count; chlorambucil dose should not exceed 0.1 mg/kg/day if bone marrow is hypoplastic. Irreversible bone marrow damage may occur with total doses approaching 6.5 mg/kg. Progressive lymphopenia may develop (recovery is generally rapid after discontinuation). Adversely affects human fertility",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     ; chromosomal damage has been documented. Reversible and irreversible sterility (when administered to prepubertal and pubertal males), azoospermia (in adult males) and amenorrhea (in females) have been observed. Possibly mutagenic and teratogenic",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     ; carcinogenic in humans",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     ; acute myelocytic leukemia and secondary malignancies may be associated with chronic therapy. Duration of treatment and higher cumulative doses are associated with a higher risk for development of leukemia. Convulsions and severe skin reactions (eg, erythema multiforme, Stevens-Johnson syndrome and toxic epidermal necrolysis) have been reported.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299014\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F149308\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     BCG: Immunosuppressants may diminish the therapeutic effect of BCG.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CloZAPine: Myelosuppressive Agents may enhance the adverse/toxic effect of CloZAPine. Specifically, the risk for agranulocytosis may be increased.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Coccidioidin Skin Test: Immunosuppressants may diminish the diagnostic effect of Coccidioidin Skin Test.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Denosumab: May enhance the adverse/toxic effect of Immunosuppressants. Specifically, the risk for serious infections may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Echinacea: May diminish the therapeutic effect of Immunosuppressants.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Leflunomide: Immunosuppressants may enhance the adverse/toxic effect of Leflunomide. Specifically, the risk for hematologic toxicity such as pancytopenia, agranulocytosis, and/or thrombocytopenia may be increased.  Management: Consider not using a leflunomide loading dose in patients receiving other immunosuppressants.  Patients receiving both leflunomide and another immunosuppressant should be monitored for bone marrow suppression at least monthly.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Natalizumab: Immunosuppressants may enhance the adverse/toxic effect of Natalizumab. Specifically, the risk of concurrent infection may be increased.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimecrolimus: May enhance the adverse/toxic effect of Immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Roflumilast: May enhance the immunosuppressive effect of Immunosuppressants.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sipuleucel-T: Immunosuppressants may diminish the therapeutic effect of Sipuleucel-T.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tacrolimus (Topical): May enhance the adverse/toxic effect of Immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tofacitinib: Immunosuppressants may enhance the immunosuppressive effect of Tofacitinib.  Management: Concurrent use with antirheumatic doses of methotrexate or other non-disease modifying antirheumatic drugs (non-DMARDs) is permitted, and this warning seems to particularly focused on more potent immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Trastuzumab: May enhance the neutropenic effect of Immunosuppressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vaccines (Inactivated): Immunosuppressants may diminish the therapeutic effect of Vaccines (Inactivated).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vaccines (Live): Immunosuppressants may enhance the adverse/toxic effect of Vaccines (Live). Vaccinial infections may develop. Immunosuppressants may diminish the therapeutic effect of Vaccines (Live).  Management: Avoid use of live organism vaccines with immunosuppressants; live-attenuated vaccines should not be given for at least 3 months after immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F1046206\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Food Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Avoid acidic foods, hot foods, and spices; delayed absorption when administered with food",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F149310\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     D (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F149325\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Animal reproduction studies have demonstrated teratogenicity. Chlorambucil crosses the human placenta. Following exposure during the first trimester, case reports have noted adverse renal effects (unilateral agenesis). Women of childbearing potential should avoid becoming pregnant while receiving treatment.",
"     <b>",
"      [U.S. Boxed Warning]: Affects human fertility; probably mutagenic and teratogenic as well",
"     </b>",
"     ; chromosomal damage has been documented. Reversible and irreversible sterility (when administered to prepubertal and pubertal males), azoospermia (in adult males) and amenorrhea (in females) have been observed. Fibrosis, vasculitis and depletion of primordial follicles have been noted on autopsy of the ovaries.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F1046194\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Liver function tests, CBC with differential, hemoglobin, leukocyte and platelet counts, serum uric acid",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1046186\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Interferes with DNA replication and RNA transcription by alkylation and cross-linking the strands of DNA; immunosuppressive activity due to suppression of lymphocytes",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1046202\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Oral: Rapid and almost completely absorbed from GI tract",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: To liver, ascitic fluid, fat; extensively bound to plasma and tissue proteins; crosses the placenta",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: &sim;99%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: In the liver to an active metabolite, phenylacetic acid mustard",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Bioavailability: 56% to 100%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life: Chlorambucil: 1.5 hours; phenylacetic acid mustard: 2.5 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak serum concentration: Chlorambucil: Within 1 hour; phenylacetic acid mustard: Within 2-4 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Elimination: 60% excreted in urine within 24 hours principally as metabolites; &lt;1% excreted as unchanged drug or phenylacetic acid mustard in urine",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dialysis: Probably not dialyzable",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F1046193\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?25/16/25861?source=see_link\">",
"      see \"Chlorambucil: Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Notify physician if fever, sore throat, persistent cough, nausea, vomiting, jaundice, skin rash, seizures, amenorrhea, unusual lumps/masses, or bleeding occurs; discontinue chlorambucil if skin reaction occurs. Women of childbearing potential should avoid becoming pregnant while on chlorambucil. Avoid acidic foods, hot foods, and spices.",
"    </p>",
"   </div>",
"   <div class=\"block adi drugH1Div\" id=\"F1046204\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Additional Information",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Myelosuppressive effects:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     WBC: Moderate",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Platelets: Moderate",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset (days): 7",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Nadir (days): 14-21",
"    </p>",
"   </div>",
"   <div class=\"block exp drugH1Div\" id=\"F149320\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Extemporaneous Preparations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hazardous agent: Use appropriate precautions for handling and disposal.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     A 2 mg/mL oral suspension may be made with tablets. Crush sixty 2 mg tablets in a mortar and reduce to a fine powder. Add small portions of methylcellulose 1% and mix to a uniform paste (total methylcellulose: 30 mL); mix while adding simple syrup in incremental proportions to",
"     <b>",
"      almost",
"     </b>",
"     60 mL; transfer to a graduated cylinder, rinse mortar and pestle with simple syrup, and add quantity of vehicle sufficient to make 60 mL. Transfer contents of graduated cylinder to an amber prescription bottle. Label &ldquo;shake well&rdquo;, &ldquo;refrigerate&rdquo;, and &ldquo;protect from light&rdquo;. Stable for 7 days refrigerated.",
"    </p>",
"    <div class=\"reference\">",
"     Dressman JB and Poust RI, &ldquo;Stability of Allopurinol and of Five Antineoplastics in Suspension,&rdquo;",
"     <i>",
"      Am J Hosp Pharm",
"     </i>",
"     , 1983, 40(4):616-8.",
"     <span class=\"pubmed-id\">",
"      6846371",
"     </span>",
"    </div>",
"    <div class=\"reference\">",
"     Nahata MC, Pai VB, and Hipple TF,",
"     <i>",
"      Pediatric Drug Formulations",
"     </i>",
"     , 5th ed, Cincinnati, OH: Harvey Whitney Books Co, 2004.",
"    </div>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Baluarte HJ, Hiner L, and Gruskin AB, &ldquo;Chlorambucil Dosage in Frequently Relapsing Nephrotic Syndrome: A Controlled Clinical Trial,&rdquo;",
"      <i>",
"       J Pediatr",
"      </i>",
"      , 1978, 92(2):295-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?35/9/35989/abstract-text/621612/pubmed\" id=\"621612\" target=\"_blank\">",
"        621612",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Durkan A, Hodson EM, Willis NS, et al, \"Non-corticosteroid Treatment for Nephrotic Syndrome in Children,\"",
"      <i>",
"       Cochrane Database Syst Rev",
"      </i>",
"      , 2005, 18(2):CD002290.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?35/9/35989/abstract-text/15846634 /pubmed\" id=\"15846634 \" target=\"_blank\">",
"        15846634",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National Institute for Occupational Safety and Health (NIOSH), \"NIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings 2012.\" Available at",
"      <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"       file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf",
"      </a>",
"      . Accessed January 21, 2013.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Singh BN and Malhotra BK, \"Effects of Food on the Clinical Pharmacokinetics of Anticancer Agents: Underlying Mechanisms and Implications for Oral Chemotherapy,\"",
"      <i>",
"       Clin Pharmacokinet",
"      </i>",
"      , 2004, 43(15):1127-56.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?35/9/35989/abstract-text/15568891/pubmed\" id=\"15568891\" target=\"_blank\">",
"        15568891",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Williams SA, Makker SP, and Grupe WE, &ldquo;Seizures: A Significant Side Effect of Chlorambucil Therapy in Children,&rdquo;",
"      <i>",
"       J Pediatr",
"      </i>",
"      , 1978, 93(3):516-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?35/9/35989/abstract-text/690782/pubmed\" id=\"690782\" target=\"_blank\">",
"        690782",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 13144 Version 35.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-61.234.146.186-06EB330AA9-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_9_35989=[""].join("\n");
var outline_f35_9_35989=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5708649\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F149339\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F149340\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1046195\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1046189\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F149314\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F149299\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1046199\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1615447\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1046198\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F149390\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F149387\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1046203\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1046188\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1046187\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299014\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F149308\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1046206\">",
"      Food Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F149310\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F149325\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1046194\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1046186\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1046202\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1046193\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1046204\">",
"      Additional Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F149320\">",
"      Extemporaneous Preparations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13144\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13144|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?34/52/35654?source=related_link\">",
"      Chlorambucil: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?25/16/25861?source=related_link\">",
"      Chlorambucil: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f35_9_35990="Carisoprodol and aspirin: Drug information";
var content_f35_9_35990=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Carisoprodol and aspirin: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?31/62/32740?source=see_link\">",
"    see \"Carisoprodol and aspirin: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F146427\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Skeletal Muscle Relaxant",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F146418\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Acute skeletal muscle pain: Oral: 1-2 tablets 4 times/day for 2-3 weeks (maximum: 8 tablets/24 hours)",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F7741252\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Children &ge;16 years: Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F146419\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Avoid use in the elderly due to risk of orthostatic hypotension and CNS depression.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F10352904\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use in renal impairment has not been studied; use with caution.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F10352905\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use in hepatic impairment has not been studied; use with caution.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F146407\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tablet: Carisoprodol 200 mg and aspirin 325 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F146398\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block csi drugH1Div\" id=\"F13493879\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Controlled Substance",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C-IV",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F146409\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Relief of discomfort associated with acute, painful skeletal muscle conditions",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F10336451\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      BEERS Criteria medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       This drug may be potentially inappropriate for use in geriatric patients (Quality of evidence - moderate; Strength of recommendation - strong).",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F7741245\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     See individual agents.",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F7741229\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to a carbamate (eg, meprobamate); serious gastrointestinal complications (eg, bleeding, perforations, obstruction) due to aspirin use; aspirin-induced asthma; acute intermittent porphyria",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F7741230\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; CNS depression: May cause CNS depression, which may impair physical or mental abilities; patients must be cautioned about performing tasks which require mental alertness (eg, operating machinery or driving); in postmarketing reports, motor vehicle accidents have been associated with use.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Gastrointestinal effects: Serious GI effects (eg, bleeding, perforation, and intestinal obstruction) may occur (possibly fatal) with aspirin use. Use with caution in patients with a history of GI bleeding from ulcers; history of poor baseline health; geriatric patients; patients taking high doses of aspirin; patients taking concurrent anticoagulants, NSAIDs, or large amounts of ethanol.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Idiosyncratic reactions: May occur (rarely) following the initial dose and may include severe weakness, transient quadriplegia, euphoria, or vision loss (temporary).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Salicylate sensitivity: Patients with sensitivity to tartrazine dyes, nasal polyps, and asthma may have an increased risk of salicylate sensitivity.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Seizures: Carisoprodol has been associated (rarely) with seizures in patients with and without seizure history.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Drug abuse: Use with caution in patients with a history of drug abuse or acute alcoholism; potential for drug dependency exists. Tolerance, psychological and physical dependence to carisoprodol or its metabolite meprobamate may occur with prolonged use. Limit use to 2-3 weeks.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Hepatic impairment: Use with caution in patients with hepatic impairment; not studied.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Renal impairment: Use with caution in patients with renal impairment; not studied.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Poor metabolizers: Carisoprodol should be used with caution in patients with reduced function alleles of CYP2C19; poor metabolizers have been shown to have a fourfold increase in exposure to carisoprodol and a 50% reduced exposure to the metabolite meprobamate compared to normal metabolizers.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; CNS depressants: Sedating effects may be potentiated when used with other CNS-depressant drugs or ethanol.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Elderly: Muscle relaxants are poorly tolerated by the elderly due to potent anticholinergic effects, sedation, and risk of fracture. Efficacy is questionable at dosages tolerated by elderly patients; avoid use (Beers Criteria).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Surgical patients: Aspirin should be avoided (if possible) in surgical patients for 1-2 weeks prior to surgery, to reduce the risk of excessive bleeding.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Abrupt discontinuation: May precipitate withdrawal after abrupt cessation of prolonged use.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F146424\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to individual components.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F146403\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ACE Inhibitors: Salicylates may diminish the antihypertensive effect of ACE Inhibitors. They may also diminish other beneficial pharmacodynamic effects desired for the treatment of CHF.  The effects are likely dose-related.  100 mg doses aspirin appear to cause no problems, whereas 300 mg doses appear to significantly affect ACE Inhibitor efficacy.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Agents with Antiplatelet Properties (e.g., P2Y12 inhibitors, NSAIDs, SSRIs, etc.): May enhance the adverse/toxic effect of Salicylates. Increased risk of bleeding may result.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alcohol (Ethyl): CNS Depressants may enhance the CNS depressant effect of Alcohol (Ethyl).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alendronate: Aspirin may enhance the adverse/toxic effect of Alendronate. Specifically gastrointestinal adverse events.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ammonium Chloride: May increase the serum concentration of Salicylates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anticoagulants: Salicylates may enhance the anticoagulant effect of Anticoagulants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antidepressants (Tricyclic, Tertiary Amine): May enhance the antiplatelet effect of Aspirin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Azelastine (Nasal): CNS Depressants may enhance the CNS depressant effect of Azelastine (Nasal).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Buprenorphine: CNS Depressants may enhance the CNS depressant effect of Buprenorphine.  Management: Consider reduced doses of CNS depressants used in combination with buprenorphine.  Consider avoiding other CNS depressants in patients thought to be at high risk of buprenorphine overuse or self-injection.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcium Channel Blockers (Nondihydropyridine): May enhance the anticoagulant effect of Salicylates.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Bepridil [Off Market].",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Carbonic Anhydrase Inhibitors: Salicylates may enhance the adverse/toxic effect of Carbonic Anhydrase Inhibitors. Salicylate toxicity might be enhanced by this same combination.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Brinzolamide; Dorzolamide.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CNS Depressants: May enhance the adverse/toxic effect of other CNS Depressants.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levocabastine (Nasal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Collagenase (Systemic): Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Collagenase (Systemic). Specifically, the risk of injection site bruising and/or bleeding may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Corticosteroids (Systemic): Salicylates may enhance the adverse/toxic effect of Corticosteroids (Systemic). These specifically include gastrointestinal ulceration and bleeding. Corticosteroids (Systemic) may decrease the serum concentration of Salicylates. Withdrawal of corticosteroids may result in salicylate toxicity.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2C19 Inducers (Strong): May increase the metabolism of CYP2C19 Substrates. Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2C19 Inhibitors (Moderate): May decrease the metabolism of CYP2C19 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2C19 Inhibitors (Strong): May decrease the metabolism of CYP2C19 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dabigatran Etexilate: Agents with Antiplatelet Properties may enhance the anticoagulant effect of Dabigatran Etexilate. Agents with Antiplatelet Properties may increase the serum concentration of Dabigatran Etexilate. This mechanism applies specifically to clopidogrel.  Management: Increase monitoring for signs/symptoms of bleeding. The Canadian product monograph for dabigatran specifically recommends avoiding concomitant use with GIIb/IIIa inhibitors or ticlopidine, or with aspirin used for stroke prevention in atrial fibrillation.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dasatinib: May enhance the anticoagulant effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Divalproex: Salicylates may increase the serum concentration of Divalproex.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Droperidol: May enhance the CNS depressant effect of CNS Depressants. Management: Consider dose reductions of droperidol or of other CNS agents (e.g., opioids, barbiturates) with concomitant use.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Drotrecogin Alfa (Activated): Salicylates may enhance the adverse/toxic effect of Drotrecogin Alfa (Activated). Bleeding may occur.  Management: Weigh potential benefits of drotrecogin against increased bleeding risk in patients who have received  platelet inhibitors including aspirin (over 650 mg daily within 1 week). Monitor for bleeding and stop infusion if clinically important bleeding occurs.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Floctafenine: May enhance the adverse/toxic effect of Aspirin. An increased risk of bleeding may be associated with use of this combination. Floctafenine may diminish the cardioprotective effect of Aspirin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ginkgo Biloba: May enhance the anticoagulant effect of Salicylates. Management: Consider alternatives to this combination of agents. Monitor for signs and symptoms of bleeding (especially intracranial bleeding) if salicylates are used in combination with ginkgo biloba.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Glucosamine: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Heparin: Aspirin may enhance the anticoagulant effect of Heparin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Anticoagulant/Antiplatelet Properties) (eg, Alfalfa, Anise, Bilberry): May enhance the adverse/toxic effect of Salicylates. Bleeding may occur.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hyaluronidase: Salicylates may diminish the therapeutic effect of Hyaluronidase.  Management: Patients receiving salicylates (particularly at larger doses) may not experience the desired clinical response to standard doses of hyaluronidase.  Larger doses of hyaluronidase may be required.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     HydrOXYzine: May enhance the CNS depressant effect of CNS Depressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hypoglycemic Agents: Salicylates may enhance the hypoglycemic effect of Hypoglycemic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ibritumomab: Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Ibritumomab. Both agents may contribute to impaired platelet function and an increased risk of bleeding.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Influenza Virus Vaccine (Live/Attenuated): May enhance the adverse/toxic effect of Salicylates. Specifically, Reye's syndrome may develop.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ketorolac (Nasal): May enhance the adverse/toxic effect of Aspirin. An increased risk of bleeding may be associated with use of this combination. Ketorolac (Nasal) may diminish the cardioprotective effect of Aspirin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ketorolac (Systemic): May enhance the adverse/toxic effect of Aspirin. An increased risk of bleeding may be associated with use of this combination. Ketorolac (Systemic) may diminish the cardioprotective effect of Aspirin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Loop Diuretics: Salicylates may diminish the diuretic effect of Loop Diuretics. Loop Diuretics may increase the serum concentration of Salicylates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Magnesium Sulfate: May enhance the CNS depressant effect of CNS Depressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methotrexate: Salicylates may increase the serum concentration of Methotrexate. Salicylate doses used for prophylaxis of cardiovascular events are not likely to be of concern.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methotrimeprazine: CNS Depressants may enhance the CNS depressant effect of Methotrimeprazine. Methotrimeprazine may enhance the CNS depressant effect of CNS Depressants.  Management: Reduce adult dose of CNS depressant agents by 50% with initiation of concomitant methotrimeprazine therapy. Further CNS depressant dosage adjustments should be initiated only after clinically effective methotrimeprazine dose is established.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metyrosine: CNS Depressants may enhance the sedative effect of Metyrosine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mirtazapine: CNS Depressants may enhance the CNS depressant effect of Mirtazapine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Multivitamins/Minerals (with ADEK, Folate, Iron): May enhance the antiplatelet effect of Aspirin. Aspirin may decrease the serum concentration of Multivitamins/Minerals (with ADEK, Folate, Iron). Specifically, aspirin may decrease absorption of ascorbic acid.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     NSAID (COX-2 Inhibitor): Aspirin may enhance the adverse/toxic effect of NSAID (COX-2 Inhibitor).  Management: Concurrent use of aspirin at doses beyond cardioprotective levels is not recommended.  While concurrent use of low-dose aspirin with a COX-2 inhibitor is permissable, patients should be monitored closely for signs/symptoms of GI ulceration/bleeding.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     NSAID (Nonselective): May enhance the adverse/toxic effect of Salicylates. An increased risk of bleeding may be associated with use of this combination. NSAID (Nonselective) may diminish the cardioprotective effect of Salicylates. Salicylates may decrease the serum concentration of NSAID (Nonselective).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Omacetaxine: Aspirin may enhance the adverse/toxic effect of Omacetaxine. Specifically, the risk for bleeding-related events may be increased.  Management: Avoid concurrent use of aspirin with omacetaxine in patients with a platelet count of less than 50,000/uL.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Omega-3 Fatty Acids: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Paraldehyde: CNS Depressants may enhance the CNS depressant effect of Paraldehyde.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pentosan Polysulfate Sodium: May enhance the adverse/toxic effect of Agents with Antiplatelet Properties. Specifically, the risk of bleeding may be increased by concurrent use of these agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pentoxifylline: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Perampanel: May enhance the CNS depressant effect of CNS Depressants. Management: Patients taking perampanel with any other drug that has CNS depressant activities should avoid complex and high-risk activities, particularly those such as driving that require alertness and coordination, until they have experience using the combination.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Potassium Acid Phosphate: May increase the serum concentration of Salicylates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     PRALAtrexate: Salicylates may increase the serum concentration of PRALAtrexate. Salicylate doses used for prophylaxis of cardiovascular events are unlikely to be of concern.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pramipexole: CNS Depressants may enhance the sedative effect of Pramipexole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Probenecid: Salicylates may diminish the therapeutic effect of Probenecid.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Prostacyclin Analogues: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rivaroxaban: Agents with Antiplatelet Properties may enhance the anticoagulant effect of Rivaroxaban.  Management: Avoid concurrent use of clopidogrel with rivaroxaban unless the anticipated benefits outweigh the risks of bleeding.  Avoid concurrent use of rivaroxaban with other antiplatelet agents whenever possible.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ROPINIRole: CNS Depressants may enhance the sedative effect of ROPINIRole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rotigotine: CNS Depressants may enhance the sedative effect of Rotigotine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Salicylates: May enhance the anticoagulant effect of other Salicylates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Selective Serotonin Reuptake Inhibitors: May enhance the antiplatelet effect of Aspirin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Serotonin/Norepinephrine Reuptake Inhibitors: May enhance the antiplatelet effect of Aspirin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Oxybate: May enhance the CNS depressant effect of CNS Depressants. Management: Consider alternatives to combined use. When combined use is needed, consider minimizing doses of one or more drugs. Use of sodium oxybate with alcohol or sedative hypnotics is contraindicated.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thrombolytic Agents: Salicylates may enhance the adverse/toxic effect of Thrombolytic Agents. An increased risk of bleeding may occur.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ticagrelor: Aspirin may enhance the antiplatelet effect of Ticagrelor. Aspirin may diminish the therapeutic effect of Ticagrelor. More specifically, the benefits of ticagrelor relative to clopidogrel may be diminished in patients receiving daily aspirin doses greater than 100-150 mg daily.  Management: Avoid daily aspirin doses greater than 100 mg in patients receiving ticagrelor.  Canadian recommendations are to avoid daily aspirin doses greater than 150 mg.  Daily low-dose aspirin (U.S.: 75-100 mg; Canada: 75-150 mg) is recommended.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tiludronate: Aspirin may decrease the serum concentration of Tiludronate.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tipranavir: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tositumomab and Iodine I 131 Tositumomab: Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Tositumomab and Iodine I 131 Tositumomab. Specifically, the risk of bleeding-related adverse events may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Treprostinil: May enhance the adverse/toxic effect of Salicylates. Bleeding may occur.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Valproic Acid: Salicylates may increase the serum concentration of Valproic Acid.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Varicella Virus-Containing Vaccines: Salicylates may enhance the adverse/toxic effect of Varicella Virus-Containing Vaccines. Reye's Syndrome may develop.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin E: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin K Antagonists (eg, warfarin): Salicylates may enhance the anticoagulant effect of Vitamin K Antagonists.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Zolpidem: CNS Depressants may enhance the CNS depressant effect of Zolpidem.  Management: Reduce the Intermezzo brand sublingual zolpidem dose to 1.75 mg for men who are also receiving other CNS depressants.  No such dose change is recommended for women.  Avoid use with other CNS depressants at bedtime; avoid use with alcohol.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F146414\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:0em;margin-left:0em;text-align:justify;display:inline\">",
"     Ethanol: May increase CNS depression; monitor for increased effects with coadministration. Caution patients about effects.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F146404\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F7741226\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Animal reproduction studies have not been conducted with this combination. See individual agents.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F146421\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Enters breast milk/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F7741228\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Carisoprodol and aspirin are excreted into breast milk. Refer to individual monographs for additional information.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F146412\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Carisoprodol-Aspirin Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     200-325 mg (100): $239.00",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F10336452\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     CNS effects (eg, mental status, excessive drowsiness); relief of pain and/or muscle spasm; signs of drug abuse in addiction-prone individuals",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F7741250\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     See individual agents.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F146411\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     See individual agents.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      American Geriatrics Society 2012 Beers Criteria Update Expert Panel, \"American Geriatrics Society Updated Beers Criteria for Potentially Inappropriate Medication Use in Older Adults,\"",
"      <i>",
"       J Am Geriatr Soc",
"      </i>",
"      , 2012, 60(4):616-31.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?35/9/35990/abstract-text/22376048/pubmed\" id=\"22376048\" target=\"_blank\">",
"        22376048",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Capone ML, Sciulli MG, Tacconelli S, et al,  &ldquo;Pharmacodynamic Interaction of Naproxen With Low-Dose Aspirin in Healthy Subjects,&rdquo;",
"      <i>",
"       J Am Coll Cardiol",
"      </i>",
"      , 2005, 45(8):1295-1301.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?35/9/35990/abstract-text/15837265/pubmed\" id=\"15837265\" target=\"_blank\">",
"        15837265",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Catella-Lawson F, Reilly MP, Kapoor SC, et al, &ldquo;Cyclooxygenase Inhibitors and the Antiplatelet Effects of Aspirin,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2001, 345(25):1809-17.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?35/9/35990/abstract-text/11752357/pubmed\" id=\"11752357\" target=\"_blank\">",
"        11752357",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Cryer B, Verlin RG, Cooper SA, et al, &ldquo;Double-Blind, Randomized, Parallel, Placebo-Controlled Study of Ibuprofen Effects on Thromboxane B2 Concentrations in Aspirin-Treated Healthy Adult Volunteers,&rdquo;",
"      <i>",
"       Clin Ther",
"      </i>",
"      , 2005, 27(2):185-191.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?35/9/35990/abstract-text/15811481/pubmed\" id=\"15811481\" target=\"_blank\">",
"        15811481",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8678 Version 43.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0505-93.125.6.160-A4AE6C8C0C-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_9_35990=[""].join("\n");
var outline_f35_9_35990=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F146427\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F146418\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7741252\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F146419\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10352904\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10352905\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F146407\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F146398\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13493879\">",
"      Controlled Substance",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F146409\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10336451\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7741245\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7741229\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7741230\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F146424\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F146403\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F146414\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F146404\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7741226\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F146421\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7741228\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F146412\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10336452\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7741250\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F146411\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8678\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8678|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?31/62/32740?source=related_link\">",
"      Carisoprodol and aspirin: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f35_9_35991="Grade I infiltrating ductal carcinoma of the breast";
var content_f35_9_35991=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F76328&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F76328&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 604px\">",
"   <div class=\"ttl\">",
"    Grade I infiltrating ductal carcinoma of the breast",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 584px; height: 239px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    (Panel A) Low power view of a well differentiated infiltrating ductal carcinoma shows tumor cells which infiltrate the stroma as solid nests and glands.",
"    <br/>",
"    (Panel B) High power view demonstrates relatively uniform nuclei with no evidence of mitotic activity.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Stuart Schnitt, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_9_35991=[""].join("\n");
var outline_f35_9_35991=null;
var title_f35_9_35992="Clinical features and diagnosis of Lambert-Eaton myasthenic syndrome";
var content_f35_9_35992=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Clinical features and diagnosis of Lambert-Eaton myasthenic syndrome",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?35/9/35992/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/9/35992/contributors\">",
"     David H Weinberg, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?35/9/35992/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/9/35992/contributors\">",
"     Jeremy M Shefner, MD, PhD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/9/35992/contributors\">",
"     Jerome B Posner, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?35/9/35992/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/9/35992/contributors\">",
"     John F Dashe, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?35/9/35992/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Dec 17, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lambert-Eaton myasthenic syndrome (LEMS) is an uncommon disorder of neuromuscular junction transmission with the primary clinical manifestation of muscle weakness. Knowledge of subtle clinical features and laboratory abnormalities that accompany LEMS permits the early identification of the disorder. Early recognition is particularly important because of its strong association with small cell lung cancer (SCLC). Although LEMS can occur at any point in the course of SCLC, it may serve as a marker for early disease.",
"   </p>",
"   <p>",
"    This topic will review the pathophysiology, clinical features, and diagnosis of LEMS. Treatment of LEMS is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/43/2744?source=see_link\">",
"     \"Treatment of Lambert-Eaton myasthenic syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PATHOPHYSIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lambert and Elmqvist, through a series of elegant intracellular muscle recordings, found that patients with what is now called Lambert-Eaton myasthenic syndrome (LEMS) had the following unique features [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/9/35992/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Normal miniature endplate potential amplitude, demonstrating normal postsynaptic sensitivity to acetylcholine (ACh)",
"     </li>",
"     <li>",
"      Markedly reduced evoked endplate potential amplitude, suggesting a significant reduction in ACh release",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Acetylcholine release was increased by increasing calcium concentrations but not by potassium-induced membrane depolarization. The identification of normal presynaptic ACh content further supported the concept that LEMS is a disorder of reduced ACh release from the presynaptic nerve terminals, despite normal ACh vesicle number, normal ACh presynaptic concentration, and normal postsynaptic acetylcholine receptors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/9/35992/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Voltage-gated calcium channel",
"    </span>",
"    &nbsp;&mdash;&nbsp;Antibodies directed against the voltage-gated calcium channel (VGCC), a large transmembrane protein with multiple subunits, play a central role in the pathophysiology of LEMS. These antibodies interfere with the normal calcium flux required for the release of acetylcholine [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/9/35992/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The alpha-1 subunit of the VGCC contains a central calcium-conducting channel, a voltage sensor, and ligand binding sites. There are many subtypes of mammalian VGCCs, each characterized by the ligand binding characteristics of the alpha-1 subunit. Among these, the L-type, N-type, and",
"    <span class=\"nowrap\">",
"     P/Q-type",
"    </span>",
"    VGCC are the most important.",
"   </p>",
"   <p>",
"    <span class=\"nowrap\">",
"     P/Q-type",
"    </span>",
"    VGCCs make up more than 95 percent of the functioning receptors at the neuromuscular junction (NMJ) and probably represent the main immunologic target in LEMS [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/9/35992/abstract/5,6\">",
"     5,6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The expression of functional VGCCs in the surface membrane of small cell lung cancer (SCLC) cells (among numerous other neural antigens) is probably responsible for most if not all cases of paraneoplastic LEMS [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/9/35992/abstract/7\">",
"     7",
"    </a>",
"    ]. Antibodies from patients with LEMS inhibit the function of the VGCCs in the surface of SCLC cells in a dose-dependent fashion, further supporting the relationship [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/9/35992/abstract/8\">",
"     8",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/35/42552?source=see_link\">",
"     \"Pathobiology and staging of small cell carcinoma of the lung\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Autoimmunity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several lines of evidence support a humoral mechanism of disease in LEMS:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Passive transfer experiments successfully induced calcium channel dysfunction in mice exposed to plasma or IgG from patients with LEMS. This calcium channel blockade could be overcome with high frequency repetitive nerve stimulation (RNS) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/9/35992/abstract/9-12\">",
"       9-12",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Such antibody exposure in mice induced presynaptic NMJ morphologic changes similar to those seen in patients with LEMS.",
"     </li>",
"     <li>",
"      Removal of antibodies utilizing therapeutic plasma exchange and immunosuppressant agents in patients with LEMS has consistently improved both the clinical deficits and the electrophysiologic disease markers [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/9/35992/abstract/9,13-15\">",
"       9,13-15",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The true incidence of LEMS is unknown, but the condition is uncommon and occurs much less frequently than myasthenia gravis, the other major disorder of neuromuscular junction transmission. In a population-based study from a region of Holland with 1.7 million inhabitants, 220 cases of myasthenia gravis and 10 of LEMS were identified over a nine-year period; the annual incidence and prevalence of LEMS was 0.48 and 2.32 per million population [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/9/35992/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Population studies have consistently shown that approximately one-half of LEMS cases are associated with a malignancy, mainly small cell lung cancer (SCLC). In the largest clinical series that included 50 patients with LEMS, SCLC was present in 21 of 25 patients (84 percent) with cancer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/9/35992/abstract/17\">",
"     17",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/35/42552?source=see_link\">",
"     \"Pathobiology and staging of small cell carcinoma of the lung\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The incidence and prevalence of LEMS in patients with SCLC are estimated to be approximately 3 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/9/35992/abstract/18,19\">",
"     18,19",
"    </a>",
"    ]. In one series of 148 consecutive patients with SCLC, 10 patients had antibodies to VGCCs, of whom 4 (2.7 percent) had LEMS [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/9/35992/abstract/20\">",
"     20",
"    </a>",
"    ]. Although the prognosis for the SCLC was better in terms of longer survival for patients with LEMS than those without LEMS [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/9/35992/abstract/21\">",
"     21",
"    </a>",
"    ], the presence of antibodies without LEMS did not result in a better prognosis.",
"   </p>",
"   <p>",
"    The other tumors most convincingly associated with LEMS are lymphoproliferative disorders, particularly Hodgkin lymphoma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/9/35992/abstract/22\">",
"     22",
"    </a>",
"    ], although there are scattered case reports of an \"atypical\" carcinoid [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/9/35992/abstract/23\">",
"     23",
"    </a>",
"    ] and malignant thymoma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/9/35992/abstract/24\">",
"     24",
"    </a>",
"    ] associated with LEMS.",
"   </p>",
"   <p>",
"    Other autoimmune disorders, such as type 1 diabetes mellitus or thyroid disorders, occur in 27 percent of LEMS patients without cancer and 11 percent of those with LEMS and SCLC [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/9/35992/abstract/25\">",
"     25",
"    </a>",
"    ]. Families of patients with non-paraneoplastic LEMS have an increased frequency of autoimmune diseases, while families of patients with paraneoplastic LEMS do not. Patients with LEMS also have an increased incidence of organ-specific autoantibodies to thyroid, gastric,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    skeletal muscle compared with controls [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/9/35992/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     CLINICAL FEATURES",
"    </span>",
"    &nbsp;&mdash;&nbsp;LEMS is a recognizable clinical syndrome that has distinct differences from the symptoms and signs seen with myasthenia gravis (MG), which is the most common clinical disorder of neuromuscular junction (NMJ) transmission. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/51/17206?source=see_link\">",
"     \"Clinical manifestations of myasthenia gravis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The paraneoplastic and autoimmune form of LEMS have similar signs and symptoms [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/9/35992/abstract/17\">",
"     17",
"    </a>",
"    ]. However, the age of LEMS onset is earlier in patients without cancer, while those with an underlying malignancy may experience more rapid progression of neurologic symptoms than those without cancer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/9/35992/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Symptoms",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinical features of LEMS were well defined by Lambert and Eaton in Minnesota [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/9/35992/abstract/28\">",
"     28",
"    </a>",
"    ] and by O'Neill and colleagues in England (",
"    <a class=\"graphic graphic_table graphicRef59702 \" href=\"mobipreview.htm?6/25/6558\">",
"     table 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/9/35992/abstract/17\">",
"     17",
"    </a>",
"    ]. Most patients present with complaints of slowly progressive proximal muscle weakness, and this feature is present in almost all patients at some point in the illness. Occasional patients have a subacute or acute presentation.",
"   </p>",
"   <p>",
"    Patients typically describe an alteration in gait or difficulty arising from a chair or managing stairs. Many describe aching or stiff muscles. Muscle fatigability or cramping is common, particularly after protracted exercise. There tends to be relative preservation of distal muscle function.",
"   </p>",
"   <p>",
"    Symmetrical muscle involvement is the rule. Upper extremity complaints are usually modest and typically involve proximal muscle function. Patients with LEMS and small cell lung cancer typically develop a more rapidly progressive course of proximal and then distal arm muscle weakness than patients who have non-tumor LEMS [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/9/35992/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Autonomic dysfunction is often present and can be an important clue to the diagnosis. Dry mouth from reduced salivation is the most common autonomic symptom and occasionally is the presenting complaint, while erectile dysfunction is common in men with LEMS. In the largest study of autonomic dysfunction in LEMS involving 30 patients, dry mouth was identified in 77 percent, and impotence was present in 45 percent of all men [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/9/35992/abstract/30\">",
"     30",
"    </a>",
"    ]. Other symptoms may include blurred vision and constipation.",
"   </p>",
"   <p>",
"    Cranial nerve involvement is present in a minority but is typically less severe and less striking than that seen in MG. Ocular symptoms, particularly ptosis, are the most common cranial nerve manifestation with LEMS. Oropharyngeal symptoms of dysarthria, dysphagia, and difficulty chewing have also been occasionally observed.",
"   </p>",
"   <p>",
"    A study comparing the clinical features of 38 patients with LEMS and 101 with MG confirmed the marked contrast in the presentation of these two NMJ disorders [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/9/35992/abstract/31\">",
"     31",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Initial limb weakness occurred in 95 percent of patients with LEMS compared with 12 percent of patients with MG",
"     </li>",
"     <li>",
"      Initial extraocular muscle weakness occurred in none of the patients with LEMS compared with 59 percent of patients with MG",
"     </li>",
"     <li>",
"      Both groups infrequently presented with oropharyngeal muscle weakness (5 and 12 percent for LEMS and MG, respectively)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    At the point of maximum severity, no patient with LEMS had weakness restricted to extraocular muscles, oropharyngeal muscles, or arms. All patients with LEMS had leg weakness. In contrast, weakness in patients with MG was purely ocular in 25 percent, purely ocular and oropharyngeal in 5 percent, and restricted to the arms as the only limb manifestation in 12 percent. These findings suggest that LEMS is unlikely in patients with limb weakness confined to the arms [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/9/35992/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    While the same study also suggests that initial eye muscle weakness does not occur in LEMS [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/9/35992/abstract/31\">",
"     31",
"    </a>",
"    ], other investigators have noted that patients with LEMS can have prominent ocular or oropharyngeal manifestations, which may be the chief or initial complaint in some. In one series of 23 patients with LEMS, for example, the presenting symptoms were ptosis, diplopia, dysarthria, or dysphagia in 7 (30 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/9/35992/abstract/32\">",
"     32",
"    </a>",
"    ]. During the course of LEMS, ptosis",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    diplopia were noted in 15 patients (65 percent), dysphagia",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    dysarthria in 12 (52 percent), and proximal limb weakness in 22 (96 percent). There is also a case report of a patient with pure ocular weakness due to LEMS [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/9/35992/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Respiratory failure",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although most patients with LEMS do not have significant diaphragmatic involvement, particularly in the early stages of the illness, respiratory failure can occur late in the course [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/9/35992/abstract/34-37\">",
"     34-37",
"    </a>",
"    ]. Thus, LEMS must be considered in the differential diagnosis of patients presenting with neuromuscular respiratory failure.",
"   </p>",
"   <p>",
"    Even in patients without respiratory symptoms, detailed investigations into respiratory muscle function with transdiaphragmatic pressure recording, sustained inspiratory force measurements, and phrenic nerve stimulation may reveal mild to moderate respiratory weakness [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/9/35992/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Signs",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinical signs of LEMS parallel the symptoms (",
"    <a class=\"graphic graphic_table graphicRef81160 \" href=\"mobipreview.htm?25/48/26381\">",
"     table 2",
"    </a>",
"    ). Proximal limb weakness without significant muscle atrophy is the most frequent finding. The degree of weakness is often less than the functional difficulty would lead one to expect, a discrepancy that sometimes leads to a misdiagnosis of conversion reaction.",
"   </p>",
"   <p>",
"    Ptosis is the most common ocular finding, but as discussed above, extraocular, pharyngeal, tongue, and neck muscles can be involved as well. Deep tendon reflexes are almost always depressed or absent.",
"   </p>",
"   <p>",
"    Maximal isometric contraction of the relevant muscle for 10 to 15 seconds can sometimes lead to temporary reappearance of previously depressed or absent deep tendon reflexes, and to temporary improvement of muscle weakness. This phenomenon, referred to by some as postexercise or postactivation facilitation, is often the defining bedside clinical observation and should be part of the routine examination of a patient with proximal muscle weakness or even complaints of weakness, especially when hyporeflexia or areflexia are conjoined. Postexercise or postactivation facilitation are also applied to an increase in compound muscle action potential amplitude that may be seen with repetitive nerve stimulation or brief exercise in patients with LEMS. (See",
"    <a class=\"local\" href=\"#H13\">",
"     'Neurophysiology'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Because of possible facilitation after exercise, reflexes and muscle power testing are best performed after a period of rest. More sustained physical activity can often induce muscle weakness (fatigable weakness). At times, this pattern can appear to represent an inconsistent effort on the part of the patient.",
"   </p>",
"   <p>",
"    A useful clinical sign is that excessive or paradoxical eyelid elevation may occur after sustained upgaze in patients with LEMS [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/9/35992/abstract/38\">",
"     38",
"    </a>",
"    ]. This finding is in contradistinction to the fatigable ptosis commonly seen in patients with MG during the same maneuver. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/51/17206?source=see_link\">",
"     \"Clinical manifestations of myasthenia gravis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Signs of autonomic dysfunction are often present with LEMS but are rarely defining. The most common are symmetric, sluggish pupillary light responses and reduced salivation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/9/35992/abstract/39\">",
"     39",
"    </a>",
"    ]. In a comprehensive study of autonomic dysfunction involving 30 patients with LEMS, abnormalities were found in tests of sudomotor function (83 percent); cardiovagal reflexes (75 percent); salivation (44 percent); and adrenergic function (37 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/9/35992/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Some patients have combined paraneoplastic cerebellar degeneration and LEMS [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/9/35992/abstract/40\">",
"     40",
"    </a>",
"    ]. In a series of Japanese patients with LEMS, 9 of 65 patients (14 percent) with SCLC had appendicular ataxia, probably from associated paraneoplastic cerebellar degeneration [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/9/35992/abstract/41\">",
"     41",
"    </a>",
"    ]. All nine patients had high titers of voltage-gated calcium channel (VGCC) antibodies compared to none of the 45 patients without cancer. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/0/40968?source=see_link\">",
"     \"Overview of paraneoplastic syndromes of the nervous system\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/22/26983?source=see_link\">",
"     \"Paraneoplastic cerebellar degeneration\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Clinical conclusions",
"    </span>",
"    &nbsp;&mdash;&nbsp;LEMS is a recognizable syndrome that has distinct clinical differences from symptoms and signs seen with myasthenia gravis. Most often, LEMS has a pattern more suggestive of a myopathy than an NMJ disorder, with slowly progressive proximal lower extremity weakness, distinctive autonomic findings, a smattering of oculobulbar findings, and recovery of lost deep tendon reflexes or improvement in muscle strength with vigorous, brief muscle activation. However, there are enough observations of patients presenting with regional weakness (ie, weakness in one area only, such as the proximal legs alone) that a high level of clinical suspicion for LEMS is important when considering the diagnosis in a patient with weakness isolated to limb, ocular, oropharyngeal, or respiratory muscles.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of LEMS is usually made on clinical grounds and confirmed by the presence of antibodies to voltage-gated calcium channel (VGCC) and by electrodiagnostic studies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/9/35992/abstract/42\">",
"     42",
"    </a>",
"    ]. Occasionally, an electrophysiologist makes the diagnosis when it was not suggested clinically on the basis of isolated low compound muscle action potential amplitudes. (See",
"    <a class=\"local\" href=\"#H13\">",
"     'Neurophysiology'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The diagnosis of LEMS deserves careful consideration for any patient who presents with proximal muscle weakness. The collection of limb weakness, dry mouth, hyporeflexia, and any combination of oropharyngeal muscle weakness or ptosis should strongly suggest the diagnosis.",
"   </p>",
"   <p>",
"    A significant degree of clinical suspicion is necessary to recognize the atypical patient, such as those who present with isolated respiratory insufficiency. Confirmation is recommended with both VGCC antibodies and nerve conduction studies.",
"   </p>",
"   <p>",
"    The aggressive search for a primary underlying malignancy is central to the management of patients with LEMS. This issue is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/43/2744?source=see_link&amp;anchor=H2#H2\">",
"     \"Treatment of Lambert-Eaton myasthenic syndrome\", section on 'Evaluation for malignancy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     VGCC antibody testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;The voltage-gated calcium channel (VGCC) radioimmunoassay detects the ability of a patient's serum to induce IgG-calcium channel complex precipitates after exposure to solubilized calcium channels.",
"   </p>",
"   <p>",
"    Antibodies against the",
"    <span class=\"nowrap\">",
"     P/Q-type",
"    </span>",
"    VGCC are present in approximately 85 to 95 percent of patients with LEMS [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/9/35992/abstract/4,41,43\">",
"     4,41,43",
"    </a>",
"    ], and radioimmunoassay for these antibodies is the preferred serologic test. In addition, antibodies to the N-type VGCC are found in about 30 to 40 percent of patients with LEMS, and there is some evidence to suggest that the presence of these antibodies increases the likelihood of small cell lung cancer (SCLC). Furthermore, one study raised the possibility that antibodies directed against domain IV of the alpha 1 subunit of",
"    <span class=\"nowrap\">",
"     P/Q-type",
"    </span>",
"    VGCC are more common in the non-tumor LEMS cases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/9/35992/abstract/44\">",
"     44",
"    </a>",
"    ]. More data are needed to determine if this will be a clinically useful observation.",
"   </p>",
"   <p>",
"    There is a low frequency of VGCC antibodies in healthy control patients, in patients with myasthenia gravis, and in patients with other autoimmune diseases, confirming the high specificity of the test when there is a high pretest probability of LEMS. However, low titer VGCC antibodies have been detected in several groups of patients, including those with other neurologic paraneoplastic disorders, those who have cancer without neurologic signs or symptoms, and those with amyotrophic lateral sclerosis.",
"   </p>",
"   <p>",
"    Test performance was evaluated in a series of 65 patients with LEMS [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/9/35992/abstract/43\">",
"     43",
"    </a>",
"    ]. High titer against",
"    <span class=\"nowrap\">",
"     anti-P/Q-type",
"    </span>",
"    VGCC antibodies were present in 62 patients (95 percent), including all 32 with a diagnosis of cancer. Lower titer",
"    <span class=\"nowrap\">",
"     anti-P/Q-type",
"    </span>",
"    and anti-N-type VGCC antibodies were present in 38 of 70 patients (54 percent) who had lung, ovarian, or breast carcinoma and paraneoplastic complications, in 22 of 90 patients (24 percent) who had cancer without overt neurologic complications, in 18 of 78 patients (23 percent) who had sporadic amyotrophic lateral sclerosis, and in 2 of 69 patients (3 percent) who had myasthenia gravis, epilepsy, or scleroderma.",
"   </p>",
"   <p>",
"    Thus, while the VGCC antibody test is confirmatory in patients who otherwise have clinical and electrophysiologic features of LEMS, the antibody test alone is not diagnostic, especially in the presence of a malignancy or amyotrophic lateral sclerosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Neurophysiology",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most patients with LEMS have a characteristic electrophysiologic pattern that supports the diagnosis of a presynaptic neuromuscular junction (NMJ) disorder. The pattern in LEMS is distinctly different from the postsynaptic NMJ changes seen in MG.",
"   </p>",
"   <p>",
"    The compound muscle action potential (CMAP) of resting muscle in patients with LEMS usually has a significantly reduced baseline amplitude [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/9/35992/abstract/45\">",
"     45",
"    </a>",
"    ]. Following high frequency (10 to 50 Hz) repetitive nerve stimulation (RNS) (",
"    <a class=\"graphic graphic_waveform graphicRef58848 \" href=\"mobipreview.htm?31/36/32322\">",
"     waveform 1",
"    </a>",
"    ) or brief (eg, 10 seconds) maximal isometric muscle activation (",
"    <a class=\"graphic graphic_figure graphicRef66509 \" href=\"mobipreview.htm?39/8/40079\">",
"     figure 1",
"    </a>",
"    ), there is a significant increment with a marked increase in the CMAP amplitude. The increase in the CMAP amplitude following high frequency stimulation is referred to as postactivation facilitation, and the increase in CMAP amplitude after brief isometric exercise is called postexercise facilitation.",
"   </p>",
"   <p>",
"    An increase in the CMAP amplitude &gt;100 percent after high frequency stimulation or exercise is considered diagnostic of a presynaptic NMJ disorder [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/9/35992/abstract/46,47\">",
"     46,47",
"    </a>",
"    ], and the increase is frequently even greater. However, some studies suggest a significant number of patients have increments with RNS below 100 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/9/35992/abstract/48,49\">",
"     48,49",
"    </a>",
"    ]. A CMAP amplitude increase of &gt;60 percent with RNS may be a better diagnostic criterion for patients with suspected LEMS who are seronegative for VGCC antibodies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/9/35992/abstract/50\">",
"     50",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The high frequency RNS test may be more sensitive than the postexercise facilitation test for the diagnosis of LEMS, but evidence is equivocal, and the test is painful [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/9/35992/abstract/51-53\">",
"     51-53",
"    </a>",
"    ]. Most experts favor using the 10 second exercise test first because it is simple and better tolerated [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/9/35992/abstract/54\">",
"     54",
"    </a>",
"    ]. The high frequency RNS test is indicated, when the level of clinical suspicion is high, for patients who do not show a diagnostic incremental value after the exercise test. It is also indicated for those unable to cooperate with intense voluntary muscle activation.",
"   </p>",
"   <p>",
"    With low frequency (2 to 3 Hz) RNS, there is often a modest decrement, similar to that seen in the postsynaptic NMJ disorders.",
"   </p>",
"   <p>",
"    An additional finding with LEMS is that the motor unit action potentials are often unstable on electromyography (EMG) needle examination, and single fiber EMG (SFEMG) often has significant jitter and transmission blocking that is characteristically improved at higher firing rates [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/9/35992/abstract/55,56\">",
"     55,56",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a systematic review and practice parameter published in 2001 by the American Association of Neuromuscular and Electrodiagnostic Medicine, the following observations and recommendations were noted [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/9/35992/abstract/46,47\">",
"     46,47",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The laboratory diagnosis of LEMS with RNS is confirmed by a reproducible postexercise increase in CMAP amplitude of at least 100 percent compared with pre-exercise baseline value.",
"     </li>",
"     <li>",
"      Single fiber EMG is more sensitive than RNS for the diagnosis of NMJ disorders, but may be less specific and less available than RNS, which is therefore the preferred initial test. However, when RNS is normal in patients with a high suspicion of an NMJ disorder, SFEMG of at least one symptomatic muscle should be performed and, if one muscle is normal, a second muscle should be studied.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Uncommonly, the incremental response and other electrophysiologic findings are only minimally abnormal, making the diagnosis of LEMS difficult. In a discussion of this issue, Lambert made the important observation that patients with LEMS usually have significant nerve conduction study abnormalities with relatively well-preserved strength, while patients with MG usually have modest EMG abnormalities in the face of rather significant weakness and fatigability [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/9/35992/abstract/57\">",
"     57",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Differential diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The differential diagnosis of LEMS includes all diseases presenting with progressive muscle weakness. The most common clinical presentation of LEMS, that of slowly progressive proximal muscle weakness, can suggest inflammatory muscle disease or limb-girdle muscular dystrophy. However, deep tendon reflexes are preserved in myopathies, but absent in LEMS unless activated by exercise. Motor neuron disease, a motor neuropathy, myasthenia gravis, or a myelopathy are less likely alternatives. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/4/27722?source=see_link\">",
"     \"Clinical manifestations and diagnosis of adult dermatomyositis and polymyositis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/23/15735?source=see_link\">",
"     \"Clinical manifestations and diagnosis of inclusion body myositis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/32/15881?source=see_link\">",
"     \"Limb-girdle muscular dystrophy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/21/40280?source=see_link\">",
"     \"Clinical features of amyotrophic lateral sclerosis and other forms of motor neuron disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/51/17206?source=see_link\">",
"     \"Clinical manifestations of myasthenia gravis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/12/32968?source=see_link\">",
"     \"Diagnosis of myasthenia gravis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    When cranial nerve abnormalities are present, the main consideration is MG. The clinical differentiation of these two neuromuscular junction disorders is discussed above. (See",
"    <a class=\"local\" href=\"#H7\">",
"     'Symptoms'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H9\">",
"     'Signs'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H13\">",
"     'Neurophysiology'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The sensory components seen with polyneuropathy or polyradiculopathy clearly distinguish those disorders from LEMS in most cases.",
"   </p>",
"   <p>",
"    Multiple cranial mononeuropathies or at times a meningeal-based disease need to be considered, but again, the pure motor nature of LEMS makes these distinctions fairly clear. The unusual presentation of fairly isolated respiratory failure has a similar differential diagnosis, including motor neuron disease, MG, and certain myopathies such as acid maltase deficiency or polymyositis.",
"   </p>",
"   <p>",
"    When prominent early in the course of LEMS, the dry mouth may suggest Sj&ouml;gren's syndrome. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/1/11287?source=see_link\">",
"     \"Clinical manifestations of Sj&ouml;gren's syndrome: Exocrine gland disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lambert-Eaton myasthenic syndrome (LEMS) is an uncommon disorder of neuromuscular junction transmission in which the primary clinical manifestation is muscle weakness.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      LEMS is a disorder of reduced acetylcholine (ACh) release from the presynaptic nerve terminals. Antibodies directed against the voltage-gated calcium channel (VGCC) interfere with the normal calcium flux required for the release of acetylcholine.",
"      <span class=\"nowrap\">",
"       P/Q-type",
"      </span>",
"      VGCCs make up greater than 95 percent of the functioning receptors at the neuromuscular junction (NMJ) and probably represent the main immunologic target in LEMS. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Pathophysiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The incidence of LEMS is unknown, but the condition is uncommon, and occurs much less frequently than myasthenia gravis (MG), the other major disorder of neuromuscular junction transmission. Approximately one-half of LEMS cases are associated with a malignancy, mainly small cell lung cancer (SCLC). (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Most patients with LEMS present with slowly progressive proximal muscle weakness, particularly involving the legs; this feature is present in almost all patients at some point in the illness. Deep tendon reflexes are typically depressed or absent. Dry mouth is the most common autonomic symptom, while erectile dysfunction is common in men. Ocular symptoms, especially ptosis and diplopia, may occur with LEMS but are rarely the presenting or dominant feature of the illness. Most patients do not have significant respiratory muscle weakness, but respiratory failure may occur late in the course. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Clinical features'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Recovery of lost deep tendon reflexes or improvement in muscle strength with vigorous, brief muscle activation is a unique aspect of LEMS. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Signs'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The diagnosis of LEMS is usually made on clinical grounds and confirmed by the presence of antibodies directed against VGCCs and by electrodiagnostic studies. A high titer",
"      <span class=\"nowrap\">",
"       P/Q-type",
"      </span>",
"      VGCC antibody is strongly suggestive of LEMS in the appropriate clinical setting. It is important to remember that",
"      <span class=\"nowrap\">",
"       P/Q-type",
"      </span>",
"      VGCC antibodies are present in a variety of clinical situations where LEMS is not present. The diagnosis of LEMS is confirmed by a reproducible postexercise increase in compound muscle action potential amplitude of at least 100 percent compared with pre-exercise baseline value. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The differential diagnosis of LEMS includes all diseases presenting with progressive muscle weakness. The most common clinical presentation of LEMS, slowly progressive proximal muscle weakness, can suggest inflammatory muscle disease or limb-girdle muscular dystrophy. Motor neuron disease, a motor neuropathy, MG, or a myelopathy are less likely alternatives. The sensory components seen with polyneuropathy or polyradiculopathy distinguish those disorders from LEMS in most cases. When cranial nerve abnormalities are present, the main consideration is MG. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Differential diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/9/35992/abstract/1\">",
"      Lambert EH, Elmqvist D. Quantal components of end-plate potentials in the myasthenic syndrome. Ann N Y Acad Sci 1971; 183:183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/9/35992/abstract/2\">",
"      Elmqvist D, Lambert EH. Detailed analysis of neuromuscular transmission in a patient with the myasthenic syndrome sometimes associated with bronchogenic carcinoma. Mayo Clin Proc 1968; 43:689.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/9/35992/abstract/3\">",
"      Molenaar PC, Newsom-Davis J, Polak RL, Vincent A. Eaton-Lambert syndrome: acetylcholine and choline acetyltransferase in skeletal muscle. Neurology 1982; 32:1061.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/9/35992/abstract/4\">",
"      Motomura M, Johnston I, Lang B, et al. An improved diagnostic assay for Lambert-Eaton myasthenic syndrome. J Neurol Neurosurg Psychiatry 1995; 58:85.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/9/35992/abstract/5\">",
"      Lang B, Pinto A, Giovannini F, et al. Pathogenic autoantibodies in the lambert-eaton myasthenic syndrome. Ann N Y Acad Sci 2003; 998:187.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/9/35992/abstract/6\">",
"      Pinto A, Gillard S, Moss F, et al. Human autoantibodies specific for the alpha1A calcium channel subunit reduce both P-type and Q-type calcium currents in cerebellar neurons. Proc Natl Acad Sci U S A 1998; 95:8328.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/9/35992/abstract/7\">",
"      Benatar M, Blaes F, Johnston I, et al. Presynaptic neuronal antigens expressed by a small cell lung carcinoma cell line. J Neuroimmunol 2001; 113:153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/9/35992/abstract/8\">",
"      Lang B, Vincent A, Murray NM, Newsom-Davis J. Lambert-Eaton myasthenic syndrome: immunoglobulin G inhibition of Ca2+ flux in tumor cells correlates with disease severity. Ann Neurol 1989; 25:265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/9/35992/abstract/9\">",
"      Lang B, Newsom-Davis J, Wray D, et al. Autoimmune aetiology for myasthenic (Eaton-Lambert) syndrome. Lancet 1981; 2:224.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/9/35992/abstract/10\">",
"      Kim YI. Passive transfer of the Lambert-Eaton myasthenic syndrome: neuromuscular transmission in mice injected with plasma. Muscle Nerve 1985; 8:162.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/9/35992/abstract/11\">",
"      Kim YI. Passively transferred Lambert-Eaton syndrome in mice receiving purified IgG. Muscle Nerve 1986; 9:523.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/9/35992/abstract/12\">",
"      Kim YI, Sanders DB, Johns TR, et al. Lambert-Eaton myasthenic syndrome: the lack of short-term in vitro effects of serum factors on neuromuscular transmission. J Neurol Sci 1988; 87:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/9/35992/abstract/13\">",
"      Dau PC, Denys EH. Plasmapheresis and immunosuppressive drug therapy in the Eaton-Lambert syndrome. Ann Neurol 1982; 11:570.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/9/35992/abstract/14\">",
"      Newsom-Davis J, Murray NM. Plasma exchange and immunosuppressive drug treatment in the Lambert-Eaton myasthenic syndrome. Neurology 1984; 34:480.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/9/35992/abstract/15\">",
"      Motomura M, Hamasaki S, Nakane S, et al. Apheresis treatment in Lambert-Eaton myasthenic syndrome. Ther Apher 2000; 4:287.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/9/35992/abstract/16\">",
"      Wirtz PW, Nijnuis MG, Sotodeh M, et al. The epidemiology of myasthenia gravis, Lambert-Eaton myasthenic syndrome and their associated tumours in the northern part of the province of South Holland. J Neurol 2003; 250:698.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/9/35992/abstract/17\">",
"      O'Neill JH, Murray NM, Newsom-Davis J. The Lambert-Eaton myasthenic syndrome. A review of 50 cases. Brain 1988; 111 ( Pt 3):577.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/9/35992/abstract/18\">",
"      Elrington GM, Murray NM, Spiro SG, Newsom-Davis J. Neurological paraneoplastic syndromes in patients with small cell lung cancer. A prospective survey of 150 patients. J Neurol Neurosurg Psychiatry 1991; 54:764.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/9/35992/abstract/19\">",
"      Payne M, Bradbury P, Lang B, et al. Prospective study into the incidence of Lambert Eaton myasthenic syndrome in small cell lung cancer. J Thorac Oncol 2010; 5:34.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/9/35992/abstract/20\">",
"      Wirtz PW, Lang B, Graus F, et al. P/Q-type calcium channel antibodies, Lambert-Eaton myasthenic syndrome and survival in small cell lung cancer. J Neuroimmunol 2005; 164:161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/9/35992/abstract/21\">",
"      Titulaer MJ, Verschuuren JJ. Lambert-Eaton myasthenic syndrome: tumor versus nontumor forms. Ann N Y Acad Sci 2008; 1132:129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/9/35992/abstract/22\">",
"      Argov Z, Shapira Y, Averbuch-Heller L, Wirguin I. Lambert-Eaton myasthenic syndrome (LEMS) in association with lymphoproliferative disorders. Muscle Nerve 1995; 18:715.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/9/35992/abstract/23\">",
"      Gutmann L, Phillips LH 2nd, Gutmann L. Trends in the association of Lambert-Eaton myasthenic syndrome with carcinoma. Neurology 1992; 42:848.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/9/35992/abstract/24\">",
"      Lauritzen M, Smith T, Fischer-Hansen B, et al. Eaton-Lambert syndrome and malignant thymoma. Neurology 1980; 30:634.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/9/35992/abstract/25\">",
"      Wirtz PW, Bradshaw J, Wintzen AR, Verschuuren JJ. Associated autoimmune diseases in patients with the Lambert-Eaton myasthenic syndrome and their families. J Neurol 2004; 251:1255.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/9/35992/abstract/26\">",
"      Lennon VA, Lambert EH, Whittingham S, Fairbanks V. Autoimmunity in the Lambert-Eaton myasthenic syndrome. Muscle Nerve 1982; 5:S21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/9/35992/abstract/27\">",
"      Wirtz PW, Wintzen AR, Verschuuren JJ. Lambert-Eaton myasthenic syndrome has a more progressive course in patients with lung cancer. Muscle Nerve 2005; 32:226.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/9/35992/abstract/28\">",
"      EATON LM, LAMBERT EH. Electromyography and electric stimulation of nerves in diseases of motor unit; observations on myasthenic syndrome associated with malignant tumors. J Am Med Assoc 1957; 163:1117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/9/35992/abstract/29\">",
"      Titulaer MJ, Wirtz PW, Kuks JB, et al. The Lambert-Eaton myasthenic syndrome 1988-2008: a clinical picture in 97 patients. J Neuroimmunol 2008; 201-202:153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/9/35992/abstract/30\">",
"      O'Suilleabhain P, Low PA, Lennon VA. Autonomic dysfunction in the Lambert-Eaton myasthenic syndrome: serologic and clinical correlates. Neurology 1998; 50:88.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/9/35992/abstract/31\">",
"      Wirtz PW, Sotodeh M, Nijnuis M, et al. Difference in distribution of muscle weakness between myasthenia gravis and the Lambert-Eaton myasthenic syndrome. J Neurol Neurosurg Psychiatry 2002; 73:766.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/9/35992/abstract/32\">",
"      Burns TM, Russell JA, LaChance DH, Jones HR. Oculobulbar involvement is typical with Lambert-Eaton myasthenic syndrome. Ann Neurol 2003; 53:270.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/9/35992/abstract/33\">",
"      Rudnicki SA. Lambert-Eaton myasthenic syndrome with pure ocular weakness. Neurology 2007; 68:1863.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/9/35992/abstract/34\">",
"      Laroche CM, Mier AK, Spiro SG, et al. Respiratory muscle weakness in the Lambert-Eaton myasthenic syndrome. Thorax 1989; 44:913.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/9/35992/abstract/35\">",
"      Barr CW, Claussen G, Thomas D, et al. Primary respiratory failure as the presenting symptom in Lambert-Eaton myasthenic syndrome. Muscle Nerve 1993; 16:712.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/9/35992/abstract/36\">",
"      Nicolle MW, Stewart DJ, Remtulla H, et al. Lambert-Eaton myasthenic syndrome presenting with severe respiratory failure. Muscle Nerve 1996; 19:1328.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/9/35992/abstract/37\">",
"      Beydoun SR. Delayed diagnosis of Lambert-Eaton myasthenic syndrome in a patient presenting with recurrent refractory respiratory failure. Muscle Nerve 1994; 17:689.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/9/35992/abstract/38\">",
"      Breen LA, Gutmann L, Brick JF, Riggs JR. Paradoxical lid elevation with sustained upgaze: a sign of Lambert-Eaton syndrome. Muscle Nerve 1991; 14:863.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/9/35992/abstract/39\">",
"      Clark CV, Newsom-Davis J, Sanders MD. Ocular autonomic nerve function in Lambert-Eaton myasthenic syndrome. Eye (Lond) 1990; 4 ( Pt 3):473.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/9/35992/abstract/40\">",
"      Mason WP, Graus F, Lang B, et al. Small-cell lung cancer, paraneoplastic cerebellar degeneration and the Lambert-Eaton myasthenic syndrome. Brain 1997; 120 ( Pt 8):1279.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/9/35992/abstract/41\">",
"      Nakao YK, Motomura M, Fukudome T, et al. Seronegative Lambert-Eaton myasthenic syndrome: study of 110 Japanese patients. Neurology 2002; 59:1773.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/9/35992/abstract/42\">",
"      Titulaer MJ, Lang B, Verschuuren JJ. Lambert-Eaton myasthenic syndrome: from clinical characteristics to therapeutic strategies. Lancet Neurol 2011; 10:1098.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/9/35992/abstract/43\">",
"      Lennon VA, Kryzer TJ, Griesmann GE, et al. Calcium-channel antibodies in the Lambert-Eaton syndrome and other paraneoplastic syndromes. N Engl J Med 1995; 332:1467.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/9/35992/abstract/44\">",
"      Pellkofer HL, Armbruster L, Krumbholz M, et al. Lambert-eaton myasthenic syndrome differential reactivity of tumor versus non-tumor patients to subunits of the voltage-gated calcium channel. J Neuroimmunol 2008; 204:136.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/9/35992/abstract/45\">",
"      Oh SJ, Kim DE, Kuruoglu R, et al. Electrophysiological and clinical correlations in the Lambert-Eaton myasthenic syndrome. Muscle Nerve 1996; 19:903.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/9/35992/abstract/46\">",
"      AAEM Quality Assurance Committee. American Association of Electrodiagnostic Medicine. Practice parameter for repetitive nerve stimulation and single fiber EMG evaluation of adults with suspected myasthenia gravis or Lambert-Eaton myasthenic syndrome: summary statement. Muscle Nerve 2001; 24:1236.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/9/35992/abstract/47\">",
"      AAEM Quality Assurance Committee. American Association of Electrodiagnostic Medicine. Literature review of the usefulness of repetitive nerve stimulation and single fiber EMG in the electrodiagnostic evaluation of patients with suspected myasthenia gravis or Lambert-Eaton myasthenic syndrome. Muscle Nerve 2001; 24:1239.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/9/35992/abstract/48\">",
"      Tim RW, Massey JM, Sanders DB. Lambert-Eaton myasthenic syndrome: electrodiagnostic findings and response to treatment. Neurology 2000; 54:2176.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/9/35992/abstract/49\">",
"      Oh SJ. Diverse electrophysiological spectrum of the Lambert-Eaton myasthenic syndrome. Muscle Nerve 1989; 12:464.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/9/35992/abstract/50\">",
"      Oh SJ, Hatanaka Y, Claussen GC, Sher E. Electrophysiological differences in seropositive and seronegative Lambert-Eaton myasthenic syndrome. Muscle Nerve 2007; 35:178.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/9/35992/abstract/51\">",
"      Bady B, Truffert A, Brechard M, et al. [Electrophysiologic data on myasthenic syndromes of the Lambert-Eaton type. A series of 23 cases]. Neurophysiol Clin 1992; 22:27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/9/35992/abstract/52\">",
"      Oh SJ, Kurokawa K, Claussen GC, Ryan HF Jr. Electrophysiological diagnostic criteria of Lambert-Eaton myasthenic syndrome. Muscle Nerve 2005; 32:515.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/9/35992/abstract/53\">",
"      Tim RW, Sanders DB. Repetitive nerve stimulation studies in the Lambert-Eaton myasthenic syndrome. Muscle Nerve 1994; 17:995.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/9/35992/abstract/54\">",
"      Hatanaka Y, Oh SJ. Ten-second exercise is superior to 30-second exercise for post-exercise facilitation in diagnosing Lambert-Eaton myasthenic syndrome. Muscle Nerve 2008; 37:572.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/9/35992/abstract/55\">",
"      Trontelj JV, St&aring;lberg E. Single motor end-plates in myasthenia gravis and LEMS at different firing rates. Muscle Nerve 1991; 14:226.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/9/35992/abstract/56\">",
"      Chaudhry V, Watson DF, Bird SJ, Cornblath DR. Stimulated single-fiber electromyography in Lambert-Eaton myasthenic syndrome. Muscle Nerve 1991; 14:1227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/9/35992/abstract/57\">",
"      Kim YI. Lambert-Eaton myasthenic syndrome: evidence for calcium channel blockade. Ann N Y Acad Sci 1987; 505:377.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5174 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-14.112.150.12-37D25D05A2-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_9_35992=[""].join("\n");
var outline_f35_9_35992=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H15\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PATHOPHYSIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Voltage-gated calcium channel",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Autoimmunity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      CLINICAL FEATURES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Symptoms",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Respiratory failure",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Signs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Clinical conclusions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      VGCC antibody testing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Neurophysiology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Differential diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEURO/5174\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEURO/5174|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?39/8/40079\" title=\"figure 1\">",
"      CMAP postexercise facilitat",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEURO/5174|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?6/25/6558\" title=\"table 1\">",
"      LEMS symptoms",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?25/48/26381\" title=\"table 2\">",
"      LEMS signs",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEURO/5174|Waveform\">",
"      <a href=\"#\" title=\"WAVEFORMS\">",
"       WAVEFORMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"mobipreview.htm?31/36/32322\" title=\"waveform 1\">",
"      Incremental response with RNS",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/21/40280?source=related_link\">",
"      Clinical features of amyotrophic lateral sclerosis and other forms of motor neuron disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/4/27722?source=related_link\">",
"      Clinical manifestations and diagnosis of adult dermatomyositis and polymyositis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/23/15735?source=related_link\">",
"      Clinical manifestations and diagnosis of inclusion body myositis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?11/1/11287?source=related_link\">",
"      Clinical manifestations of Sj&ouml;gren's syndrome: Exocrine gland disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?16/51/17206?source=related_link\">",
"      Clinical manifestations of myasthenia gravis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/12/32968?source=related_link\">",
"      Diagnosis of myasthenia gravis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/32/15881?source=related_link\">",
"      Limb-girdle muscular dystrophy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/0/40968?source=related_link\">",
"      Overview of paraneoplastic syndromes of the nervous system",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/22/26983?source=related_link\">",
"      Paraneoplastic cerebellar degeneration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/35/42552?source=related_link\">",
"      Pathobiology and staging of small cell carcinoma of the lung",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?2/43/2744?source=related_link\">",
"      Treatment of Lambert-Eaton myasthenic syndrome",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f35_9_35993="Tattooing in adolescents and adults";
var content_f35_9_35993=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Tattooing in adolescents and adults",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?35/9/35993/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/9/35993/contributors\">",
"     R Michelle Schmidt, MD, MPH",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/9/35993/contributors\">",
"     Myrna L Armstrong, EdD, RN, FAAN",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?35/9/35993/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/9/35993/contributors\">",
"     Amy B Middleman, MD, MPH, MS Ed",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?35/9/35993/contributors\">",
"     Deputy Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/9/35993/contributors\">",
"     Mary M Torchia, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/9/35993/contributors\">",
"     Fenny H Lin, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?35/9/35993/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Dec 13, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H110576378\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many healthcare professionals associate body art with criminal activity or psychiatric disturbance, based in part on some early descriptive studies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/9/35993/abstract/1-3\">",
"     1-3",
"    </a>",
"    ]; some are still trying to make that case [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/9/35993/abstract/4,5\">",
"     4,5",
"    </a>",
"    ]. Individuals often associate tattoos and body piercings with gang members, prisoners, military personnel, or rebellious teenagers [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/9/35993/abstract/4,5\">",
"     4,5",
"    </a>",
"    ]. In reality, however, a variety of people, including professionals, clergy, or other \"respected members of society\" acquire body art for an assortment of reasons. Unfortunately, a healthcare professional's negative attitude about body art may interfere with the optimal treatment of patients with these types of ornamentation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/9/35993/abstract/6-8\">",
"     6-8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The history and health hazards associated with tattooing will be reviewed here. Body piercing is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/2/10282?source=see_link\">",
"     \"Body piercing in adolescents and young adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H110576573\">",
"    <span class=\"h1\">",
"     HISTORY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Tattooing has been prevalent for thousands of years in a variety of cultures. Tattooed mummies from Egypt, Peru, and the Philippines have been radiocarbon-dated as far back as 2000 BC [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/9/35993/abstract/9\">",
"     9",
"    </a>",
"    ]. The word tattoo is derived from the Tahitian word \"ta-tau\", which means \"the results of tapping\" and describes the raking process by which the Polynesians applied their tattoos. Historically, the Japanese have used handheld, nonmechanized instruments to apply intricate tattoos, which often cover large portions of the body. Polynesia and Japan are believed to be responsible for the introduction of modern tattooing into Western cultures via the exposure of European and American sailors to these practices while on commercial or naval visits [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/9/35993/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H110576639\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Information regarding the prevalence of tattooing among adolescents and young adults continues to be published, and the numbers show progressively increasing amounts of body art, which has become mainstream among individuals aged 16 to 25 years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/9/35993/abstract/10-15\">",
"     10-15",
"    </a>",
"    ]. In one cross-sectional convenience sample of 2101 adolescents in 1995, 10 percent had tattoos [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/9/35993/abstract/16\">",
"     16",
"    </a>",
"    ]. Data from surveys of high school and college students (13 to 25 years of age) indicate a prevalence of 15 to 25 percent for tattooing [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/9/35993/abstract/11-13,17,18\">",
"     11-13,17,18",
"    </a>",
"    ]. In a secondary analysis of survey data in 2002 from a nationally representative sample of 6702 adolescents (11 to 21 years of age), 4.5 percent of adolescents had permanent tattoos [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/9/35993/abstract/5\">",
"     5",
"    </a>",
"    ]. A 2003 survey of 1010 people conducted by Ohio University found that one in every seven adults has a tattoo, with young adults about 10 times more likely to have one compared with their parents [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/9/35993/abstract/19\">",
"     19",
"    </a>",
"    ]. In a 2007 Pew Research Center report examining body art, 36 percent of 18- to 25-year-olds and 40 percent of 26- to 40-year-olds have at least one tattoo [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/9/35993/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although tattooing has been associated with risk-taking behaviors, the population sampled appears to affect the behaviors associated with body art [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/9/35993/abstract/4,5\">",
"     4,5",
"    </a>",
"    ]. In adolescent clinics, tattooing was significantly and independently associated with other high-risk behaviors, including sexual intercourse (in 83 percent of the tattooed versus 36 percent of the nontattooed adolescents), binge drinking (78 versus 45 percent), smoking (63 versus 25 percent), marijuana use (38 versus 12 percent), fighting (54 versus 40 percent), inflicted injury (38 versus 17 percent), gang membership (14 versus 4 percent), truancy (60 versus 26 percent), and school failure (50 versus 29 percent). In a smaller survey (484 adolescents), tattooing and body piercing were associated with disordered eating behaviors, gateway drug use, hard drug use, sexual activity, and suicide [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/9/35993/abstract/4\">",
"     4",
"    </a>",
"    ]. In another study, college students with tattoos reported substantively and significantly greater frequency of premarital sexual activity than nonpierced and nontattooed college students [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/9/35993/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Individuals with body art may readily admit that they are risk-takers, but studies of college students have found an inconsistent frequency of high-risk behaviors among tattooed youth [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/9/35993/abstract/12,17,18,22-24\">",
"     12,17,18,22-24",
"    </a>",
"    ]. One study found that college students with four or more tattoos, seven or more piercings, or piercings located in their nipples or genitals were significantly more likely to report high-risk behaviors than students without these criteria [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/9/35993/abstract/25\">",
"     25",
"    </a>",
"    ]. Students with and without body art share similar demographic characteristics, such as natural parent households, positive family relationships, parents with college degrees, daily prayer habits, and moderate to strong religious faith [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/9/35993/abstract/25-28\">",
"     25-28",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H110577480\">",
"    <span class=\"h2\">",
"     Motivational factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of motivational factors have been suggested:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The desire to experiment with body art may be a normal developmental drive for some adolescents, a means to redefine themselves and take control of their bodies and their identities.",
"     </li>",
"     <li>",
"      Friends provide major support for the body art. In one study, the magnitude of a friend's influence was about double that of the family's, whether the friends have or do not have body art themselves [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/9/35993/abstract/29,30\">",
"       29,30",
"      </a>",
"      ]. Among adolescents, body art may be viewed as normative.",
"     </li>",
"     <li>",
"      A means of making individuals feel unique [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/9/35993/abstract/16-18,29\">",
"       16-18,29",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      A means of injury during self-mutilation",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H110578099\">",
"    <span class=\"h1\">",
"     THE TATTOOING PROCESS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most tattooing is done in commercial studios, although studio artists may establish temporary locations (eg, flea markets, rock concerts, and fraternity parties) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/9/35993/abstract/31\">",
"     31",
"    </a>",
"    ]. Commercial studios are preferable because the likelihood is greater that the tattoo will be applied using sanitary techniques. Although tattoo artists often refer to themselves as professionals, very few complete apprenticeships, and there is no standardized procedural curriculum. Artists routinely learn their trade either by self-teaching or by observing others. Few states require examinations and continuing education about anatomy, universal precautions, disease transmission, skin diseases, sterilization procedures, sanitation, personal hygiene, or after-care instructions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/9/35993/abstract/32\">",
"     32",
"    </a>",
"    ]. Unlike hair stylists and nail technicians, who complete a structured curriculum (yet do not perform invasive procedures), tattoo artists are not required to complete any formal training, even in states that require examinations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/9/35993/abstract/32,33\">",
"     32,33",
"    </a>",
"    ] .",
"   </p>",
"   <p>",
"    Commercial tattoo artists place the tattoo into the skin using a handheld, electric-powered machine. This device is held several centimeters away from the skin and functions like a sewing machine with a needle bar moving up and down between 50 to 3000 times per minute [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/9/35993/abstract/34\">",
"     34",
"    </a>",
"    ]. Several needles may be attached to the end of the needle bar and are responsible for inserting the pigment into the skin. The artist uses different numbers of needles for the desired artistic effect. As examples, a single needle can create a fine line, a group of 14 needles can fill in color, and smaller groups of needles can create thicker lines or shading. The skin is repeatedly punctured using the solid bore needles to allow the tattoo pigment to leach into the dermis, where it is taken up by macrophages [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/9/35993/abstract/9,35\">",
"     9,35",
"    </a>",
"    ]. The depth of the puncture varies from 1 to 4 mm [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/9/35993/abstract/34\">",
"     34",
"    </a>",
"    ]. During the tattooing process, blood and serosanguineous fluid seep onto the skin and are wiped away by the artist [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/9/35993/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The client often chooses a design from numerous illustrations on display at the studio or provides the artist with an illustration of the desired tattoo. Before the tattoo is actually placed, the skin should be cleaned with an alcohol-and-iodine solution. The design is then drawn on the skin by hand or with a stenciling machine. Ink is applied to the design by dipping the needles into disposable ink cups before application to the skin.",
"   </p>",
"   <p>",
"    The US Food and Drug Administration (FDA) considers tattoo inks to be cosmetics and the pigments used in the inks to be color additives [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/9/35993/abstract/36,37\">",
"     36,37",
"    </a>",
"    ]. As color additives, the pigments used in the inks are subject to premarket approval under the Federal Food, Drug, and Cosmetic Act. However, the FDA generally has not exercised this regulatory authority [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/9/35993/abstract/36\">",
"     36",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Coloring agents include inorganic metallic salts, different types of organic molecules, and organic dyes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/9/35993/abstract/38\">",
"     38",
"    </a>",
"    ]. Auxiliary ingredients may be added to modify the properties of the ink to make it suitable for tattooing [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/9/35993/abstract/39\">",
"     39",
"    </a>",
"    ]. The composition of inks has changed over time; aluminum, oxygen, titanium, and carbon are more common than metallic salts such as mercury, cadmium, and cobalt, but metallic salts continue to be used [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/9/35993/abstract/40,41\">",
"     40,41",
"    </a>",
"    ]. Allergenic metals (eg, chromium, nickel, and cobalt) may exceed safe allergologic limits [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/9/35993/abstract/41\">",
"     41",
"    </a>",
"    ]. Most of the commercially available tattoo compounds are azo pigments or polycyclic compounds, some of which are carcinogenic. (See",
"    <a class=\"local\" href=\"#H110582469\">",
"     'Hypersensitivity reactions'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H110622044\">",
"     'Cancer'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    After the tattoo is applied, petroleum jelly or a similar substitute is applied to the skin to prevent oozing of serosanguineous fluid. After the tattoo has been applied, the artist bandages the tattoo and should provide after-care instructions, including recommending that the client cleanse the site twice daily with an antimicrobial soap and avoid contact with the site except for cleaning [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/9/35993/abstract/9,34,35\">",
"     9,34,35",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Amateur tattoos are often applied or placed by friends or acquaintances in an unclean environment. These tattoos often have crude designs and are placed using primitive instruments, such as pencils, pens, or other sharp objects. The pigments also are unconventional and may incorporate available materials, such as charcoal, ink, or mascara. Adolescents may obtain amateur tattoos because they cannot find a studio that will tattoo minors or because they cannot afford studio tattoo rates [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/9/35993/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H110578228\">",
"    <span class=\"h1\">",
"     RISKS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The risks associated with tattooing can be divided into purchase risks, possession risks, and health risks [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/9/35993/abstract/16,34,42\">",
"     16,34,42",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H110578290\">",
"    <span class=\"h2\">",
"     Purchase risks",
"    </span>",
"    &nbsp;&mdash;&nbsp;Purchase risks surround the purchase of a tattoo and include expense and pain. Impulsive purchasing of a product, such as when a teen quickly makes a decision in favor of a tattoo, can lead to purchase risks. Teens may overpay for body art, endure pain during the procedure, and experience infection because they did not know about the importance of skin care. Adolescents tend to have high purchase risks.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H110578298\">",
"    <span class=\"h2\">",
"     Possession risks",
"    </span>",
"    &nbsp;&mdash;&nbsp;Possession risk refers to the risk of a negative response from others when the tattoo is noticed. Although the tattoo may have significant meaning to the adolescent, parents, teachers, and others frequently express displeasure with it. Thus, the tattoo has a risk associated with potentiating low self-esteem. Possession risks may become the motivation for tattoo removal if, over time, the tattoo's symbolization of uniqueness or identity becomes a stigma, focus of negative comments, or problem with clothes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/9/35993/abstract/43\">",
"     43",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H110578322\">",
"    <span class=\"h2\">",
"     Health risks",
"    </span>",
"    &nbsp;&mdash;&nbsp;Tattooing is associated with health risks, yet the medical literature lacks data on the incidence of these dangers compared with the overall incidence of body art in the United States [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/9/35993/abstract/31\">",
"     31",
"    </a>",
"    ]. This lack of data is a result of infrequent reporting of complications to state health departments or in the medical literature, rather than an infrequency of complications.",
"   </p>",
"   <p>",
"    Most health risks are related to infectious complications or localized skin reactions, but the potential of blood-borne diseases is present [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/9/35993/abstract/44\">",
"     44",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H110578581\">",
"    <span class=\"h3\">",
"     Localized infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Tattooing may be associated with localized skin infection due to",
"    <em>",
"     Staphylococcus aureus",
"    </em>",
"    and other organisms, including nontuberculous mycobacteria (eg,",
"    <em>",
"     Mycobacterium chelonae, M. haemophilum",
"    </em>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/9/35993/abstract/35,44-50\">",
"     35,44-50",
"    </a>",
"    ]. The risk of infection is greater in individuals with newly acquired tattoos because of diminished skin integrity following the procedure.",
"   </p>",
"   <p>",
"    Several outbreaks of community-associated methicillin-resistant",
"    <em>",
"     S. aureus",
"    </em>",
"    (CA-MRSA) among tattoo recipients were reported in communities in Ohio, Kentucky, and Vermont during the time period of June 2004 to August 2005 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/9/35993/abstract/45\">",
"     45",
"    </a>",
"    ]. A total of 34 primary cases and 10 secondary cases (among persons living in the same house or with close personal contact) were identified. Investigation by the Centers for Disease Control and Prevention (CDC) found that although gloves were worn by all tattooists, adherence to other infection-control measures (eg, changing gloves between clients, hand hygiene, skin antisepsis, disinfection of equipment and surfaces) was not practiced. In addition, three of the tattooists associated with outbreaks had been recently incarcerated, a known risk factor for MRSA infection. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/21/30042?source=see_link&amp;anchor=H12#H12\">",
"     \"Epidemiology and clinical spectrum of methicillin-resistant Staphylococcus aureus infections in children\", section on 'Epidemiology and risk factors'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Outbreaks and individual cases of tattoo inoculation with",
"    <em>",
"     M. chelonae",
"    </em>",
"    have also been reported [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/9/35993/abstract/46-49,51-54\">",
"     46-49,51-54",
"    </a>",
"    ]. The cases shared several common features: lesions of varying morphology (eg, red papules, pustules, lichenoid papules and plaques) occurring predominantly in areas of gray pigment; onset within 10 days to 5 months of tattoo placement (usually within one to three weeks); and response to appropriate antibiotics (eg, macrolides and quinolones) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/9/35993/abstract/46-49\">",
"     46-49",
"    </a>",
"    ]. The outbreaks were associated with commercially-obtained pre-diluted gray ink and the case reports to the use of nonsterile water for dilution of black ink to the desired shade of gray [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/9/35993/abstract/48,49\">",
"     48,49",
"    </a>",
"    ] The clinical manifestations, diagnosis, and treatment of nontuberculous mycobacterial skin and soft tissue infections are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/34/7722?source=see_link\">",
"     \"Overview of nontuberculous mycobacterial skin and soft tissue infections in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    To avoid tattoo-related infection, the United States Centers for Disease Control and Prevention and Food and Drug Administration (FDA) recommend that tattoo artists [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/9/35993/abstract/48,55\">",
"     48,55",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Avoid using products that are not intended for use in tattooing (eg, drawing ink)",
"     </li>",
"     <li>",
"      Avoid dilution of ink before tattooing; if dilution is necessary use only sterile water",
"     </li>",
"     <li>",
"      Avoid use of nonsterile water (eg, tap water, bottled water, filtered water, distilled water) to wash the skin before or rinse equipment during tattoo placement",
"     </li>",
"     <li>",
"      Follow aseptic techniques during tattooing (ie, hand hygiene and the use of disposable gloves)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The risk of localized infection can be reduced when the individual receiving the tattoo understands the procedure, obtains it in a studio that uses sterile procedures, and follows appropriate after-care instructions regarding cleaning and maintenance. We suggest soap and water as an appropriate after-care solution. (See",
"    <a class=\"local\" href=\"#H110578099\">",
"     'The tattooing process'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The FDA encourages health care providers to report tattoo-related adverse events, including infection, to the",
"    <a class=\"external\" href=\"file://www.fda.gov/Safety/MedWatch/default.htm\">",
"     FDA MedWatch",
"    </a>",
"    program [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/9/35993/abstract/37\">",
"     37",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H110579191\">",
"    <span class=\"h3\">",
"     Systemic infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Systemic infection complicates tattoos less frequently than local infection. Systemic infection is more likely to occur in people who have had amateur tattoos or have not followed the after-care instructions. In the past, syphilis was transmitted by tattooists who held the needles in their mouths or used saliva to mix pigments [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/9/35993/abstract/35,44\">",
"     35,44",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H110581914\">",
"    <span class=\"h4\">",
"     Infective endocarditis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Infective endocarditis is a rare complication of tattooing, reported in one patient with frequent tattooing during a five-year period [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/9/35993/abstract/56-58\">",
"     56-58",
"    </a>",
"    ]. Nonetheless, healthcare providers should consider the possibility of IE in any patient who presents with unusual clinical events (eg, unexplained fever, rigors, weakness, myalgia, arthralgia, lethargy, or malaise) between one week and two months after tattooing or body piercing [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/9/35993/abstract/59,60\">",
"     59,60",
"    </a>",
"    ]. As body art continues to be a mainstream activity, proactive education about the risk of infection is recommended for parents and children. Education about the possibility of IE should be extended into the community to include body artists, since many adolescents may return to the body artist before the healthcare provider if infection occurs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/9/35993/abstract/16,31,34,58\">",
"     16,31,34,58",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The American Heart Association does not recommend prophylactic antibiotics for patients with congenital heart disease (CHD) before obtaining body art (tattoos or body piercings) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/9/35993/abstract/61\">",
"     61",
"    </a>",
"    ]. However, it has been suggested by several clinicians who have cared for patients with CHD who developed IE after body art [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/9/35993/abstract/60-64\">",
"     60-64",
"    </a>",
"    ], including 61 percent of the physician members of the International Society of Adult Congenital Cardiac Disease (now known as the International Society for Adult Congenital Heart Disease), 57 percent of pediatric cardiologists in 16 medical centers in the United Kingdom, and 28 percent of the Japanese Circulation Society Joint Working Groups for Guidelines for Management of Infective Endocarditis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/9/35993/abstract/63,65,66\">",
"     63,65,66",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/36/585?source=see_link\">",
"     \"Antimicrobial prophylaxis for bacterial endocarditis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The diagnosis and treatment of infective endocarditis are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/15/27896?source=see_link\">",
"     \"Infective endocarditis in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H110581951\">",
"    <span class=\"h4\">",
"     Hepatitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hepatitis B and C can be transmitted during tattooing via reused or inadequately sterilized instruments [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/9/35993/abstract/67-70\">",
"     67-70",
"    </a>",
"    ]. In a meta-analysis of 83 studies, the pooled odds ratio of hepatitis C among tattoo recipients was 2.74 (95% CI 2.38-3.15) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/9/35993/abstract/70\">",
"     70",
"    </a>",
"    ]. In another meta-analysis involving 62 studies, increased risk for hepatitis C was associated with tattoos applied in prisons or by friends; among studies that identified the venue for tattooing, there was no definitive evidence of increased risk for tattoos applied in studio parlors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/9/35993/abstract/69\">",
"     69",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Hepatitis B is especially worrisome because it is highly contagious, even with minimal blood exposure, and because state regulations do not require hepatitis B immunization for tattoo artists [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/9/35993/abstract/32,35,71\">",
"     32,35,71",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/31/4602?source=see_link\">",
"     \"Epidemiology, transmission, and prevention of hepatitis B virus infection\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/7/2169?source=see_link\">",
"     \"Epidemiology and transmission of hepatitis C virus infection\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/55/41849?source=see_link\">",
"     \"Screening for and diagnosis of chronic hepatitis C virus infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H110582163\">",
"    <span class=\"h4\">",
"     HIV infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many healthcare providers consider tattooing to be a risk factor for HIV infection. In the United States, there have been no clearly established cases of HIV infection caused by tattooing [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/9/35993/abstract/35,44\">",
"     35,44",
"    </a>",
"    ]. Although HIV may be transmitted through tattooing methods, the relationship needs to be more clearly defined. Certainly, the risk of contracting either hepatitis or HIV can be reduced by using new needles with each tattooing and by selecting a studio with an educated artist. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/0/31749?source=see_link&amp;anchor=H5#H5\">",
"     \"Epidemiology of pediatric HIV infection\", section on 'Risk factors for HIV acquisition'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H110582462\">",
"    <span class=\"h3\">",
"     Skin reactions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Generalized skin reactions, such as acquired hypersensitivity reactions to the tattoo pigment, can occur [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/9/35993/abstract/72\">",
"     72",
"    </a>",
"    ]. Tattoo pigments are not FDA approved for intradermal use and contain nonstandardized ingredients. In one study, samples of 30 tattoo inks were chemically analyzed and results compared with the information supplied by the manufacturer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/9/35993/abstract/73\">",
"     73",
"    </a>",
"    ]. Among the 30 pigment samples, the most commonly identified elements were aluminum (87 percent), oxygen (73 percent), titanium (67 percent), and carbon (67 percent). The elemental analysis was usually consistent with the information supplied by the manufacturer, but there were important exceptions. Further research indicates that some pigments are industrial-grade colors suitable for printers' ink or automobile paint [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/9/35993/abstract/74,75\">",
"     74,75",
"    </a>",
"    ]. Most tattoo pigment manufacturers do not provide a description of the enclosed materials, but one state (California) requires that tattoo pigments provide an itemization of ingredients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/9/35993/abstract/32\">",
"     32",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/40/3721?source=see_link\">",
"     \"Overview of dermatitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Less common skin reactions that may occur with tattooing include sarcoidal reactions, scleroderma, keloid formations, and hypertrophic scars [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/9/35993/abstract/35,76,77\">",
"     35,76,77",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H110582469\">",
"    <span class=\"h4\">",
"     Hypersensitivity reactions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Delayed hypersensitivity reactions localized to the site of ink injection are well described in association with metallic salts used in tattoo pigments (eg, mercury, chromium, cadmium, cobalt, nickel) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/9/35993/abstract/35,39,41,78\">",
"     35,39,41,78",
"    </a>",
"    ]. Anaphylaxis is less common, although a case report described a patient who presented with systemic symptoms beginning 12 hours after the procedure and no symptoms at the site of the injections [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/9/35993/abstract/79\">",
"     79",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Temporary tattooing is also associated with hypersensitivity reactions. Localized hypersensitivity reactions have been reported after the use of henna for temporary tattoos [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/9/35993/abstract/72,74,80-85\">",
"     72,74,80-85",
"    </a>",
"    ]. The addition of paraphenylenediamine (PPD) to henna is highly sensitizing and has been reported to cause localized scarring in some children, as well as anaphylaxis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/9/35993/abstract/72\">",
"     72",
"    </a>",
"    ]. Temporary tattooing does not fall under the review of the FDA [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/9/35993/abstract/84\">",
"     84",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Dermatitis from a fresh tattoo (nonhenna) can initially be treated with a topical glucocorticoid unless it is draining (suggesting superinfection, which requires antimicrobial therapy). Referral to an allergist or dermatologist may be warranted for patients who develop severe local reaction to tattoo pigments or henna or those determined to proceed with tattooing, since these patients may be at increased risk for serious systemic hypersensitivity reaction. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/40/3721?source=see_link&amp;anchor=H17#H17\">",
"     \"Overview of dermatitis\", section on 'Treatment'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H110622044\">",
"    <span class=\"h3\">",
"     Cancer",
"    </span>",
"    &nbsp;&mdash;&nbsp;Whether tattoo pigments have local or systemic carcinogenic effects is unclear [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/9/35993/abstract/39\">",
"     39",
"    </a>",
"    ]. Some components of tattoo ink have been classified by the International Agency for Research on Cancer as carcinogenic (eg, cadmium and cadmium compounds) or possibly carcinogenic (eg, cobalt sulfate and other soluble cobalt salts, carbon black) to humans [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/9/35993/abstract/86\">",
"     86",
"    </a>",
"    ]. However, an extensive review of the literature (1938 to 2011) found only 50 cases of skin cancer arising in tattoos (23 cases of squamous cell carcinoma and keratoacanthoma, 16 cases of melanoma, and 11 cases of basal-cell carcinoma) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/9/35993/abstract/39\">",
"     39",
"    </a>",
"    ]. The small number of reported cases suggests a coincidental rather than causal association, but higher quality studies are needed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H110583650\">",
"    <span class=\"h3\">",
"     Other complications",
"    </span>",
"    &nbsp;&mdash;&nbsp;A variety of other complications can occur depending upon the site of the tattoo.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The presence of nonstandardized ingredients in tattoo pigments may produce difficulties with radiologic imaging. Burning sensation and intense pain over tattooed sites that contain heavy deposits of metallic oxides or iron or titanium have been reported [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/9/35993/abstract/87-89\">",
"       87-89",
"      </a>",
"      ]. These particles may act as conductors during magnetic resonance imaging, although there is some debate about this [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/9/35993/abstract/90\">",
"       90",
"      </a>",
"      ]. At least one author has recommended that patients be screened for tattoos before undergoing radiographic procedures [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/9/35993/abstract/91\">",
"       91",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Whether lumbar tattoos merit special consideration in patients who require lumbar epidural analgesia remains controversial [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/9/35993/abstract/87,92-96\">",
"       87,92-96",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Tattoos that are located in operative fields (eg, abdominal tattoos) may require special procedures for preservation [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/9/35993/abstract/97\">",
"       97",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Placement of a tattoo near or within a melanocytic nevus can make it difficult to monitor for changes suggestive of melanoma [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/9/35993/abstract/98\">",
"       98",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?43/1/44056?source=see_link&amp;anchor=H15#H15\">",
"       \"Acquired melanocytic nevi (moles)\", section on 'Surveillance'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H156639639\">",
"    <span class=\"h3\">",
"     Pregnancy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Issues related to tattooing in pregnancy are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/62/35816?source=see_link&amp;anchor=H2865321#H2865321\">",
"     \"The skin, hair, nails, and mucous membranes during pregnancy\", section on 'Tattoos and piercing'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H110584116\">",
"    <span class=\"h1\">",
"     REMOVAL",
"    </span>",
"    &nbsp;&mdash;&nbsp;Tattoo removal is more complicated and more expensive than is tattoo application. One method for hiding an undesirable tattoo is to cover it with another design. In the past, the most frequently used removal processes involved abrasive techniques that would remove the superficial epidermal layer and allow the pigment to leach out of the skin. Other methods included cryosurgery, thermal cautery, and surgical resection. More recently, tattoos have been removed with laser therapy. All removal methods, including the laser, can leave visible scars [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/9/35993/abstract/35,99\">",
"     35,99",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Lasers employing different wavelengths can be used to remove different tattoo pigments. The actual mechanism of ink removal is not well understood, but it is thought that the laser pulse fractures the tattoo pigment into small particles that are then taken up by local macrophages or scavenger cells or eliminated transepidermally [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/9/35993/abstract/100,101\">",
"     100,101",
"    </a>",
"    ]. Cases of regional lymphadenopathy following laser tattoo removal have been reported, raising additional questions about pigment safety [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/9/35993/abstract/102,103\">",
"     102,103",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although laser removal is generally safe, skin hypo- or hyperpigmentation and hypersensitivity reactions (especially among people who experienced this reaction with the tattoo application) are potential complications [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/9/35993/abstract/100,104,105\">",
"     100,104,105",
"    </a>",
"    ]. Laser treatment of some tattoo pigments is associated with the creation of toxic",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    carcinogenic compounds [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/9/35993/abstract/106,107\">",
"     106,107",
"    </a>",
"    ]. Furthermore, laser treatment requires several sessions, can be costly, and is not covered under most insurance plans.",
"   </p>",
"   <p>",
"    Technologic advances may facilitate safe and effective tattoo removal. One such advance is the development of a microencapsulated biodegradable and bioabsorbable ink [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/9/35993/abstract/108\">",
"     108",
"    </a>",
"    ]. The ink is contained in beads made of a synthetic polymer that is commonly used in surgical glue and artificial joints. Like other tattoo inks, it provides permanent skin marking. However, when exposed to laser energy, the beads fall apart, and the exposed pigment is resorbed by the body.",
"   </p>",
"   <p>",
"    In animal studies, Freedom-2 tattoos were more effectively removed with laser treatment than India ink tattoos (52 versus 22 percent two weeks after laser treatment and 65 versus 27 percent nine weeks after treatment) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/9/35993/abstract/109\">",
"     109",
"    </a>",
"    ]. The long-term safety of Freedom-2 ink has yet to be established [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/9/35993/abstract/108\">",
"     108",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H110584456\">",
"    <span class=\"h1\">",
"     ROLE OF THE PRIMARY CARE PROVIDER",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients are more likely to discuss the issue of body art if the clinician does not speak or act judgmentally. Adolescents in particular are attuned to nonverbal cues. If these are dismissive, a teen may truncate discussions with his or her clinician and instead discuss body art with someone who provides him or her with inaccurate information. Teens often will seek advice from a commercial tattoo artist instead of discussing the issue with their healthcare providers [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/9/35993/abstract/16,110-112\">",
"     16,110-112",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The role of the clinician is to provide patients with factual information to permit informed decision-making about tattoo application [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/9/35993/abstract/113\">",
"     113",
"    </a>",
"    ]. The following guidelines may be used when counseling about tattooing [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/9/35993/abstract/110,114\">",
"     110,114",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Remind teens that most reputable studios require individuals to be 18 years old before a tattoo can be applied without parental permission. Many studios will not accept a note from the parent and require the parent to accompany his or her child to the studio.",
"     </li>",
"     <li>",
"      Encourage the patients to talk to others who have been tattooed.",
"     </li>",
"     <li>",
"      Talk with the parents and urge them to accompany their",
"      <span class=\"nowrap\">",
"       child/adolescent",
"      </span>",
"      to a body art studio to encourage more honest dialogue about the procedure before the actual procurement [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/9/35993/abstract/31\">",
"       31",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Remind patients they can take time to make decisions about tattoos and urge them not to make the decision under pressure, in haste, or while intoxicated.",
"     </li>",
"     <li>",
"      Patients should consider their choices of tattoo design and body site carefully. Remind them people may have negative judgments about certain tattoo designs and locations. Encourage placement on body parts where patients have control over who sees the tattoo [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/9/35993/abstract/43\">",
"       43",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Encourage patients to examine several studios before selecting one, to watch the artist place a tattoo, and to avoid commercial establishments in shopping malls. Remind patients of the health risks involved with amateur tattooing. Individuals should make sure the artist uses disposable gloves and disposable or adequately sterilized needles before each procedure. Also, the body site for tattooing should be thoroughly cleaned with an antimicrobial solution. After-care instructions should be provided.",
"     </li>",
"     <li>",
"      Remind patients that no topical anesthetic is used for tattooing.",
"     </li>",
"     <li>",
"      Patients should be aware of risks for infection, including hepatitis B or C, HIV, or local skin infections, even when good technique is used. Allergic reaction to tattoo pigment also may develop.",
"     </li>",
"     <li>",
"      Patients should be aware that most tattoo artists are unlicensed and that most states do not require formal training. Furthermore, the artists are not required to obtain hepatitis B immunization in most states. Tattoo studios are loosely regulated, and the depth and quality of standards vary from state to state. Finally, tattoo pigments are not FDA approved for intradermal application.",
"     </li>",
"     <li>",
"      Remind patients about the costs involved for application of tattoos. They should be aware that tattoos should be considered permanent, since they are costly to remove.",
"     </li>",
"     <li>",
"      Friends, rather than family, of adolescents seem to influence decisions about body art [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/9/35993/abstract/28\">",
"       28",
"      </a>",
"      ]. Clinicians should provide targeted and repeated education to transmit the message of effective decision-making and evaluation of risks, particularly in adolescents with congenital heart disease [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/9/35993/abstract/58\">",
"       58",
"      </a>",
"      ]. This education should begin during the early elementary grades, since some students start to obtain body art around fifth to seventh grade [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/9/35993/abstract/31,34\">",
"       31,34",
"      </a>",
"      ]. &nbsp;",
"     </li>",
"     <li>",
"      Brochures, health education videos, and informational Web sites are available (",
"      <a class=\"graphic graphic_table graphicRef59132 \" href=\"mobipreview.htm?33/61/34779\">",
"       table 1",
"      </a>",
"      ). Clinicians should become knowledgeable about the regulations in their cities, counties, and states regarding body art. The National Environmental Health Association (NEHA) has created a professional advisory document for those wishing to develop regulations for the body art industry [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/9/35993/abstract/32,33,115\">",
"       32,33,115",
"      </a>",
"      ]. Several states already have used the NEHA code when implementing newly adopted body art regulations for their states.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?2/35/2610?source=see_link\">",
"       \"Patient information: Tattoos and body piercings (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H110585603\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Tattooing has become frequent among adolescents and adults. Surveys evaluating the association between tattooing and high-risk behaviors have inconsistent results. (See",
"      <a class=\"local\" href=\"#H110576639\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Tattooing may be performed by either a commercial or an amateur artist. The tattooing technique and after-care instructions may influence the likelihood of complications. (See",
"      <a class=\"local\" href=\"#H110578099\">",
"       'The tattooing process'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The risks associated with tattoos can be divided into purchase risks (cost, pain), possession risks (negative response from others), and health risks. (See",
"      <a class=\"local\" href=\"#H110578228\">",
"       'Risks'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Health risks include localized infection, systemic infection, and skin reactions. (See",
"      <a class=\"local\" href=\"#H110578322\">",
"       'Health risks'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Tattoo removal is more complicated, takes more time, and is more expensive than the actual tattoo application. (See",
"      <a class=\"local\" href=\"#H110584116\">",
"       'Removal'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The role of the primary care clinician is to provide patients with factual information that permits informed decision-making about tattooing. (See",
"      <a class=\"local\" href=\"#H110584456\">",
"       'Role of the primary care provider'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/9/35993/abstract/1\">",
"      Raspa RF, Cusack J. Psychiatric implications of tattoos. Am Fam Physician 1990; 41:1481.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/9/35993/abstract/2\">",
"      Farrow JA, Schwartz RH, Vanderleeuw J. Tattooing behavior in adolescence. A comparison study. Am J Dis Child 1991; 145:184.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/9/35993/abstract/3\">",
"      Baker SP, Robertson LS, Spitz WU. Tattoos, alcohol, and violent death. J Forensic Sci 1971; 16:219.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/9/35993/abstract/4\">",
"      Carroll ST, Riffenburgh RH, Roberts TA, Myhre EB. Tattoos and body piercings as indicators of adolescent risk-taking behaviors. Pediatrics 2002; 109:1021.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/9/35993/abstract/5\">",
"      Roberts TA, Ryan SA. Tattooing and high-risk behavior in adolescents. Pediatrics 2002; 110:1058.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/9/35993/abstract/6\">",
"      Ferguson H. Body piercing. BMJ 1999; 319:1627.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/9/35993/abstract/7\">",
"      Stuppy DJ, Armstrong ML, Casals-Ariet C. Attitudes of health care providers and students towards tattooed people. J Adv Nurs 1998; 27:1165.",
"     </a>",
"    </li>",
"    <li>",
"     Kuchinski A, Pereira P, Armstrong ML. Caring for piercing clients: Attitudes, secondary trauma, and forensic evidence. Mosby's Nursing Consult, August 2006. Available at: www.nursingconsult.com (Accessed on May 20, 2008).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/9/35993/abstract/9\">",
"      Sperry K. Tattoos and tattooing. Part I: History and methodology. Am J Forensic Med Pathol 1991; 12:313.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/9/35993/abstract/10\">",
"      Mayers LB, Judelson DA, Moriarty BW, Rundell KW. Prevalence of body art (body piercing and tattooing) in university undergraduates and incidence of medical complications. Mayo Clin Proc 2002; 77:29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/9/35993/abstract/11\">",
"      Drews DR, Allison CK, Probst JR. Behavioral and self-concept differences in tattooed and nontattooed college students. Psychol Rep 2000; 86:475.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/9/35993/abstract/12\">",
"      Forbes GB. College students with tattoos and piercings: motives, family experiences, personality factors, and perception by others. Psychol Rep 2001; 89:774.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/9/35993/abstract/13\">",
"      Greif J, Hewitt W, Armstrong ML. Tattooing and body piercing. Body art practices among college students. Clin Nurs Res 1999; 8:368.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/9/35993/abstract/14\">",
"      Laumann AE, Derick AJ. Tattoos and body piercings in the United States: a national data set. J Am Acad Dermatol 2006; 55:413.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/9/35993/abstract/15\">",
"      Mayers L, Chiffriller S. Sequential survey of body piercing and tattooing prevalence and medical complication incidence among college students. Arch Pediatr Adolesc Med 2007; 161:1219.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/9/35993/abstract/16\">",
"      Armstrong ML, Murphy KP. Tattooing: another adolescent risk behavior warranting health education. Appl Nurs Res 1997; 10:181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/9/35993/abstract/17\">",
"      Armstrong ML, Owen DC, Roberts AE, Koch JR. College students and tattoos. Influence of image, identity, family, and friends. J Psychosoc Nurs Ment Health Serv 2002; 40:20.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/9/35993/abstract/18\">",
"      Armstrong ML, Owen DC, Roberts AE, Koch JR. College tattoos: more than skin deep. Dermatol Nurs 2002; 14:317.",
"     </a>",
"    </li>",
"    <li>",
"     Hargrove T, Stempel GH. A marked divide: Tattooing rate varies by generation. Scripps Howard News Service, July 22, 2003. Available at: www.newspolls.org/story.php?story_id=19 (Accessed on May 20, 2008).",
"    </li>",
"    <li>",
"     Kohut A, Parker K, Keeter S, et al. How young people view their lives, futures and politics: A portrait of \"generation next.\" Pew Research Center: For the people and the press. January 9, 2007. Full report available at: file://people-press.org/reports/pdf/300.pdf (Accessed on June 19, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/9/35993/abstract/21\">",
"      Koch JR, Roberts AE, Armstrong ML, Owen DC. College students, tattoos, and sexual activity. Psychol Rep 2005; 97:887.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/9/35993/abstract/22\">",
"      Nathanson C, Paulhus DL, Williams KM. Personality and misconduct correlates of body modification and other cultural deviance markers. J Res Personality 2006; 40:779.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/9/35993/abstract/23\">",
"      Tate JC, Shelton BL. Personality correlates of tattooing and body piercing in a college sample: the kids are alright. Personality and Individual Differences 2008; 45:281.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/9/35993/abstract/24\">",
"      Frederick CM, Bradley KA. A different kind of normal: Psychological and motivational characteristics of young adult tattooers and body piercers. North American Journal of Psychology 2000; 2:281.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/9/35993/abstract/25\">",
"      Koch JR, Roberts AE, Armstrong ML, Owen DC. Body art, deviance, and American college students. Soc Sci J 2010; 106:467.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/9/35993/abstract/26\">",
"      Rivardo MG, Keelan CM. Body modifications, sexual activity, and religious practices. Psychol Rep 2010; 106:467.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/9/35993/abstract/27\">",
"      Koch JR, Roberts AE, Armstrong ML, Owen DC. Correlations of religious belief and practice with college students' tattoo-related behavior. Psychol Rep 2004; 94:425.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/9/35993/abstract/28\">",
"      Armstrong ML, Roberts AE, Owen DC, Koch JR. Contemporary college students and body piercing. J Adolesc Health 2004; 35:58.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/9/35993/abstract/29\">",
"      Armstrong ML, Roberts AE, Owen DC, Koch JR. Toward building a composite of college student influences with body art. Issues Compr Pediatr Nurs 2004; 27:277.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/9/35993/abstract/30\">",
"      Roberts AE, Koch JR, Armstrong ML, Owen DC. Correlates of tattoos and reference groups. Psychol Rep 2006; 99:933.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/9/35993/abstract/31\">",
"      Armstrong ML, Kelly L. Tattooing, body piercing, and branding are on the rise: perspectives for school nurses. J Sch Nurs 2001; 17:12.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/9/35993/abstract/32\">",
"      Armstrong ML. Tattooing, body piercing, and permanent cosmetics: a historical and current view of state regulations, with continuing concerns. J Environ Health 2005; 67:38.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/9/35993/abstract/33\">",
"      Armstrong ML, Koch JR, Saunders JC, et al. The hole picture: risks, decision making, purpose, regulations, and the future of body piercing. Clin Dermatol 2007; 25:398.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/9/35993/abstract/34\">",
"      Armstrong ML, McConnell C. Tattooing in adolescents: more common than you think--the phenomenon and risks. J Sch Nurs 1994; 10:26.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/9/35993/abstract/35\">",
"      Sperry K. Tattoos and tattooing. Part II: Gross pathology, histopathology, medical complications, and applications. Am J Forensic Med Pathol 1992; 13:7.",
"     </a>",
"    </li>",
"    <li>",
"     US Food and Drug Administration.Tattoos and permanent makeup. file://www.fda.gov/Cosmetics/ProductandIngredientSafety/ProductInformation/ucm108530.htm (Accessed on August 27, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/9/35993/abstract/37\">",
"      LeBlanc PM, Hollinger KA, Klontz KC. Tattoo ink-related infections--awareness, diagnosis, reporting, and prevention. N Engl J Med 2012; 367:985.",
"     </a>",
"    </li>",
"    <li>",
"     Baumler W, Vasold R, Lundsgaard J, Talberg HJ. Chemical used in tattooing and permanent make up products. In: Workshop on Technical/Scientific and Regulatory Issues on the Safety of Tattoos, Body Piercing and of Related Practices, Papameletiou D, Schwela D, Zenie A.  (Eds), European commission, Ispra, VA 2004. p.21.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/9/35993/abstract/39\">",
"      Kluger N, Koljonen V. Tattoos, inks, and cancer. Lancet Oncol 2012; 13:e161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/9/35993/abstract/40\">",
"      Beute TC, Miller CH, Timko AL, Ross EV. In vitro spectral analysis of tattoo pigments. Dermatol Surg 2008; 34:508.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/9/35993/abstract/41\">",
"      Forte G, Petrucci F, Cristaudo A, Bocca B. Market survey on toxic metals contained in tattoo inks. Sci Total Environ 2009; 407:5997.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/9/35993/abstract/42\">",
"      Armstrong ML. Adolescent tattoos: educating vs. pontificating. Pediatr Nurs 1995; 21:561.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/9/35993/abstract/43\">",
"      Armstrong ML, Roberts AE, Koch JR, et al. Motivation for contemporary tattoo removal: a shift in identity. Arch Dermatol 2008; 144:879.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/9/35993/abstract/44\">",
"      Long GE, Rickman LS. Infectious complications of tattoos. Clin Infect Dis 1994; 18:610.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/9/35993/abstract/45\">",
"      Centers for Disease Control and Prevention (CDC). Methicillin-resistant Staphylococcus aureus skin infections among tattoo recipients--Ohio, Kentucky, and Vermont, 2004-2005. MMWR Morb Mortal Wkly Rep 2006; 55:677.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/9/35993/abstract/46\">",
"      Kappel S, Cotliar J. Inoculation of Mycobacteria chelonae from a tattoo. J Am Acad Dermatol 2011; 64:998.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/9/35993/abstract/47\">",
"      Drage LA, Ecker PM, Orenstein R, et al. An outbreak of Mycobacterium chelonae infections in tattoos. J Am Acad Dermatol 2010; 62:501.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/9/35993/abstract/48\">",
"      Centers for Disease Control and Prevention (CDC). Tattoo-associated nontuberculous mycobacterial skin infections--multiple states, 2011-2012. MMWR Morb Mortal Wkly Rep 2012; 61:653.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/9/35993/abstract/49\">",
"      Kennedy BS, Bedard B, Younge M, et al. Outbreak of Mycobacterium chelonae infection associated with tattoo ink. N Engl J Med 2012; 367:1020.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/9/35993/abstract/50\">",
"      Giulieri S, Morisod B, Edney T, et al. Outbreak of Mycobacterium haemophilum infections after permanent makeup of the eyebrows. Clin Infect Dis 2011; 52:488.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/9/35993/abstract/51\">",
"      Preda VA, Maley M, Sullivan JR. Mycobacterium chelonae infection in a tattoo site. Med J Aust 2009; 190:278.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/9/35993/abstract/52\">",
"      Kluger N, Muller C, Gral N. Atypical mycobacteria infection following tattooing: review of an outbreak in 8 patients in a French tattoo parlor. Arch Dermatol 2008; 144:941.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/9/35993/abstract/53\">",
"      Wolf R, Wolf D. A tattooed butterfly as a vector of atypical Mycobacteria. J Am Acad Dermatol 2003; 48:S73.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/9/35993/abstract/54\">",
"      de Quatrebarbes J. Epidemie a Mycobacterium chelonae chez un tatoueur. Ann Dermatol Venereol 2005; 132:2.",
"     </a>",
"    </li>",
"    <li>",
"     US Food and Drug Administration. Tattoo inks pose health risks. file://www.fda.gov/ForConsumers/ConsumerUpdates/ucm316357.htm (Accessed on August 27, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/9/35993/abstract/56\">",
"      Satchithananda DK, Walsh J, Schofield PM. Bacterial endocarditis following repeated tattooing. Heart 2001; 85:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/9/35993/abstract/57\">",
"      Shebani SO, Miles HF, Simmons P, et al. Awareness of the risk of endocarditis associated with tattooing and body piercing among patients with congenital heart disease and paediatric cardiologists in the United Kingdom. Arch Dis Child 2007; 92:1013.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/9/35993/abstract/58\">",
"      Armstrong ML, DeBoer S, Cetta F. Infective endocarditis after body art: a review of the literature and concerns. J Adolesc Health 2008; 43:217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/9/35993/abstract/59\">",
"      Raja SG, Shad SK, Dreyfus GD. Body piercing: a rare cause of mitral valve endocarditis. J Heart Valve Dis 2004; 13:854.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/9/35993/abstract/60\">",
"      Goldrick BA. Bubonic plague and HIV. The delta 32 connection. Am J Nurs 2003; 103:26.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/9/35993/abstract/61\">",
"      Wilson W, Taubert KA, Gewitz M, et al. Prevention of infective endocarditis: guidelines from the American Heart Association: a guideline from the American Heart Association Rheumatic Fever, Endocarditis, and Kawasaki Disease Committee, Council on Cardiovascular Disease in the Young, and the Council on Clinical Cardiology, Council on Cardiovascular Surgery and Anesthesia, and the Quality of Care and Outcomes Research Interdisciplinary Working Group. Circulation 2007; 116:1736.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/9/35993/abstract/62\">",
"      Weinberg JB, Blackwood RA. Case report of Staphylococcus aureus endocarditis after navel piercing. Pediatr Infect Dis J 2003; 22:94.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/9/35993/abstract/63\">",
"      Cetta F, Graham LC, Lichtenberg RC, Warnes CA. Piercing and tattooing in patients with congenital heart disease: patient and physician perspectives. J Adolesc Health 1999; 24:160.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/9/35993/abstract/64\">",
"      Millar BC, Moore JE. Antibiotic prophylaxis, body piercing and infective endocarditis. J Antimicrob Chemother 2004; 53:123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/9/35993/abstract/65\">",
"      Delahaye F, Wong J, Mills PG. Infective endocarditis: a comparison of international guidelines. Heart 2007; 93:524.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/9/35993/abstract/66\">",
"      Niwa K, Nakazawa M, Miyatake K, et al. Survey of prophylaxis and management of infective endocarditis in patients with congenital heart disease: Japanese nationwide survey. Circ J 2003; 67:585.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/9/35993/abstract/67\">",
"      Hayes MO, Harkness GA. Body piercing as a risk factor for viral hepatitis: an integrative research review. Am J Infect Control 2001; 29:271.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/9/35993/abstract/68\">",
"      Haley RW, Fischer RP. Commercial tattooing as a potentially important source of hepatitis C infection. Clinical epidemiology of 626 consecutive patients unaware of their hepatitis C serologic status. Medicine (Baltimore) 2001; 80:134.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/9/35993/abstract/69\">",
"      Tohme RA, Holmberg SD. Transmission of hepatitis C virus infection through tattooing and piercing: a critical review. Clin Infect Dis 2012; 54:1167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/9/35993/abstract/70\">",
"      Jafari S, Copes R, Baharlou S, et al. Tattooing and the risk of transmission of hepatitis C: a systematic review and meta-analysis. Int J Infect Dis 2010; 14:e928.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/9/35993/abstract/71\">",
"      Tope WD. State and territorial regulation of tattooing in the United States. J Am Acad Dermatol 1995; 32:791.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/9/35993/abstract/72\">",
"      Dron P, Lafourcade MP, Leprince F, et al. Allergies associated with body piercing and tattoos: a report of the Allergy Vigilance Network. Eur Ann Allergy Clin Immunol 2007; 39:189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/9/35993/abstract/73\">",
"      Timko AL, Miller CH, Johnson FB, Ross E. In vitro quantitative chemical analysis of tattoo pigments. Arch Dermatol 2001; 137:143.",
"     </a>",
"    </li>",
"    <li>",
"     FDA CFSAN/Office of Cosmetics and Colors Tattoos and Permanent Makeup. (2006). Available at: www.cfsan.fda.gov/~dms/cos-204.html (Accessed on May 20, 2008).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/9/35993/abstract/75\">",
"      Engel E, Santarelli F, Vasold R, et al. Modern tattoos cause high concentrations of hazardous pigments in skin. Contact Dermatitis 2008; 58:228.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/9/35993/abstract/76\">",
"      Dickinson JA. Sarcoidal reactions in tattoos. Arch Dermatol 1969; 100:315.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/9/35993/abstract/77\">",
"      Blobstein SH, Weiss HD, Myskowski PL. Sarcoidal granulomas in tattoos. Cutis 1985; 36:423.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/9/35993/abstract/78\">",
"      Neri I, Guareschi E, Savoia F, Patrizi A. Childhood allergic contact dermatitis from henna tattoo. Pediatr Dermatol 2002; 19:503.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/9/35993/abstract/79\">",
"      Lee-Wong M, Karagic M, Silverberg N. Anaphylactic reaction to permanent tattoo ink. Ann Allergy Asthma Immunol 2009; 103:88.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/9/35993/abstract/80\">",
"      Farrow C. Hair dye and henna tattoo exposure. Emerg Nurse 2002; 10:19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/9/35993/abstract/81\">",
"      Simpson-Dent SL, Hunt SH, Davison SC, Wakelin SH. Tattoo dermatitis from primary sensitization to clothing dyes. Contact Dermatitis 2001; 45:248.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/9/35993/abstract/82\">",
"      Jappe U, Hausen BM, Petzoldt D. Erythema-multiforme-like eruption and depigmentation following allergic contact dermatitis from a paint-on henna tattoo, due to para-phenylenediamine contact hypersensitivity. Contact Dermatitis 2001; 45:249.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/9/35993/abstract/83\">",
"      Mohamed M, Nixon R. Severe allergic contact dermatitis induced by paraphenylenediamine in paint-on temporary 'tattoos'. Australas J Dermatol 2000; 41:168.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/9/35993/abstract/84\">",
"      Zapolanski T, Jacob SE. Avoiding paraphenylenediamine exposure in children. Pediatr Ann 2008; 37:104.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/9/35993/abstract/85\">",
"      Jacob SE, Zapolanski T, Chayavichitsilp P, et al. p-Phenylenediamine in black henna tattoos: a practice in need of policy in children. Arch Pediatr Adolesc Med 2008; 162:790.",
"     </a>",
"    </li>",
"    <li>",
"     World Health Organization. International Agency for Research on Cancer. IARC Monographs on the evaluation of carcinogenic risks to humans. file://monographs.iarc.fr/ENG/Classification/index.php (Accessed on May 16, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/9/35993/abstract/87\">",
"      DeBoer S, Fishman D, Chwals W, et al. Body piercing/tattooing and trauma diagnostic imaging: medical myths vs realities. J Trauma Nurs 2007; 14:35.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/9/35993/abstract/88\">",
"      Mercier FJ, Bonnet MP. Tattooing and various piercing: anaesthetic considerations. Curr Opin Anaesthesiol 2009; 22:436.",
"     </a>",
"    </li>",
"    <li>",
"     Barclay, L. Anesthetic care for magnetic resonance imaging reviewed. Medscape Medical News. file://cme.medscape.com/viewarticle/589122_print (Accessed on August 17, 2009).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/9/35993/abstract/90\">",
"      Armstrong ML, Elkins L. Body art and MRI. Am J Nurs 2005; 105:65.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/9/35993/abstract/91\">",
"      Elster AD, Link KM, Carr JJ. Patient screening prior to MR imaging: a practical approach synthesized from protocols at 15 U. S. medical centers. AJR Am J Roentgenol 1994; 162:195.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/9/35993/abstract/92\">",
"      Kuczkowski KM. Lumbar tattoos and lumbar epidural analgesia: unresolved controversies. Can J Anaesth 2008; 55:127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/9/35993/abstract/93\">",
"      Ginsburg G. Lumbar tattoos and labour epidurals: bare bones evidence. J Obstet Gynaecol Can 2009; 31:203, 204.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/9/35993/abstract/94\">",
"      Mavropoulos A, Camann W. Use of a lumbar tattoo to aid spinal anesthesia for cesarean delivery. Int J Obstet Anesth 2009; 18:98.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/9/35993/abstract/95\">",
"      Kluger N. Body art and pregnancy. Eur J Obstet Gynecol Reprod Biol 2010; 153:3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/9/35993/abstract/96\">",
"      Kluger N, Fraitag S, Guillot B, Sleth JC. Why puncturing a lumbar tattoo during epidural analgesia cannot induce an epidermoid tumor. Reg Anesth Pain Med 2010; 35:317.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/9/35993/abstract/97\">",
"      Smit JM, Scheele K, Lapid O, Hoogbergen MM. Management of tattoos in the operative field. Ann Plast Surg 2010; 64:125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/9/35993/abstract/98\">",
"      Kluger N, Thomas L. The dragon with atypical mole syndrome. Arch Dermatol 2008; 144:948.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/9/35993/abstract/99\">",
"      Anderson R. Regarding tattoos: is that sunlight, or an oncoming train at the end of the tunnel? Arch Dermatol 2001; 137:210.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/9/35993/abstract/100\">",
"      Kilmer SL. Laser treatment of tattoos. Dermatol Clin 1997; 15:409.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/9/35993/abstract/101\">",
"      Ho DD, London R, Zimmerman GB, Young DA. Laser-tattoo removal--a study of the mechanism and the optimal treatment strategy via computer simulations. Lasers Surg Med 2002; 30:389.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/9/35993/abstract/102\">",
"      Izikson L, Avram M, Anderson RR. Transient immunoreactivity after laser tattoo removal: report of two cases. Lasers Surg Med 2008; 40:231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/9/35993/abstract/103\">",
"      Wenzel SM. Current concepts in laser tattoo removal. Skin Therapy Lett 2010; 15:3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/9/35993/abstract/104\">",
"      Ashinoff R, Levine VJ, Soter NA. Allergic reactions to tattoo pigment after laser treatment. Dermatol Surg 1995; 21:291.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/9/35993/abstract/105\">",
"      Holzer AM, Burgin S, Levine VJ. Adverse effects of Q-switched laser treatment of tattoos. Dermatol Surg 2008; 34:118.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/9/35993/abstract/106\">",
"      Cui Y, Spann AP, Couch LH, et al. Photodecomposition of Pigment Yellow 74, a pigment used in tattoo inks. Photochem Photobiol 2004; 80:175.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/9/35993/abstract/107\">",
"      Vasold R, Naarmann N, Ulrich H, et al. Tattoo pigments are cleaved by laser light-the chemical analysis in vitro provide evidence for hazardous compounds. Photochem Photobiol 2004; 80:185.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/9/35993/abstract/108\">",
"      Removable permanent tattoo ink. Med Lett Drugs Ther 2007; 49:75.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/9/35993/abstract/109\">",
"      Shawgo RS, Kundakovic L, Farinelli W, et al. In vivo evaluation of pigments engineered for removal. Lasers Surg Med Suppl 2006; 18:19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/9/35993/abstract/110\">",
"      Armstrong ML, Ekmark E, Brooks B. Body piercing: promoting informed decision making. J Sch Nurs 1995; 11:20.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/9/35993/abstract/111\">",
"      Armstrong JF. Bombs and other blasts. RN 1998; 61:26.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/9/35993/abstract/112\">",
"      Caliendo C, Armstrong ML, Roberts AE. Self-reported characteristics of women and men with intimate body piercings. J Adv Nurs 2005; 49:474.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/9/35993/abstract/113\">",
"      Vanston DC, Scott JM. Health risks, medical complications and negative social implications associated with adolescent tattoo and body piercing practices. Vulnerable Child and Youth Studies 2008; 3:221.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/9/35993/abstract/114\">",
"      Armstrong M, McConnell C. Promoting informed decision-making about tattooing for adolescents. J Sch Nurs 1994; 10:27.",
"     </a>",
"    </li>",
"    <li>",
"     Body Art: A comprehensive guidebook and model code. Published by NEHA; Denver, CO 1999.",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 15721 Version 13.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-203.80.222.8-62FEFCC119-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_9_35993=[""].join("\n");
var outline_f35_9_35993=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H110585603\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H110576378\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H110576573\">",
"      HISTORY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H110576639\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H110577480\">",
"      Motivational factors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H110578099\">",
"      THE TATTOOING PROCESS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H110578228\">",
"      RISKS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H110578290\">",
"      Purchase risks",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H110578298\">",
"      Possession risks",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H110578322\">",
"      Health risks",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H110578581\">",
"      - Localized infection",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H110579191\">",
"      - Systemic infection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H110581914\">",
"      Infective endocarditis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H110581951\">",
"      Hepatitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H110582163\">",
"      HIV infection",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H110582462\">",
"      - Skin reactions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H110582469\">",
"      Hypersensitivity reactions",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H110622044\">",
"      - Cancer",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H110583650\">",
"      - Other complications",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H156639639\">",
"      - Pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H110584116\">",
"      REMOVAL",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H110584456\">",
"      ROLE OF THE PRIMARY CARE PROVIDER",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H110585603\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PEDS/15721\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/15721|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?33/61/34779\" title=\"table 1\">",
"      Body art information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?43/1/44056?source=related_link\">",
"      Acquired melanocytic nevi (moles)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?0/36/585?source=related_link\">",
"      Antimicrobial prophylaxis for bacterial endocarditis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/2/10282?source=related_link\">",
"      Body piercing in adolescents and young adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/21/30042?source=related_link\">",
"      Epidemiology and clinical spectrum of methicillin-resistant Staphylococcus aureus infections in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?2/7/2169?source=related_link\">",
"      Epidemiology and transmission of hepatitis C virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/0/31749?source=related_link\">",
"      Epidemiology of pediatric HIV infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?4/31/4602?source=related_link\">",
"      Epidemiology, transmission, and prevention of hepatitis B virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/15/27896?source=related_link\">",
"      Infective endocarditis in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?3/40/3721?source=related_link\">",
"      Overview of dermatitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/34/7722?source=related_link\">",
"      Overview of nontuberculous mycobacterial skin and soft tissue infections in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?2/35/2610?source=related_link\">",
"      Patient information: Tattoos and body piercings (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/55/41849?source=related_link\">",
"      Screening for and diagnosis of chronic hepatitis C virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/62/35816?source=related_link\">",
"      The skin, hair, nails, and mucous membranes during pregnancy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f35_9_35994="Prognosis and treatment of immunoglobulin light chain (AL) amyloidosis and light and heavy chain deposition diseases";
var content_f35_9_35994=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"6\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Prognosis and treatment of immunoglobulin light chain (AL) amyloidosis and light and heavy chain deposition diseases",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?35/9/35994/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/9/35994/contributors\">",
"     S Vincent Rajkumar, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?35/9/35994/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/9/35994/contributors\">",
"     Richard J Glassock, MD, MACP",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/9/35994/contributors\">",
"     Robert A Kyle, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/9/35994/contributors\">",
"     Steve J Schwab, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?35/9/35994/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/9/35994/contributors\">",
"     Rebecca F Connor, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?35/9/35994/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 3, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Immunoglobulin light chain (AL) amyloidosis (previously referred to as primary amyloidosis), light chain deposition disease (LCDD), and heavy chain deposition disease (HCDD) are monoclonal plasma cell proliferative disorders that are characterized by tissue deposits of light chain or heavy chain fragments, leading to organ dysfunction. The incidence of AL amyloidosis is approximately one-tenth that of multiple myeloma. In approximately 10 percent of patients with AL amyloidosis, multiple myeloma is also present at the time of initial diagnosis; the clinical course and treatment of these patients is dependent on which of the two diseases is dominant in terms of end-organ damage and symptoms. Less than 1 percent of patients with isolated AL amyloidosis at diagnosis develop multiple myeloma at a future time point.",
"   </p>",
"   <p>",
"    The prognosis and treatment of AL amyloidosis will be reviewed in detail here. The treatment of LCDD and HCDD is also reviewed briefly. The pathogenesis, clinical features, and diagnosis of these disorders and the diagnosis of primary amyloidosis are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/62/35815?source=see_link\">",
"     \"Pathogenesis of immunoglobulin light chain (AL) amyloidosis and light and heavy chain deposition diseases\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/15/7418?source=see_link\">",
"     \"Clinical presentation, laboratory manifestations, and diagnosis of immunoglobulin light chain (AL) amyloidosis (primary amyloidosis)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15768474\">",
"    <span class=\"h1\">",
"     PRE-TREATMENT EVALUATION",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15770357\">",
"    <span class=\"h2\">",
"     Assessment",
"    </span>",
"    &nbsp;&mdash;&nbsp;To best treat patients with AL amyloidosis, the initial evaluation must confirm the diagnosis, establish the extent and sites of disease, and evaluate for comorbidities that are likely to have an impact on treatment options. The diagnosis of AL amyloidosis is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/15/7418?source=see_link\">",
"     \"Clinical presentation, laboratory manifestations, and diagnosis of immunoglobulin light chain (AL) amyloidosis (primary amyloidosis)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In addition to a history and physical examination, it is our practice to perform the following pre-treatment studies in patients with AL amyloidosis:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Laboratory studies include a complete blood count with differential, chemistries with liver and renal function and electrolytes, prothrombin time (PT), partial thromboplastin time (PTT), electrophoresis of the serum and urine, immunoelectrophoresis of the serum and urine, serum free light chain assay, 24-hour urinary protein and creatinine clearance, brain natriuretic peptide (BNP), troponin, NT-proBNP, thyroid stimulating hormone (TSH), and cortisol level. Factor X levels should be included for patients with abnormal bleeding or abnormal",
"      <span class=\"nowrap\">",
"       PT/PTT",
"      </span>",
"      testing.",
"     </li>",
"     <li>",
"      Unilateral bone marrow aspirate and biopsy with immunohistochemical staining for kappa and lambda and Congo red staining for amyloid. If available, fluorescent in situ hybridization studies similar to those done in myeloma should be considered. The prognostic value of these studies in AL amyloidosis is not well-established, but there are data that patients with t(11;14) have a poorer prognosis [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/9/35994/abstract/1\">",
"       1",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?10/23/10618?source=see_link\">",
"       \"Staging and prognostic studies in multiple myeloma\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Cardiac involvement should be evaluated with an electrocardiogram, echocardiogram, and chest radiograph. A cardiac magnetic resonance imaging study may be valuable in certain circumstances. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?23/10/23722?source=see_link&amp;anchor=H139244#H139244\">",
"       \"Clinical manifestations and diagnosis of amyloid cardiomyopathy\", section on 'Differential diagnosis'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Patients with neurologic symptoms should be evaluated with electromyography (EMG) and nerve conduction studies. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?11/22/11623?source=see_link\">",
"       \"Musculoskeletal manifestations of amyloidosis\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?13/51/14137?source=see_link&amp;anchor=H19#H19\">",
"       \"Myopathies of systemic disease\", section on 'Amyloid myopathy'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Gastrointestinal involvement should be evaluated with stool guaiac studies. Craniocaudal liver span should be documented with an ultrasound or computed tomography. Patients with symptoms of gastroparesis should undergo a study of gastric emptying. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?42/12/43209?source=see_link&amp;anchor=H17#H17\">",
"       \"Etiology and diagnosis of delayed gastric emptying\", section on 'Scintigraphic gastric emptying'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Patients with suspected pulmonary involvement should undergo pulmonary function testing.",
"     </li>",
"     <li>",
"      Men and women with child-bearing potential should receive counseling about the potential effect of treatment on their fertility and options for fertility-preserving measures. Given the urgent need for treatment, options for women are limited, but men can often participate in sperm banking. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?37/7/38010?source=see_link\">",
"       \"Fertility preservation in patients undergoing gonadotoxic treatment or gonadal resection\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15770364\">",
"    <span class=\"h2\">",
"     Organ involvement defined",
"    </span>",
"    &nbsp;&mdash;&nbsp;For treatment purposes, organ involvement by amyloidosis is defined by consensus criteria created in 2005 at the 10th International Symposium on Amyloid and Amyloidosis and revised in 2011 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/9/35994/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Kidney &mdash; Direct biopsy verification with clinical or laboratory evidence of organ dysfunction or, if amyloid deposits have been confirmed at another site, 24-hour urine protein &gt;0.5",
"      <span class=\"nowrap\">",
"       g/day,",
"      </span>",
"      predominantly albumin. Other causes of proteinuria (eg, poorly controlled diabetes mellitus or uncontrolled hypertension) should be excluded.",
"     </li>",
"     <li>",
"      Heart &mdash; Direct biopsy verification with clinical or laboratory evidence of organ dysfunction or, if amyloid deposits have been confirmed at another site, echocardiogram with mean wall thickness (interventricular septum and posterior wall) &gt;12 mm with no other cardiac cause or an elevated NT-ProBNP (&gt;332",
"      <span class=\"nowrap\">",
"       ng/L)",
"      </span>",
"      in the absence of renal failure or atrial fibrillation.",
"     </li>",
"     <li>",
"      Liver &mdash; Direct biopsy verification with laboratory evidence of organ dysfunction or, if amyloid deposits have been confirmed at another site, total liver span &gt;15 cm in the absence of heart failure or alkaline phosphatase &gt;1.5 times institutional upper limit of normal.",
"     </li>",
"     <li>",
"      Nerve &mdash; Clinical symmetric lower extremity sensorimotor peripheral neuropathy or gastric-emptying disorder, pseudo-obstruction, voiding dysfunction not related to direct organ infiltration.",
"     </li>",
"     <li>",
"      Gastrointestinal tract &mdash; Direct biopsy verification with symptoms (eg, diarrhea, motility disturbances, and weight loss). Identification of vascular only amyloid deposits without symptoms should not be considered intestinal organ involvement.",
"     </li>",
"     <li>",
"      Lung &mdash; Direct biopsy verification with symptoms and an interstitial radiographic pattern.",
"     </li>",
"     <li>",
"      Soft tissue &mdash; Clinical tongue enlargement, arthropathy, claudication (presumed vascular amyloid), skin, myopathy by biopsy or pseudohypertrophy, lymph node involvement (may be localized), carpal tunnel syndrome.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     TREATMENT OF PRIMARY AMYLOIDOSIS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15768563\">",
"    <span class=\"h1\">",
"     INITIAL TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Our approach to the initial management of patients with AL amyloidosis varies depending on whether patients are eligible to pursue high dose",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?21/54/22376?source=see_link\">",
"     melphalan",
"    </a>",
"    followed by autologous hematopoietic cell transplantation (HCT):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients eligible for HCT are either treated on clinical trials investigating HCT or offered HCT outside of a study setting provided that the patient has been carefully evaluated and the procedure can be done in a center with adequate expertise in performing the procedure in patients with AL amyloidosis (",
"      <a class=\"graphic graphic_algorithm graphicRef88825 \" href=\"mobipreview.htm?42/10/43181\">",
"       algorithm 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H10605386\">",
"       'Clinical trials'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Patients not eligible for HCT are offered therapy on clinical trials or treated with",
"      <span class=\"nowrap\">",
"       <a class=\"drug drug_general\" href=\"mobipreview.htm?21/54/22376?source=see_link\">",
"        melphalan",
"       </a>",
"       /",
"       <a class=\"drug drug_general\" href=\"mobipreview.htm?33/4/33856?source=see_link\">",
"        dexamethasone",
"       </a>",
"      </span>",
"      (",
"      <a class=\"graphic graphic_algorithm graphicRef88826 \" href=\"mobipreview.htm?11/29/11742\">",
"       algorithm 2",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Melphalan and dexamethasone'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15768578\">",
"    <span class=\"h2\">",
"     Determining transplant eligibility",
"    </span>",
"    &nbsp;&mdash;&nbsp;Eligibility for autologous HCT in AL amyloidosis varies across countries and institutions. In most European countries, autologous HCT is offered primarily to patients less than 65 years of age. In the United States, a strict age-limit is not used. Instead, decisions are made on a case-by-case basis based upon \"physiologic age\" and vary across institutions. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/50/19241?source=see_link\">",
"     \"Determining eligibility for autologous hematopoietic cell transplantation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In general, patients should meet the following criteria in order to be eligible for autologous HCT in AL amyloidosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/9/35994/abstract/4,5\">",
"     4,5",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Physiologic age &le;70 years",
"     </li>",
"     <li>",
"      Troponin T &lt;0.06",
"      <span class=\"nowrap\">",
"       ng/mL",
"      </span>",
"     </li>",
"     <li>",
"      NT-proBNP &lt;5000",
"      <span class=\"nowrap\">",
"       ng/L",
"      </span>",
"     </li>",
"     <li>",
"      Creatinine clearance &ge;30",
"      <span class=\"nowrap\">",
"       mL/min",
"      </span>",
"      (unless on chronic stable dialysis)",
"     </li>",
"     <li>",
"      Eastern Cooperative Oncology Group (ECOG) performance status &le;2 (",
"      <a class=\"graphic graphic_table graphicRef72901 \" href=\"mobipreview.htm?9/15/9467\">",
"       table 1",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      New York Heart Association functional status Class I or II (",
"      <a class=\"graphic graphic_table graphicRef52683 \" href=\"mobipreview.htm?3/2/3117\">",
"       table 2",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      No more than two organs significantly involved (liver, heart, kidney, or autonomic nerve)",
"     </li>",
"     <li>",
"      No large pleural effusions",
"     </li>",
"     <li>",
"      No dependency on oxygen therapy",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These are guidelines; the decision on transplant eligibility should be made based on a risk-benefit assessment and the needs and wishes of the patient. Of importance, patients with severe (&lt;25 percent) factor X deficiency have a transplant-related mortality rate that approaches 50 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/9/35994/abstract/6\">",
"     6",
"    </a>",
"    ]. Splenectomy may be performed in such patients in an effort to increase factor X levels prior to HCT [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/9/35994/abstract/7\">",
"     7",
"    </a>",
"    ]. Cardiac and renal transplantation followed by HCT has been used in selected patients with cardiac and renal amyloidosis, respectively. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/10/23722?source=see_link\">",
"     \"Clinical manifestations and diagnosis of amyloid cardiomyopathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Support for the use of these transplant eligibility criteria comes from retrospective analyses and small prospective series that have demonstrated the adverse prognostic importance of organ involvement in patients with AL amyloidosis undergoing HCT [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/9/35994/abstract/8-13\">",
"     8-13",
"    </a>",
"    ]. As an example, in a series of 21 transplanted patients, the most striking finding was the prognostic value of the number of clinical manifestations of amyloidosis at the time of transplantation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/9/35994/abstract/8\">",
"     8",
"    </a>",
"    ]. The criteria used included creatinine clearance &lt;30",
"    <span class=\"nowrap\">",
"     mL/min,",
"    </span>",
"    nephrotic syndrome, heart failure, neuropathy, or hepatomegaly associated with an alkaline phosphatase concentration &gt;200 international",
"    <span class=\"nowrap\">",
"     units/L.",
"    </span>",
"    Patients with less than two of these manifestations had a much higher overall (92 versus 11 percent) and event-free (46 versus 11 percent) survival than those with two or more manifestations. The poor outcomes in the latter group were primarily due to a greater than 75 percent incidence of toxic death with intensive therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15768806\">",
"    <span class=\"h2\">",
"     Patients eligible for transplant",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with AL amyloidosis must choose between initial treatment with chemotherapy alone or management with high dose",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?21/54/22376?source=see_link\">",
"     melphalan",
"    </a>",
"    followed by autologous hematopoietic stem cell rescue. Although one study has suggested that there might be a component of graft-versus-tumor effect in patients receiving myeloablative or nonmyeloablative allogeneic HCT, allogeneic HCT is not considered a treatment option given an extremely high incidence of transplant-related mortality [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/9/35994/abstract/14\">",
"     14",
"    </a>",
"    ]. Often the best management includes enrollment on a well designed clinical trial. (See",
"    <a class=\"local\" href=\"#H10605386\">",
"     'Clinical trials'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15770082\">",
"    <span class=\"h3\">",
"     Choice of therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;For patients eligible for hematopoietic cell transplantation (HCT), we suggest the use of high dose",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?21/54/22376?source=see_link\">",
"     melphalan",
"    </a>",
"    followed by autologous HCT, rather than chemotherapy alone, provided that the center has adequate expertise in performing the procedure in patients with AL amyloidosis (",
"    <a class=\"graphic graphic_algorithm graphicRef88825 \" href=\"mobipreview.htm?42/10/43181\">",
"     algorithm 1",
"    </a>",
"    ). Studies of HCT in amyloidosis have had mixed results, and patients should be encouraged to participate in clinical trials. Retrospective studies have suggested improved overall survival and improved quality of life among patients with AL amyloidosis undergoing HCT when compared with those undergoing chemotherapy alone. While the results of a small randomized trial suggested no benefit from HCT, a number of flaws in study design question the applicability of these results to this patient population.",
"   </p>",
"   <p>",
"    The following reports are representative of the studies that have compared HCT with standard chemotherapy in patients with AL amyloidosis:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A retrospective matched-pair case-control single center study indicated that transplanted patients had better four-year overall survival rates than a control group, matched for similar eligibility characteristics, receiving chemotherapy (71 versus 41 percent, respectively) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/9/35994/abstract/15\">",
"       15",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In another retrospective review conducted at the Mayo Clinic, there were 229 patients who met Mayo criteria for HCT but did",
"      <strong>",
"       not",
"      </strong>",
"      receive HCT, and instead were treated with various combinations of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?21/54/22376?source=see_link\">",
"       melphalan",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/13/32983?source=see_link\">",
"       colchicine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/39/33399?source=see_link\">",
"       carmustine",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?1/29/1498?source=see_link\">",
"       vincristine",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/9/35994/abstract/16\">",
"       16",
"      </a>",
"      ]. Their median survival was 42 months, in excess of the expected median survival of 18 months for all patients with AL amyloidosis suggesting that patients eligible for HCT are an inherently good-risk group, and do relatively well with chemotherapy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/9/35994/abstract/17\">",
"       17",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a phase III French trial, 100 patients with AL amyloidosis were randomly assigned to receive treatment with either monthly courses of oral",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?21/54/22376?source=see_link\">",
"       melphalan",
"      </a>",
"      plus",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?33/4/33856?source=see_link\">",
"       dexamethasone",
"      </a>",
"      (melphalan 10",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      per day PO on days 1 to 4 plus dexamethasone 40",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      PO on days 1 to 4) or autologous HCT (conditioning regimen: melphalan 200",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      IV; dose reduced to 140",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      for patients &ge;65, ejection fraction &lt;30 percent, calculated creatinine clearance &lt;30",
"      <span class=\"nowrap\">",
"       mL/min,",
"      </span>",
"      or severe liver disease) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/9/35994/abstract/18\">",
"       18",
"      </a>",
"      ]. At a median follow-up of three years, the following were noted:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Median actuarial survival was significantly better in the oral chemotherapy arm (57 versus 22 months, hazard ratio 0.57; 95% CI 0.32-0.99). The hazard ratio did not change after adjustment for the main prognostic factors (eg, performance status, number of involved organs, renal insufficiency, or cardiac involvement).",
"     </li>",
"     <li>",
"      Early transplant-related mortality in this report was 24 percent, higher than the 13 to 14 percent reported by referral centers that specialize in this rare disorder [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/9/35994/abstract/10,19,20\">",
"       10,19,20",
"      </a>",
"      ]. A landmark analysis performed in patients who survived at least six months after receiving their assigned treatment showed no advantage of high-dose",
"      <span class=\"nowrap\">",
"       <a class=\"drug drug_general\" href=\"mobipreview.htm?21/54/22376?source=see_link\">",
"        melphalan",
"       </a>",
"       /autologous",
"      </span>",
"      HCT over oral melphalan plus",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?33/4/33856?source=see_link\">",
"       dexamethasone",
"      </a>",
"      .",
"     </li>",
"     <li>",
"      Subgroup analysis revealed no difference in overall survival between the two treatment arms for those with high-risk disease, while there was a nonsignificant difference in three-year overall survival between treatment arms for those with low-risk disease (58 percent for high-dose",
"      <span class=\"nowrap\">",
"       <a class=\"drug drug_general\" href=\"mobipreview.htm?21/54/22376?source=see_link\">",
"        melphalan",
"       </a>",
"       /HCT",
"      </span>",
"      versus 80 percent for oral",
"      <span class=\"nowrap\">",
"       melphalan/",
"       <a class=\"drug drug_general\" href=\"mobipreview.htm?33/4/33856?source=see_link\">",
"        dexamethasone",
"       </a>",
"       ).",
"       <br/>",
"       <br/>",
"       Although",
"      </span>",
"      this is the only randomized trial to compare HCT with conventional dose therapy to treat AL amyloidosis, there are some serious concerns regarding this study that need to be considered. The treatment-related mortality rate of 24 percent with HCT in this study is more than twice the expected rate, and may be related to the fact that over one-third of enrolled patients had poor cardiac status and involvement of three or more organs.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    With better patient selection and by using a risk-adapted approach, results with HCT may be superior to that of chemotherapy alone [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/9/35994/abstract/15,16,21-23\">",
"     15,16,21-23",
"    </a>",
"    ]. As an example, a multicenter phase II trial performed by ECOG reported a treatment-related mortality of 10 percent with a median survival that had not been reached after a median of 30.3 months [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/9/35994/abstract/24\">",
"     24",
"    </a>",
"    ]. We believe that HCT still has a role in selected patients with AL amyloidosis, but that the procedure should be done in referral centers with adequate expertise in performing the procedure for this group of patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15769190\">",
"    <span class=\"h3\">",
"     Hematopoietic cell transplantation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Autologous hematopoietic cell transplantation (HCT) allows for the delivery of myeloablative doses of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?21/54/22376?source=see_link\">",
"     melphalan",
"    </a>",
"    aimed at the underlying plasma cell dyscrasia that must be controlled to allow for regression of tissue amyloid deposits. The successful use of myeloablative chemotherapy followed by autologous HCT is consistent with the need for higher doses of chemotherapy to achieve the desired response [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/9/35994/abstract/8,9,21,25-27\">",
"     8,9,21,25-27",
"    </a>",
"    ]. Unlike in multiple myeloma, induction chemotherapy is not usually administered prior to HCT. Studies that have compared HCT with conventional chemotherapy are described above. (See",
"    <a class=\"local\" href=\"#H15770082\">",
"     'Choice of therapy'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Some patients have shown complete clinical recovery following HCT, with improvement in their quality of life [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/9/35994/abstract/28\">",
"     28",
"    </a>",
"    ]. The largest series is a highly selected group of 421 patients treated with high-dose",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?21/54/22376?source=see_link\">",
"     melphalan",
"    </a>",
"    (100 to 200",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"     )",
"    </span>",
"    followed by autologous HCT [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/9/35994/abstract/19,29\">",
"     19,29",
"    </a>",
"    ]. Major results from this study included:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The 100-day treatment-related mortality (TRM) was 11 percent, similar to that noted in other studies [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/9/35994/abstract/10,20,30\">",
"       10,20,30",
"      </a>",
"      ]. The TRM in the most recent five-year period was lower at 5.6 percent, probably reflecting better patient selection and improvements in supportive care. The overall one-year mortality was 19 percent. Median survival was 6.3 years.",
"     </li>",
"     <li>",
"      Complete response (CR) was obtained in 34 percent. Patients who attained a CR had superior median event-free (8.3 versus 2 years) and median overall (13.2 versus 5.9 years) survival.",
"     </li>",
"     <li>",
"      For the 307 patients deemed ineligible for HCT (age &gt;80, uncompensated heart failure, left ventricular ejection fraction &lt;40 percent, persisting pleural effusion, systolic pressure &lt;90 mmHg, O2 saturation on room air &lt;95 percent, or a performance status &ge;3), median survival was only four months from the time of evaluation [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/9/35994/abstract/19\">",
"       19",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Treatment-related mortality, rates of CR, and median survivals were similar in older (65 to 79 years) and younger (&lt;65 years) patients eligible for, and receiving, HCT [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/9/35994/abstract/31\">",
"       31",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A higher dose of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?21/54/22376?source=see_link\">",
"       melphalan",
"      </a>",
"      (200",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"       )",
"      </span>",
"      was associated with a higher CR rate and improved overall survival.",
"     </li>",
"     <li>",
"      Improvement in the function of at least one organ system (eg, hepatic, renal, cardiac, neurologic) occurred in 79 percent of those achieving a CR, and in 39 percent of those who did not achieve CR status.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Renal responses to dose-intensive",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?21/54/22376?source=see_link\">",
"     melphalan",
"    </a>",
"    and autologous HCT have also been described and are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/29/13784?source=see_link&amp;anchor=H10#H10\">",
"     \"Renal amyloidosis\", section on 'Response to therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Following HCT, we consider further therapy based on the extent of disease and degree of response achieved. This is discussed in more detail below. (See",
"    <a class=\"local\" href=\"#H95727747\">",
"     'Modification of therapy based on degree of initial response'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15769212\">",
"    <span class=\"h3\">",
"     Melphalan dosing",
"    </span>",
"    &nbsp;&mdash;&nbsp;The standard preparative (conditioning) regimen used for HCT in AL amyloid is",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?21/54/22376?source=see_link\">",
"     melphalan",
"    </a>",
"    (MEL) at a dose of 200",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"     .",
"    </span>",
"    Even in transplant eligible patients, the treatment-related mortality (TRM) is higher in AL amyloidosis than in myeloma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/9/35994/abstract/32\">",
"     32",
"    </a>",
"    ]. Although a risk-adapted dosing strategy using lower conditioning doses of MEL has been evaluated in an attempt to reduce TRM, this has been associated with lower efficacy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/9/35994/abstract/19,21,27,33\">",
"     19,21,27,33",
"    </a>",
"    ]. Patients who are considered to be ineligible to receive a melphalan dose of 200",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    are probably best treated with non-transplant approaches. One exception is patients who are on chronic stable dialysis and are being considered for transplantation in whom a reduced MEL dose of 140",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    is used. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/47/31482?source=see_link&amp;anchor=H8#H8\">",
"     \"Autologous hematopoietic cell transplantation in multiple myeloma\", section on 'Preparative chemotherapy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15767052\">",
"    <span class=\"h2\">",
"     Patients not eligible for transplant",
"    </span>",
"    &nbsp;&mdash;&nbsp;While high dose",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?21/54/22376?source=see_link\">",
"     melphalan",
"    </a>",
"    followed by autologous hematopoietic cell rescue is the preferred therapy for patients with AL amyloidosis, greater than 80 percent of newly diagnosed patients will be ineligible for transplant due to advanced age, renal insufficiency, advanced heart failure, or multiorgan involvement. There is controversy regarding the preferred management of these patients, and participation in clinical trials should be encouraged. For those who are not eligible for a clinical trial, or who do not wish to participate in a clinical trial, we suggest the combination of melphalan plus",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    (",
"    <a class=\"graphic graphic_algorithm graphicRef88826 \" href=\"mobipreview.htm?11/29/11742\">",
"     algorithm 2",
"    </a>",
"    ). This preference is largely based upon its low toxicity profile, oral administration, and known efficacy. While early reports of trials incorporating novel agents demonstrate encouraging response rates, we generally reserve these agents for patients who do not respond to or relapse following initial treatment with melphalan plus dexamethasone. (See",
"    <a class=\"local\" href=\"#H10605386\">",
"     'Clinical trials'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    For many years,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?21/54/22376?source=see_link\">",
"     melphalan",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    was the standard treatment of patients with AL amyloidosis who were not candidates for HT [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/9/35994/abstract/17,34-39\">",
"     17,34-39",
"    </a>",
"    ]. The melphalan-prednisone regimen has largely been replaced by the melphalan-",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    regimen described below as front-line therapy in these patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Melphalan and dexamethasone",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?21/54/22376?source=see_link\">",
"     Melphalan",
"    </a>",
"    (0.22",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day PO on days 1 through 4 every 28 days) combined with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    (40",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    PO on days 1 through 4 every 28 days) is considered a standard regimen for patients with AL amyloidosis not candidates for HCT. This regimen is well tolerated with cytopenias being the most common dose-limiting toxicity. Approximately 60 percent of patients will demonstrate an at least partial hematologic response. A hematologic response is required for functional improvement of involved organs (organ response). While this is currently the preferred treatment option in patients who are not candidates for HCT, response rates are much lower in patients with advanced cardiac involvement [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/9/35994/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In one study, 46 patients with AL amyloid who did not meet criteria for HCT because of severe organ damage were treated with this regimen [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/9/35994/abstract/40\">",
"     40",
"    </a>",
"    ]. Prophylactic",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?25/62/26601?source=see_link\">",
"     omeprazole",
"    </a>",
"    (20",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    PO),",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/45/35536?source=see_link\">",
"     ciprofloxacin",
"    </a>",
"    (250 mg PO twice per day), and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/15/20730?source=see_link\">",
"     itraconazole",
"    </a>",
"    (100",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    PO), were also given for the first 10 days of each cycle. Treatment was continued for up to nine courses. The following findings were noted [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/9/35994/abstract/40\">",
"     40",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Complete and overall response rates were noted in 33 and 67 percent of the patients, respectively, following a median of four treatment courses (4.5 months).",
"     </li>",
"     <li>",
"      Seventy-one percent of the 31 responding patients (ie, monoclonal protein decreased by at least 50 percent), achieved significant functional improvement of involved organs. No functional improvement was noted in the 15 patients not responding to treatment.",
"     </li>",
"     <li>",
"      At a median follow-up of five years, median progression-free and overall survivals were 3.8 and 5.1 years, respectively [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/9/35994/abstract/41\">",
"       41",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Complete remissions were durable, being maintained for at least three years in 70 percent of patients. In relapsing patients, the amyloid clone remained sensitive to this regimen, and complete remission could be restored by repeat treatment [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/9/35994/abstract/41\">",
"       41",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Other studies have demonstrated inferior results, which are thought to be at least partially explained by a higher incidence of cardiac involvement in the patient populations:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      A study of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?21/54/22376?source=see_link\">",
"       melphalan",
"      </a>",
"      plus",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?33/4/33856?source=see_link\">",
"       dexamethasone",
"      </a>",
"      in 40 consecutive patients with AL amyloid and symptomatic cardiac involvement who did not meet criteria for HCT, the hematologic response rate was 58 percent with 13 percent complete responses [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/9/35994/abstract/42\">",
"       42",
"      </a>",
"      ]. Median survival was 10.5 months; baseline predictors of survival included gender, troponin I, and interventricular septal thickness.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      In another study, 61 patients with advanced AL amyloid who were not eligible for HCT were treated with intravenous",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?21/54/22376?source=see_link\">",
"       melphalan",
"      </a>",
"      (16",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      on day 1) and oral",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?33/4/33856?source=see_link\">",
"       dexamethasone",
"      </a>",
"      (40",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      on days 1 to 4), in 28-day cycles [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/9/35994/abstract/43\">",
"       43",
"      </a>",
"      ]. In this study, 92 percent of patients had involvement of two or more organs and 82 percent were NYHA Class III or IV (",
"      <a class=\"graphic graphic_table graphicRef52683 \" href=\"mobipreview.htm?3/2/3117\">",
"       table 2",
"      </a>",
"      ). Estimated median overall survival was 17.5 months, and 28 percent died before the third cycle of chemotherapy was completed. Adverse prognostic factors for overall survival included elevated cardiac troponin T and NT-ProBNP plasma levels, and a poor Karnofsky index before the start of treatment.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Together, these studies demonstrate that",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?21/54/22376?source=see_link\">",
"     melphalan",
"    </a>",
"    plus",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    is an active combination for patients with AL amyloidosis. Despite this, better treatments are needed and patients, especially those with cardiac involvement, should be encouraged to participate in clinical trials. Our approach is to assess response closely and switch therapy if an optimal response is not achieved. Patients who are at high risk for complications due to Mayo Stage III cardiac involvement (cardiac troponin &gt;0.035",
"    <span class=\"nowrap\">",
"     microg/L",
"    </span>",
"    and NT-proBNP &gt;332",
"    <span class=\"nowrap\">",
"     ng/L)",
"    </span>",
"    are switched to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/63/11257?source=see_link\">",
"     bortezomib",
"    </a>",
"    -based therapies if they fail to attain at least a partial response by six weeks or a very good partial response by three months. Patients who are Stage I or II are switched to bortezomib-based regimens if they fail to attain at least a partial response by three months or a very good partial response by six months. (See",
"    <a class=\"local\" href=\"#H15770350\">",
"     'Response assessment'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H865232\">",
"    <span class=\"h3\">",
"     Bortezomib-based regimens",
"    </span>",
"    &nbsp;&mdash;&nbsp;Studies have investigated the use of proteosome inhibitors (eg,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/63/11257?source=see_link\">",
"     bortezomib",
"    </a>",
"    ) in combination with other agents for patients with newly diagnosed or",
"    <span class=\"nowrap\">",
"     relapsed/refractory",
"    </span>",
"    AL amyloidosis. Randomized trials comparing these regimens to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?21/54/22376?source=see_link\">",
"     melphalan",
"    </a>",
"    plus",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    in patients with newly diagnosed AL amyloidosis are ongoing.",
"   </p>",
"   <p>",
"    Regimens containing the proteosome inhibitor",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/63/11257?source=see_link\">",
"     bortezomib",
"    </a>",
"    have demonstrated promise with rapid responses seen in a majority of patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/9/35994/abstract/44,45\">",
"     44,45",
"    </a>",
"    ]. As examples:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      A single center retrospective series of 43 patients with AL amyloidosis treated with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?10/63/11257?source=see_link\">",
"       bortezomib",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?33/4/33856?source=see_link\">",
"       dexamethasone",
"      </a>",
"      (CyBorD) reported an overall hematologic response rate of 81 percent (42 percent complete) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/9/35994/abstract/46\">",
"       46",
"      </a>",
"      ]. After a median follow-up of 14 months, the estimated two-year progression-free survival was 67 percent and 41 percent for newly diagnosed and relapsed patients, respectively. Prior to treatment, 74 percent had cardiac involvement (46 percent Mayo Cardiac Stage III). Three patients proceeded with HCT. Thirty percent of patients developed peripheral neuropathy, which resulted in treatment discontinuation in 14 percent.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      In another retrospective analysis of 17 patients with AL amyloidosis treated with another dosing variant of CyBorD, 16 patients demonstrated a hematologic response (12 complete) with a median time to response of two months [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/9/35994/abstract/47\">",
"       47",
"      </a>",
"      ]. Prior to treatment, 10 patients had symptomatic cardiac involvement and 14 patients had two or more organs involved. Three patients became eligible for HCT. Toxicities included mild cytopenias, mild to moderate peripheral neuropathy (two patients), and infections (three patients).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Randomized trials are needed to determine whether regimens incorporating novel agents will result in a survival benefit. An ongoing randomized trial by the Eastern Cooperative Oncology Group is comparing",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?21/54/22376?source=see_link\">",
"     melphalan",
"    </a>",
"    plus",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    versus melphalan, dexamethasone plus",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/63/11257?source=see_link\">",
"     bortezomib",
"    </a>",
"    . A similar trial is also ongoing in Europe. When a bortezomib-based regimen is used, the suggested regimen consists of subcutaneous bortezomib 1.3",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    once a week, oral",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    500 mg (total dose) once a week, and oral dexamethasone 40 mg once a week. Depending upon the degree of cytopenias and other side effects, an alternative is to administer these agents for three consecutive weeks followed by a one-week break before proceeding with subsequent cycles.",
"   </p>",
"   <p>",
"    The use of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/63/11257?source=see_link\">",
"     bortezomib",
"    </a>",
"    as well as other agents such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/25/16793?source=see_link\">",
"     lenalidomide",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/62/29673?source=see_link\">",
"     thalidomide",
"    </a>",
"    in relapsed or refractory disease is discussed in more detail below. (See",
"    <a class=\"local\" href=\"#H21\">",
"     'Relapsed or refractory disease'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15770350\">",
"    <span class=\"h1\">",
"     RESPONSE ASSESSMENT",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23381668\">",
"    <span class=\"h2\">",
"     Measuring response",
"    </span>",
"    &nbsp;&mdash;&nbsp;Three months following the completion of planned therapy (or sooner if the outcome is unfavorable), the response to treatment should be documented by history, physical examination, laboratory studies (serum free light chain assay, NT-proBNP, 24-hour urinary protein and creatinine clearance, electrophoresis of the serum and urine, immunoelectrophoresis of the serum and urine, alkaline phosphatase), and other diagnostic studies (echocardiogram, radiographic measurement of the liver, EMG, nerve conduction studies).",
"   </p>",
"   <p>",
"    Using information gathered from this evaluation, hematologic and organ response is determined by the criteria validated by the Roundtable on Clinical Research in Immunoglobulin Light-chain Amyloidosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/9/35994/abstract/2,48,49\">",
"     2,48,49",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Hematologic response:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Complete response (CR) &mdash; Normalization of the FLC levels and ratio, negative serum and urine immunofixation",
"     </li>",
"     <li>",
"      Very good partial response &mdash; Reduction in the difference between involved FLC and uninvolved FLC (dFLC) to &lt;40",
"      <span class=\"nowrap\">",
"       mg/L",
"      </span>",
"     </li>",
"     <li>",
"      Partial response (PR) &mdash; A greater than 50 percent reduction in the dFLC",
"     </li>",
"     <li>",
"      No response &mdash; Less than a PR",
"     </li>",
"     <li>",
"      Progression &mdash; Free light chain increase of 50 percent to &gt;100",
"      <span class=\"nowrap\">",
"       mg/L.",
"      </span>",
"      If patient achieved a CR previously, any detectable M protein or abnormal FLC ratio (light chain must be double). If patient achieved a PR previously, 50 percent increase in serum M protein to &gt;0.5",
"      <span class=\"nowrap\">",
"       g/dL",
"      </span>",
"      or 50 percent increase in urine M protein to &gt;200",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      (a visible peak must be present).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Organ response:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Cardiac response &mdash; NT-proBNP response (&gt;30 percent and &gt;300",
"      <span class=\"nowrap\">",
"       ng/L",
"      </span>",
"      decrease in patients with baseline NT-proBNP &ge;650",
"      <span class=\"nowrap\">",
"       ng/L)",
"      </span>",
"      or NYHA class response (&ge;2 class decrease in subjects with baseline NYHA class 3 or 4).",
"     </li>",
"     <li>",
"      Cardiac progression &mdash; NT-proBNP progression (&gt;30 percent and &gt;300",
"      <span class=\"nowrap\">",
"       ng/L",
"      </span>",
"      increase) or cardiac troponin progression (&ge;33 percent increase) or ejection fraction progression (&ge;10 percent decrease).",
"     </li>",
"     <li>",
"      Kidney response &mdash; 50 percent decrease (at least 0.5",
"      <span class=\"nowrap\">",
"       g/day)",
"      </span>",
"      of 24-hour urine protein (urine protein must be &gt;0.5",
"      <span class=\"nowrap\">",
"       g/day",
"      </span>",
"      pretreatment). Creatinine and creatinine clearance must not worsen by 25 percent over baseline.",
"     </li>",
"     <li>",
"      Kidney progression &mdash; 50 percent increase (at least 1",
"      <span class=\"nowrap\">",
"       g/day)",
"      </span>",
"      of 24-hour urine protein to",
"      <span class=\"nowrap\">",
"       &gt;1g/day",
"      </span>",
"      or 25 percent worsening of serum creatinine or creatinine clearance.",
"     </li>",
"     <li>",
"      Liver response &mdash; 50 percent decrease in abnormal alkaline phosphatase value. Decrease in liver size radiographically at least 2 cm.",
"     </li>",
"     <li>",
"      Liver progression &mdash; 50 percent increase of alkaline phosphatase above the lowest value.",
"     </li>",
"     <li>",
"      Peripheral nervous system response &mdash; Improvement in electromyogram nerve conduction velocity.",
"     </li>",
"     <li>",
"      Peripheral nervous system progression &mdash; Progressive neuropathy by electromyography or nerve conduction velocity.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Response to treatment correlates with overall survival (OS) (",
"    <a class=\"graphic graphic_figure graphicRef86503 \" href=\"mobipreview.htm?43/44/44750\">",
"     figure 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef86505 \" href=\"mobipreview.htm?34/49/35614\">",
"     figure 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/9/35994/abstract/48,49\">",
"     48,49",
"    </a>",
"    ]. In a study from the Mayo Clinic, the median OS was superior in patients who achieved a 90 percent decrease in FLC levels [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/9/35994/abstract/50\">",
"     50",
"    </a>",
"    ]. This level of reduction was the best predictor of survival in a regression analysis and is now considered the goal of therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H95727747\">",
"    <span class=\"h2\">",
"     Modification of therapy based on degree of initial response",
"    </span>",
"    &nbsp;&mdash;&nbsp;Any patient who does not achieve a hematologic partial response (PR) should be considered to have refractory disease and proceed with further therapy. Similarly, any patient who experiences organ progression should also proceed with further therapy. (See",
"    <a class=\"local\" href=\"#H21\">",
"     'Relapsed or refractory disease'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    We also consider further therapy or a change in therapy based on the extent of disease and degree of response achieved with initial treatment as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For patients with Mayo Stage III cardiac involvement (cardiac troponin &gt;0.035",
"      <span class=\"nowrap\">",
"       mcg/L",
"      </span>",
"      and NT-proBNP &gt;332",
"      <span class=\"nowrap\">",
"       ng/L)",
"      </span>",
"      who undergo HCT, we suggest",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?10/63/11257?source=see_link\">",
"       bortezomib",
"      </a>",
"      -based therapy if they fail to attain a very good partial response by day 100. (See",
"      <a class=\"local\" href=\"#H863020\">",
"       'Bortezomib-based regimens'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      For patients with Mayo Stage I or II disease who undergo HCT, we suggest",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?10/63/11257?source=see_link\">",
"       bortezomib",
"      </a>",
"      -based regimens if they fail to attain at least a partial response by day 100.",
"     </li>",
"     <li>",
"      For patients with Mayo Stage III cardiac involvement who do not undergo HCT, a treatment change is suggested if they fail to attain at least a partial response by six weeks or a very good partial response by three months; if the patient was originally treated with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?21/54/22376?source=see_link\">",
"       melphalan",
"      </a>",
"      plus",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?33/4/33856?source=see_link\">",
"       dexamethasone",
"      </a>",
"      , the treatment would be changed to a",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?10/63/11257?source=see_link\">",
"       bortezomib",
"      </a>",
"      -based regimen, and vice versa.",
"     </li>",
"     <li>",
"      For patients with Mayo Stage I or II disease who do not undergo HCT, a treatment change is suggested if they fail to attain at least a partial response by three months or a very good partial response by six months.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23381716\">",
"    <span class=\"h2\">",
"     Monitoring disease status over time",
"    </span>",
"    &nbsp;&mdash;&nbsp;Since therapeutic decisions are made based on extent of response in AL amyloidosis, patients need to be followed regularly with appropriate tests to monitor and assess hematologic and organ response. We follow patients monthly for the first year and while on active therapy. At these monthly visits, we routinely perform serum protein electrophoresis and serum free light chain assay. For organ response, the tests depend on the type or existing organ involvement and any new suspected organ involvement based on clinical features, and include serum troponin, NT-ProBNP, creatinine, 24-hour urine protein electrophoresis, liver function tests, electrocardiography, and echocardiography. The frequency of the tests used to assess organ response varies according to the clinical condition, but is usually every three months.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     RELAPSED OR REFRACTORY DISEASE",
"    </span>",
"    &nbsp;&mdash;&nbsp;For patients who relapse after",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?21/54/22376?source=see_link\">",
"     melphalan",
"    </a>",
"    -",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    or HCT, treatment options include",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/63/11257?source=see_link\">",
"     bortezomib",
"    </a>",
"    -based regimens and immunomodulatory-based regimens [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/9/35994/abstract/45,51-53\">",
"     45,51-53",
"    </a>",
"    ]. There are no good data to determine which of these regimens will be of most benefit; the choice will be dictated by patient and physician preferences, expected toxicity, drug availability, and insurance coverage.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H863020\">",
"    <span class=\"h2\">",
"     Bortezomib-based regimens",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/63/11257?source=see_link\">",
"     Bortezomib",
"    </a>",
"    has significant activity in AL amyloidosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/9/35994/abstract/51,54\">",
"     51,54",
"    </a>",
"    ]. Retrospective, phase I and phase II trials have demonstrated an overall response rate of 70 to 80 percent with complete responses in 25 to 40 percent of patients. Expected toxicities include cytopenias, gastrointestinal distress, and peripheral neuropathy. Treatment with bortezomib has not been compared with other therapies in a randomized fashion. A phase III study comparing",
"    <span class=\"nowrap\">",
"     bortezomib/",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?21/54/22376?source=see_link\">",
"      melphalan",
"     </a>",
"     /",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?33/4/33856?source=see_link\">",
"      dexamethasone",
"     </a>",
"    </span>",
"    with",
"    <span class=\"nowrap\">",
"     melphalan/dexamethasone",
"    </span>",
"    is in progress.",
"   </p>",
"   <p>",
"    The following studies have investigated the use of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/63/11257?source=see_link\">",
"     bortezomib",
"    </a>",
"    in this population:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      A retrospective analysis evaluated the use of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?10/63/11257?source=see_link\">",
"       bortezomib",
"      </a>",
"      (1.3",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      on days 1, 4, 8, and 11 every 21 days) with or without",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?33/4/33856?source=see_link\">",
"       dexamethasone",
"      </a>",
"      (40",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      on days 1 through 4 every 21 days) in 94 patients with AL amyloidosis [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/9/35994/abstract/51\">",
"       51",
"      </a>",
"      ]. Often, patients with poor performance status received reduced doses. Results included:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Complete and overall response rates were 47 and 81 percent, respectively, for the 18 previously untreated patients, and 20 and 68 percent, respectively, for the 76 previously treated patients.",
"     </li>",
"     <li>",
"      The most common nonhematologic toxicities were peripheral sensory neuropathy with or without neuropathic pain, exacerbation of orthostatic hypotension, peripheral edema, and constipation or diarrhea.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      A nonrandomized phase II trial evaluated single-agent",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?10/63/11257?source=see_link\">",
"       bortezomib",
"      </a>",
"      administered either once-weekly (1.6",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      days 1, 8, 15, 22 of 35-day cycles) or twice-weekly (1.3",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      days 1, 4, 8, and 11 of 21-day cycles) to 70 patients with relapsed AL amyloidosis [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/9/35994/abstract/44\">",
"       44",
"      </a>",
"      ]. Patients with advanced cardiac disease (eg, NYHA class III of IV heart disease) were excluded. Results included:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Patients receiving once-weekly",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?10/63/11257?source=see_link\">",
"       bortezomib",
"      </a>",
"      had a hematologic response rate of 69 percent with 38 percent complete responses. The median time to response was 2.1 months. Responses lasted at least one year in 79 percent. Survival at 12 months was 94 percent. Grade",
"      <span class=\"nowrap\">",
"       3/4/5",
"      </span>",
"      toxicities were seen in 53 percent of patients.",
"     </li>",
"     <li>",
"      Patients receiving twice-weekly",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?10/63/11257?source=see_link\">",
"       bortezomib",
"      </a>",
"      had a hematologic response rate of 67 percent with 24 percent complete responses. The median time to response was 0.7 months. Responses lasted at least one year in 76 percent. Survival at 12 months was 84 percent. Grade",
"      <span class=\"nowrap\">",
"       3/4/5",
"      </span>",
"      toxicities were seen in 79 percent of patients.",
"     </li>",
"     <li>",
"      The most common severe (grade",
"      <span class=\"nowrap\">",
"       3/4)",
"      </span>",
"      toxicities were thrombocytopenia, fatigue, vomiting, diarrhea, syncope, and pneumonia. Less severe but common nonhematologic toxicities included peripheral neuropathy, infections, cardiac disorders, orthostatic hypotension, cough, and pruritus. Two patients died of potentially treatment-related interstitial lung disease and acute cardiac failure within 30 days of administration of twice-weekly",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?10/63/11257?source=see_link\">",
"       bortezomib",
"      </a>",
"      .",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/63/11257?source=see_link\">",
"     Bortezomib",
"    </a>",
"    has also been administered in combination with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    (CyBorD) with rapid responses in patients with and without cardiac involvement. (See",
"    <a class=\"local\" href=\"#H865232\">",
"     'Bortezomib-based regimens'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Together, these data demonstrate activity of both once-weekly and twice-weekly",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/63/11257?source=see_link\">",
"     bortezomib",
"    </a>",
"    in relapsed AL amyloidosis. While the response time appears slower with once-weekly administration, the toxicities are markedly less. In clinical practice, as with myeloma, a reduced dose of bortezomib administered once weekly may reduce the risk of neuropathy and neuropathic pain.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H862793\">",
"    <span class=\"h2\">",
"     Immunomodulatory derivatives",
"    </span>",
"    &nbsp;&mdash;&nbsp;The immunomodulatory derivatives,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/62/29673?source=see_link\">",
"     thalidomide",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/25/16793?source=see_link\">",
"     lenalidomide",
"    </a>",
"    , have demonstrated efficacy among patients with relapsed AL amyloidosis, but have not been compared with other regimens in this setting. Of importance, the dosing used is lower than that used in patients with multiple myeloma. In general, lenalidomide-based regimens are preferred to thalidomide-based regimens.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H865576\">",
"    <span class=\"h3\">",
"     Lenalidomide-based regimens",
"    </span>",
"    &nbsp;&mdash;&nbsp;The combination of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/25/16793?source=see_link\">",
"     lenalidomide",
"    </a>",
"    (initial dose 25",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    PO for 21 days of a 28-day cycle) plus low dose",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    (40 mg once per week) with or without",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    is a reasonable option for patients with relapsed AL amyloidosis. Of importance, the initial dose of lenalidomide as used in multiple myeloma (ie, 25",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    was poorly tolerated in those with AL amyloidosis. A lower dose, in the range of 5 to 15",
"    <span class=\"nowrap\">",
"     mg/day,",
"    </span>",
"    has been better tolerated [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/9/35994/abstract/55\">",
"     55",
"    </a>",
"    ]. The combination of lenalidomide plus dexamethasone is associated with an increased risk of thrombosis and therefore requires thromboprophylaxis. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/57/29594?source=see_link&amp;anchor=H10#H10\">",
"     \"Thrombotic complications following treatment of multiple myeloma with thalidomide and its analogues\", section on 'Lenalidomide'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Two studies have evaluated the efficacy of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?16/25/16793?source=see_link\">",
"       lenalidomide",
"      </a>",
"      (initial dose 25",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      PO for 21 days of a 28-day cycle) with or without",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?33/4/33856?source=see_link\">",
"       dexamethasone",
"      </a>",
"      in patients with AL amyloid [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/9/35994/abstract/56,57\">",
"       56,57",
"      </a>",
"      ]. Overall response rates for subjects taking both medications were 67 to 75 percent, with complete responses in 16 percent [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/9/35994/abstract/55\">",
"       55",
"      </a>",
"      ]. In one of the studies, organ responses were seen in 42 percent of patients who received at least three cycles of therapy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/9/35994/abstract/56\">",
"       56",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A phase",
"      <span class=\"nowrap\">",
"       I/II",
"      </span>",
"      dose-escalation study in 26 patients with de novo AL amyloidosis reported complete hematologic responses in 42 percent of patients when",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?16/25/16793?source=see_link\">",
"       lenalidomide",
"      </a>",
"      15 mg per day was combined with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?21/54/22376?source=see_link\">",
"       melphalan",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?33/4/33856?source=see_link\">",
"       dexamethasone",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/9/35994/abstract/58\">",
"       58",
"      </a>",
"      ]. At a median follow-up of 19 months, the estimated rates of overall and event-free survival at two years were 81 and 54 percent, respectively.",
"     </li>",
"     <li>",
"      A phase",
"      <span class=\"nowrap\">",
"       I/II",
"      </span>",
"      dose escalation study in 37 patients with AL amyloidosis reported hematologic responses in 20 patients (three complete) following treatment with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?16/25/16793?source=see_link\">",
"       lenalidomide",
"      </a>",
"      (15 mg per day on days 1 to 21),",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      (100 mg per day on days 1 to 10), and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?33/4/33856?source=see_link\">",
"       dexamethasone",
"      </a>",
"      (20 mg on days 1 to 4), administered every 28 days [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/9/35994/abstract/59\">",
"       59",
"      </a>",
"      ]. Median time to progression was 10 months and the estimated two-year survival rate was 41 percent.",
"     </li>",
"     <li>",
"      In a phase II trial, 35 patients with AL amyloidosis were treated with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?16/25/16793?source=see_link\">",
"       lenalidomide",
"      </a>",
"      (15 mg daily on days 1 through 21), oral",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      (300",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      on days 1, 8, and 15), and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?33/4/33856?source=see_link\">",
"       dexamethasone",
"      </a>",
"      (40 mg on days 1, 8, 15, and 22) administered every four weeks [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/9/35994/abstract/60\">",
"       60",
"      </a>",
"      ]. For those who continued on therapy long-term, cyclophosphamide was continued for a maximum of 12 cycles, while lenalidomide treatment was limited to two years. Cardiac stage III disease and involvement of at least three organs was seen in 43 and 28 percent of patients, respectively. Hematologic responses were seen in 77 percent and organ responses were seen in 29 percent. The median time to organ response was 4.1 months (range 0.9 to 12.2 months). Median survival was 37.8 months and one- and two-year survival rates were 71 and 59 percent, respectively. The most common toxicities were cytopenias, fatigue, edema, gastrointestinal, and rash.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Together, these studies suggest that",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/25/16793?source=see_link\">",
"     lenalidomide",
"    </a>",
"    -based regimens are active in patients with relapsed AL amyloidosis and associated with acceptable toxicity. The low levels of neurotoxicity make them particularly attractive for patients with baseline neuropathy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H865651\">",
"    <span class=\"h3\">",
"     Thalidomide-based regimens",
"    </span>",
"    &nbsp;&mdash;&nbsp;The combination of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/62/29673?source=see_link\">",
"     thalidomide",
"    </a>",
"    plus low dose",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    (40 mg once per week) with or without",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    is an option for patients with relapsed AL amyloidosis. Of importance, higher doses of thalidomide, such as those used in multiple myeloma are poorly tolerated in patients with AL amyloid [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/9/35994/abstract/61,62\">",
"     61,62",
"    </a>",
"    ]. In order to minimize toxicities when using thalidomide in patients with amyloidosis, therapy can be initiated at low doses of thalidomide (50 to 100",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    and increased slowly to a maximum of 200",
"    <span class=\"nowrap\">",
"     mg/day,",
"    </span>",
"    as tolerated. The combination of thalidomide plus dexamethasone is associated with an increased risk of thrombosis and therefore requires thromboprophylaxis. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/57/29594?source=see_link&amp;anchor=H5#H5\">",
"     \"Thrombotic complications following treatment of multiple myeloma with thalidomide and its analogues\", section on 'Thalidomide plus dexamethasone'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      In one trial, 31 patients with relapsed or refractory AL amyloidosis were treated with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?28/62/29673?source=see_link\">",
"       thalidomide",
"      </a>",
"      (initial dose 100",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      by mouth at night, with escalation to 400",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      if tolerated) plus",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?33/4/33856?source=see_link\">",
"       dexamethasone",
"      </a>",
"      (20",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      by mouth on days 1 through 4 every 21 days) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/9/35994/abstract/63\">",
"       63",
"      </a>",
"      ]. Complete and overall responses were noted in 19 and 48 percent, respectively. Treatment-related toxicity was seen in 65 percent; symptomatic bradycardia was a common adverse reaction (25 percent).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      In another",
"      <span class=\"nowrap\">",
"       safety/efficacy",
"      </span>",
"      trial, 75 patients with AL amyloidosis received the combination of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?28/62/29673?source=see_link\">",
"       thalidomide",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?33/4/33856?source=see_link\">",
"       dexamethasone",
"      </a>",
"      (CTD regimen) using one of two different regimens [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/9/35994/abstract/64\">",
"       64",
"      </a>",
"      ]:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      CTD regimen &mdash; 21-day cycles including",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      (500 mg PO once per week),",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?28/62/29673?source=see_link\">",
"       thalidomide",
"      </a>",
"      (initial dose 100",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      PO continuously, increased after four weeks to 200",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      if tolerated), and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?33/4/33856?source=see_link\">",
"       dexamethasone",
"      </a>",
"      (40",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      PO on days 1 to 4 and 9 to 12 of each cycle).",
"     </li>",
"     <li>",
"      Attenuated CTD regimen (aCTD, used in those &gt;70 years of age, or with heart failure or significant fluid overload) &mdash; 28-day cycles including",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      (500 mg PO on days 1, 8, and 15),",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?28/62/29673?source=see_link\">",
"       thalidomide",
"      </a>",
"      (starting dose 50",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      PO, increased by 50",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      at four-week intervals as tolerated), and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?33/4/33856?source=see_link\">",
"       dexamethasone",
"      </a>",
"      (20",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      PO on days 1 to 4 and 15 to 18).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Complete responses were seen in 21 percent; overall response rates for those receiving aCTD or CTD were not significantly different (61 versus 76 percent, respectively). Although organ responses were seen in some patients, no patient with end-stage renal failure became dialysis independent, and no objective cardiac responses were observed.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Estimated three-year survivals for those achieving CR, PR, or no response were 100, 82, and zero (median survival 17 months), respectively. Grade 1 fatigue and constipation were noted in all patients, toxicities of at least grade 2 were noted in 52 percent, and toxicity of grade 3 or greater needing dose reduction or discontinuation was seen in 32 percent.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Together, these studies demonstrate that",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/62/29673?source=see_link\">",
"     thalidomide",
"    </a>",
"    has activity in patients with relapsed AL amyloidosis. Despite this, other regimens are generally preferred, when available, due to the high rate of toxicity with thalidomide.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H863317\">",
"    <span class=\"h1\">",
"     PROGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The prognosis of AL amyloidosis varies considerably depending on the nature, number, and extent of organ involvement. For example, AL amyloidosis has a poor long-term prognosis when detected at an advanced stage [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/9/35994/abstract/17,34,36,65,66\">",
"     17,34,36,65,66",
"    </a>",
"    ]. Median survival may be as short as four to six months, with cardiac or hepatic failure, and infection being the major causes of death. In one series, heart failure accounted for 51 percent of deaths, with renal failure and infection accounting for 15 percent each [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/9/35994/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    On the other hand, patients with limited organ involvement can expect a median survival in excess of five years with current therapy as discussed below. Some of the key prognostic factors that affect the outcome of AL amyloidosis include the presence and severity of cardiac involvement [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/9/35994/abstract/67,68\">",
"     67,68",
"    </a>",
"    ] and the presence of concurrent myeloma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/9/35994/abstract/69\">",
"     69",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H863345\">",
"    <span class=\"h2\">",
"     Prognostic models",
"    </span>",
"    &nbsp;&mdash;&nbsp;While multiple prognostic models have been proposed for patients with amyloidosis, three simple models that incorporate N-terminal pro-brain natriuretic peptide (NT-pro-BNP) and cardiac troponin are easily applied at the point of care (",
"    <a class=\"graphic graphic_table graphicRef83744 \" href=\"mobipreview.htm?22/57/23451\">",
"     table 3",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef83742 \" href=\"mobipreview.htm?5/35/5693\">",
"     table 4",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      <strong>",
"       NT-pro-BNP plus cardiac troponin T (Mayo Stage)",
"      </strong>",
"      &mdash; Clinical information from 242 patients with newly diagnosed AL amyloidosis seen at a single institution was used to develop a prognostic model using cardiac biomarkers [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/9/35994/abstract/70\">",
"       70",
"      </a>",
"      ]. Patients were classified as having stage I, II, or III disease based upon whether they had none, one, or both of the following findings: NT-pro-BNP &ge;332",
"      <span class=\"nowrap\">",
"       ng/L",
"      </span>",
"      and cardiac troponin T &ge;0.035",
"      <span class=\"nowrap\">",
"       microg/L.",
"      </span>",
"      Median survivals for those not undergoing hematopoietic cell transplantation with stage I, II, and III amyloid were 26 months, 11 months, and 4 months, respectively (",
"      <a class=\"graphic graphic_table graphicRef83742 \" href=\"mobipreview.htm?5/35/5693\">",
"       table 4",
"      </a>",
"      ). Another study reported that this model predicted prognosis in patients with AL amyloid undergoing hematopoietic cell transplantation (HCT), with stage III patients having a median survival of less than one year despite HCT [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/9/35994/abstract/71\">",
"       71",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      Of note, some laboratories measure cardiac troponin I instead of T. If cardiac troponin I is used instead of T, a value of &ge;0.10",
"      <span class=\"nowrap\">",
"       microg/L",
"      </span>",
"      is considered a risk factor in this model.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       NT-pro-BNP, cardiac troponin T, and serum uric acid",
"      </strong>",
"      &mdash; Another model using data from 1977 subjects with AL amyloidosis classified patients as having stage I, II, III, or IV disease based upon the identification of zero, 1, 2, or 3 of the following risk factors: NT-pro-BNP &ge;332",
"      <span class=\"nowrap\">",
"       ng/L,",
"      </span>",
"      cardiac troponin T &ge;0.035",
"      <span class=\"nowrap\">",
"       microg/L,",
"      </span>",
"      and serum uric acid &gt;8.0",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/9/35994/abstract/72\">",
"       72",
"      </a>",
"      ]. Median survival times were 37, 29, 11, and 4 months, respectively. Among the 293 patients with AL amyloidosis undergoing HCT, the median overall survival from the time of HCT was not reached at a median follow-up of 26 months (range: zero to 10 years) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/9/35994/abstract/72\">",
"       72",
"      </a>",
"      ]. Median overall survivals for those with zero or one adverse risk factors were not reached, compared with 55 and 16 months for those with two or three adverse risk factors, respectively.",
"      <br/>",
"      <br/>",
"      A modified version of this model was validated using data from a second cohort of 313 patients with AL amyloidosis from the same institution to develop an amyloid early mortality score demonstrating one-year survival rates of 88, 76, 54, and 31 percent, respectively (",
"      <a class=\"graphic graphic_table graphicRef83744 \" href=\"mobipreview.htm?22/57/23451\">",
"       table 3",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/9/35994/abstract/73\">",
"       73",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <strong>",
"       NT-pro-BNP, cardiac troponin T, and serum free light chains (Revised Mayo Stage)",
"      </strong>",
"      &mdash; Another revised model was developed using data from 810 patients with newly diagnosed AL amyloidosis seen at a single institution and validated in another 303 patients undergoing HCT and 103 patients enrolled onto different clinical trials [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/9/35994/abstract/74\">",
"       74",
"      </a>",
"      ]. Patients were classified as having stage I, II, III, or IV disease based upon the identification of zero, 1, 2, or 3 of the following risk factors: NT-pro-BNP &ge;1800",
"      <span class=\"nowrap\">",
"       ng/L,",
"      </span>",
"      cardiac troponin T &ge;0.025",
"      <span class=\"nowrap\">",
"       microg/L,",
"      </span>",
"      and a difference between involved and uninvolved serum free light chains &ge;18",
"      <span class=\"nowrap\">",
"       mg/dL.",
"      </span>",
"      Median overall survival from diagnosis was 94, 40, 14, and 6 months, respectively. For patients undergoing HCT, the four-year estimated overall survival rates were 87, 72, 56, and 46 percent, respectively, with median overall survivals of not reached, 97, 58, and 22 months (",
"      <a class=\"graphic graphic_table graphicRef83742 \" href=\"mobipreview.htm?5/35/5693\">",
"       table 4",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The Mayo Stage and Revised Mayo Stage (",
"    <a class=\"graphic graphic_table graphicRef83742 \" href=\"mobipreview.htm?5/35/5693\">",
"     table 4",
"    </a>",
"    ) are useful for assessment of prognosis and comparison of results across trials. The early mortality score is particularly useful in identifying patients at the highest risk of death in the first year following diagnosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H864230\">",
"    <span class=\"h2\">",
"     Coexisting myeloma",
"    </span>",
"    &nbsp;&mdash;&nbsp;AL amyloidosis can occur in patients with other plasma cell dyscrasias, including multiple myeloma and Waldenstr&ouml;m macroglobulinemia. When multiple myeloma and AL amyloidosis are diagnosed in the same patient, the myeloma is typically diagnosed before or around the time of the amyloid diagnosis. Less commonly, myeloma develops more than six months after the diagnosis of amyloid. Patients that have a coexisting myeloma have a worse prognosis than patients who do not. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/15/7418?source=see_link&amp;anchor=H2#H2\">",
"     \"Clinical presentation, laboratory manifestations, and diagnosis of immunoglobulin light chain (AL) amyloidosis (primary amyloidosis)\", section on 'Relation to other plasma cell disorders'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In a retrospective analysis of 147 patients with biopsy-proven primary systemic amyloidosis who also had specialized testing for determination of circulating plasma cells, 20 patients had concurrent multiple myeloma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/9/35994/abstract/69\">",
"     69",
"    </a>",
"    ]. Of the subset of patients with &ge;2 percent circulating plasma cells, 50 percent had clinical multiple myeloma, a rate significantly higher than the 12 percent incidence seen in those with fewer circulating plasma cells. Patients with both AL and myeloma had a significantly worse prognosis than those with AL alone (14 versus 32 months). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/13/35034?source=see_link&amp;anchor=H17#H17\">",
"     \"Clinical features, laboratory manifestations, and diagnosis of multiple myeloma\", section on 'Peripheral smear'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10605386\">",
"    <span class=\"h1\">",
"     CLINICAL TRIALS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Often there is no better therapy to offer a patient than enrollment onto a well-designed, scientifically valid, peer-reviewed clinical trial. Additional information and instructions for referring a patient to an appropriate research center can be obtained from the United States National Institutes of Health (",
"    <a class=\"external\" href=\"file://www.clinicaltrials.gov/\">",
"     www.clinicaltrials.gov",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Areas of interest include the use of hematopoietic cell transplantation, new combinations of available agents, the use of novel agents studied in related diseases (eg,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/33/33303?source=see_link\">",
"     pomalidomide",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/9/35994/abstract/75\">",
"     75",
"    </a>",
"    ]), and experimental agents designed to degrade or interfere with the formation of amyloid fibrils. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/53/23383?source=see_link&amp;anchor=H9#H9\">",
"     \"Treatment of secondary (AA) amyloidosis\", section on 'Investigational approaches'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h1\">",
"     TREATMENT OF LCDD OR HCDD",
"    </span>",
"    &nbsp;&mdash;&nbsp;Data on the treatment of LCDD and HCDD are limited. The therapeutic approaches are similar to those employed for patients with multiple myeloma. The goal is to control the plasma cell proliferative disorder in order to preserve renal function and improve survival, using chemotherapy and, in selected cases, autologous hematopoietic cell transplantation (HCT) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/9/35994/abstract/76-81\">",
"     76-81",
"    </a>",
"    ]. Serial free light chain assays can be used to monitor response to treatment in LCDD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/9/35994/abstract/82\">",
"     82",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?8/29/8666?source=see_link\">",
"     \"Determination of initial therapy in patients with multiple myeloma\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Retrospective observations suggest that",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?21/54/22376?source=see_link\">",
"     melphalan",
"    </a>",
"    for up to two years may stabilize or even improve renal function in LCDD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/9/35994/abstract/65,83\">",
"     65,83",
"    </a>",
"    ], but only if therapy is begun when the plasma creatinine concentration is below 4",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (352",
"    <span class=\"nowrap\">",
"     micromol/L)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/9/35994/abstract/84\">",
"     84",
"    </a>",
"    ]. Renal transplantation is associated with recurrence of LCDD in the transplanted kidney and can only be entertained if accompanied by chemotherapy or HCT to control the plasma cell proliferative disorder [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/9/35994/abstract/76,85\">",
"     76,85",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    As with AL amyloid, the prognosis of LCDD and HCDD vary considerably depending on the nature, number, and extent of organ involvement. In a study of 63 patients with LCDD, the following prognostic factors were determined [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/9/35994/abstract/86\">",
"     86",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Age and serum creatinine at presentation were the major predictive factors for the development of renal failure.",
"     </li>",
"     <li>",
"      Age, presence of coexisting multiple myeloma, and evidence of extra-renal light chain deposition were independent predictors of overall survival.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20880512\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Primary (AL) amyloidosis, light chain deposition disease (LCDD), and heavy chain deposition diseases (HCDD) are monoclonal plasma cell proliferative disorders characterized by tissue deposits of light chain or heavy chain fragments, leading to organ dysfunction. These disorders have a poor long-term prognosis, with cardiac or hepatic failure, and infection being the major causes of death. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?23/10/23722?source=see_link\">",
"       \"Clinical manifestations and diagnosis of amyloid cardiomyopathy\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?13/29/13784?source=see_link\">",
"       \"Renal amyloidosis\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?11/63/12280?source=see_link&amp;anchor=H8#H8\">",
"       \"Gastrointestinal amyloidosis\", section on 'Hepatic amyloidosis'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      To best treat patients with AL amyloidosis, the initial evaluation must confirm the diagnosis, establish the extent and sites of disease, and evaluate for comorbidities that are likely to have an impact on treatment options. (See",
"      <a class=\"local\" href=\"#H15768474\">",
"       'Pre-treatment evaluation'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Our approach to the initial management of patients with AL amyloidosis varies depending on whether patients are eligible to pursue high dose",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?21/54/22376?source=see_link\">",
"       melphalan",
"      </a>",
"      followed by autologous hematopoietic cell transplantation (HCT). Eligibility for autologous HCT in AL amyloidosis varies across countries and institutions. In general, patients with poor performance status, major comorbidities, involvement of three or more organs, and advanced cardiac amyloidosis are not considered transplant candidates. (See",
"      <a class=\"local\" href=\"#H15768578\">",
"       'Determining transplant eligibility'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      <strong>",
"       HCT eligible patients",
"      </strong>",
"      &mdash; We suggest that patients eligible for HCT be treated with high dose",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?21/54/22376?source=see_link\">",
"       melphalan",
"      </a>",
"      followed by hematopoietic stem cell rescue rather than chemotherapy, provided that HCT can be performed in referral centers with adequate expertise in the procedure for this group of patients (",
"      <a class=\"graphic graphic_algorithm graphicRef88825 \" href=\"mobipreview.htm?42/10/43181\">",
"       algorithm 1",
"      </a>",
"      ) (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). With better patient selection, and by using a risk-adapted approach, results with HCT may be superior to those obtained following chemotherapy. (See",
"      <a class=\"local\" href=\"#H15770082\">",
"       'Choice of therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <strong>",
"       Not eligible for HCT",
"      </strong>",
"      &mdash; We recommend that patients not eligible for HCT be treated with",
"      <span class=\"nowrap\">",
"       <a class=\"drug drug_general\" href=\"mobipreview.htm?21/54/22376?source=see_link\">",
"        melphalan",
"       </a>",
"       /",
"       <a class=\"drug drug_general\" href=\"mobipreview.htm?33/4/33856?source=see_link\">",
"        dexamethasone",
"       </a>",
"      </span>",
"      rather than other combinations (",
"      <a class=\"graphic graphic_algorithm graphicRef88826 \" href=\"mobipreview.htm?11/29/11742\">",
"       algorithm 2",
"      </a>",
"      ) (",
"      <a class=\"grade\" href=\"._grade_3?title=Grade 1C\">",
"       Grade 1C",
"      </a>",
"      ). Patients who are at high risk for complications due to Mayo Stage III cardiac involvement (cardiac troponin &gt;0.035",
"      <span class=\"nowrap\">",
"       mcg/L",
"      </span>",
"      and NT-proBNP &gt;332",
"      <span class=\"nowrap\">",
"       ng/L)",
"      </span>",
"      are switched to",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?10/63/11257?source=see_link\">",
"       bortezomib",
"      </a>",
"      -based therapy (eg, CyBorD) if they fail to attain at least a partial response by six weeks or a very good partial response by three months. Patients who are Stage I or II are switched to bortezomib-based regimens if they fail to attain at least a partial response by three months or a very good partial response by six months. Participation in a well-conducted research trial is always a reasonable alternative. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Melphalan and dexamethasone'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <strong>",
"       Relapsed disease",
"      </strong>",
"      &mdash; For patients with relapsed disease, the use of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?10/63/11257?source=see_link\">",
"       bortezomib",
"      </a>",
"      -based or immunomodulatory-based regimens is a reasonable approach. There are no good data to determine which of these regimens will be of most benefit; the choice will be dictated by patient and physician preferences, expected toxicity, drug availability, and insurance coverage. As an example, a bortezomib-based regimen may be preferred for patients with severe cardiac involvement while a",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?16/25/16793?source=see_link\">",
"       lenalidomide",
"      </a>",
"      -based regimen may be preferred for patients with peripheral neuropathy. (See",
"      <a class=\"local\" href=\"#H21\">",
"       'Relapsed or refractory disease'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Three months following the completion of planned therapy (or sooner if the outcome is unfavorable), the response to treatment should be documented by history, physical examination, laboratory studies (serum free light chain assay, NT-proBNP, 24-hour urinary protein and creatinine clearance, electrophoresis of the serum and urine, immunoelectrophoresis of the serum and urine, alkaline phosphatase), and other diagnostic studies (echocardiogram, radiographic measurement of the liver, EMG, nerve conduction studies). (See",
"      <a class=\"local\" href=\"#H15770350\">",
"       'Response assessment'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      We consider further therapy or a change in treatment regimen based on the extent of disease and degree of response achieved. (See",
"      <a class=\"local\" href=\"#H95727747\">",
"       'Modification of therapy based on degree of initial response'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      The prognosis of AL amyloidosis varies considerably depending on the nature, number, and extent of organ involvement. While multiple prognostic models have been proposed for patients with amyloidosis, three simple models that incorporate N-terminal pro-brain natriuretic peptide (NT-pro-BNP) and cardiac troponin are easily applied at the point of care (",
"      <a class=\"graphic graphic_table graphicRef83744 \" href=\"mobipreview.htm?22/57/23451\">",
"       table 3",
"      </a>",
"      and",
"      <a class=\"graphic graphic_table graphicRef83742 \" href=\"mobipreview.htm?5/35/5693\">",
"       table 4",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H863317\">",
"       'Prognosis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Data on the treatment of LCDD and HCDD are limited. The therapeutic approaches are similar to those employed for patients with multiple myeloma. The goal is to control the plasma cell proliferative disorder in order to preserve renal function and improve survival, using chemotherapy and, in selected cases, autologous HCT. (See",
"      <a class=\"local\" href=\"#H22\">",
"       'Treatment of LCDD or HCDD'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/9/35994/abstract/1\">",
"      Bryce AH, Ketterling RP, Gertz MA, et al. Translocation t(11;14) and survival of patients with light chain (AL) amyloidosis. Haematologica 2009; 94:380.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/9/35994/abstract/2\">",
"      Gertz MA, Comenzo R, Falk RH, et al. Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): a consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis, Tours, France, 18-22 April 2004. Am J Hematol 2005; 79:319.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/9/35994/abstract/3\">",
"      Merlini G, Seldin DC, Gertz MA. Amyloidosis: pathogenesis and new therapeutic options. J Clin Oncol 2011; 29:1924.",
"     </a>",
"    </li>",
"    <li>",
"     file://msmart.org/amyloid.pdf (Accessed on June 21, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/9/35994/abstract/5\">",
"      Gertz MA. How to manage primary amyloidosis. Leukemia 2012; 26:191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/9/35994/abstract/6\">",
"      Choufani EB, Sanchorawala V, Ernst T, et al. Acquired factor X deficiency in patients with amyloid light-chain amyloidosis: incidence, bleeding manifestations, and response to high-dose chemotherapy. Blood 2001; 97:1885.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/9/35994/abstract/7\">",
"      Comenzo RL. How I treat amyloidosis. Blood 2009; 114:3147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/9/35994/abstract/8\">",
"      Moreau P, Leblond V, Bourquelot P, et al. Prognostic factors for survival and response after high-dose therapy and autologous stem cell transplantation in systemic AL amyloidosis: a report on 21 patients. Br J Haematol 1998; 101:766.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/9/35994/abstract/9\">",
"      Comenzo RL, Vosburgh E, Falk RH, et al. Dose-intensive melphalan with blood stem-cell support for the treatment of AL (amyloid light-chain) amyloidosis: survival and responses in 25 patients. Blood 1998; 91:3662.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/9/35994/abstract/10\">",
"      Goodman HJ, Gillmore JD, Lachmann HJ, et al. Outcome of autologous stem cell transplantation for AL amyloidosis in the UK. Br J Haematol 2006; 134:417.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/9/35994/abstract/11\">",
"      Porrata LF, Gertz MA, Litzow MR, et al. Early lymphocyte recovery predicts superior survival after autologous hematopoietic stem cell transplantation for patients with primary systemic amyloidosis. Clin Cancer Res 2005; 11:1210.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/9/35994/abstract/12\">",
"      Leung N, Slezak JM, Bergstralh EJ, et al. Acute renal insufficiency after high-dose melphalan in patients with primary systemic amyloidosis during stem cell transplantation. Am J Kidney Dis 2005; 45:102.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/9/35994/abstract/13\">",
"      Cordes S, Dispenzieri A, Lacy MQ, et al. Ten-year survival after autologous stem cell transplantation for immunoglobulin light chain amyloidosis. Cancer 2012; 118:6105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/9/35994/abstract/14\">",
"      Sch&ouml;nland SO, Lokhorst H, Buzyn A, et al. Allogeneic and syngeneic hematopoietic cell transplantation in patients with amyloid light-chain amyloidosis: a report from the European Group for Blood and Marrow Transplantation. Blood 2006; 107:2578.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/9/35994/abstract/15\">",
"      Dispenzieri A, Kyle RA, Lacy MQ, et al. Superior survival in primary systemic amyloidosis patients undergoing peripheral blood stem cell transplantation: a case-control study. Blood 2004; 103:3960.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/9/35994/abstract/16\">",
"      Dispenzieri A, Lacy MQ, Kyle RA, et al. Eligibility for hematopoietic stem-cell transplantation for primary systemic amyloidosis is a favorable prognostic factor for survival. J Clin Oncol 2001; 19:3350.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/9/35994/abstract/17\">",
"      Kyle RA, Gertz MA, Greipp PR, et al. A trial of three regimens for primary amyloidosis: colchicine alone, melphalan and prednisone, and melphalan, prednisone, and colchicine. N Engl J Med 1997; 336:1202.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/9/35994/abstract/18\">",
"      Jaccard A, Moreau P, Leblond V, et al. High-dose melphalan versus melphalan plus dexamethasone for AL amyloidosis. N Engl J Med 2007; 357:1083.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/9/35994/abstract/19\">",
"      Skinner M, Sanchorawala V, Seldin DC, et al. High-dose melphalan and autologous stem-cell transplantation in patients with AL amyloidosis: an 8-year study. Ann Intern Med 2004; 140:85.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/9/35994/abstract/20\">",
"      Gertz MA, Lacy MQ, Dispenzieri A, et al. Stem cell transplantation for the management of primary systemic amyloidosis. Am J Med 2002; 113:549.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/9/35994/abstract/21\">",
"      Comenzo RL, Gertz MA. Autologous stem cell transplantation for primary systemic amyloidosis. Blood 2002; 99:4276.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/9/35994/abstract/22\">",
"      Gertz MA, Lacy MQ, Dispenzieri A, et al. Trends in day 100 and 2-year survival after auto-SCT for AL amyloidosis: outcomes before and after 2006. Bone Marrow Transplant 2011; 46:970.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/9/35994/abstract/23\">",
"      Gertz MA, Lacy MQ, Dispenzieri A, et al. Autologous stem cell transplant for immunoglobulin light chain amyloidosis: a status report. Leuk Lymphoma 2010; 51:2181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/9/35994/abstract/24\">",
"      Gertz MA, Blood E, Vesole DH, et al. A multicenter phase 2 trial of stem cell transplantation for immunoglobulin light-chain amyloidosis (E4A97): an Eastern Cooperative Oncology Group Study. Bone Marrow Transplant 2004; 34:149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/9/35994/abstract/25\">",
"      Comenzo RL, Sanchorawala V, Fisher C, et al. Intermediate-dose intravenous melphalan and blood stem cells mobilized with sequential GM+G-CSF or G-CSF alone to treat AL (amyloid light chain) amyloidosis. Br J Haematol 1999; 104:553.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/9/35994/abstract/26\">",
"      Casserly LF, Fadia A, Sanchorawala V, et al. High-dose intravenous melphalan with autologous stem cell transplantation in AL amyloidosis-associated end-stage renal disease. Kidney Int 2003; 63:1051.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/9/35994/abstract/27\">",
"      Gertz MA, Lacy MQ, Dispenzieri A, et al. Risk-adjusted manipulation of melphalan dose before stem cell transplantation in patients with amyloidosis is associated with a lower response rate. Bone Marrow Transplant 2004; 34:1025.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/9/35994/abstract/28\">",
"      Seldin DC, Anderson JJ, Sanchorawala V, et al. Improvement in quality of life of patients with AL amyloidosis treated with high-dose melphalan and autologous stem cell transplantation. Blood 2004; 104:1888.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/9/35994/abstract/29\">",
"      Cibeira MT, Sanchorawala V, Seldin DC, et al. Outcome of AL amyloidosis after high-dose melphalan and autologous stem cell transplantation: long-term results in a series of 421 patients. Blood 2011; 118:4346.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/9/35994/abstract/30\">",
"      Tsai SB, Seldin DC, Quillen K, et al. High-dose melphalan and stem cell transplantation for patients with AL amyloidosis: trends in treatment-related mortality over the past 17 years at a single referral center. Blood 2012; 120:4445.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/9/35994/abstract/31\">",
"      Seldin DC, Anderson JJ, Skinner M, et al. Successful treatment of AL amyloidosis with high-dose melphalan and autologous stem cell transplantation in patients over age 65. Blood 2006; 108:3945.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/9/35994/abstract/32\">",
"      Wechalekar AD, Hawkins PN, Gillmore JD. Perspectives in treatment of AL amyloidosis. Br J Haematol 2008; 140:365.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/9/35994/abstract/33\">",
"      Perfetti V, Siena S, Palladini G, et al. Long-term results of a risk-adapted approach to melphalan conditioning in autologous peripheral blood stem cell transplantation for primary (AL) amyloidosis. Haematologica 2006; 91:1635.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/9/35994/abstract/34\">",
"      Kyle RA, Gertz MA, Greipp PR, et al. Long-term survival (10 years or more) in 30 patients with primary amyloidosis. Blood 1999; 93:1062.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/9/35994/abstract/35\">",
"      Tan SY, Pepys MB, Hawkins PN. Treatment of amyloidosis. Am J Kidney Dis 1995; 26:267.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/9/35994/abstract/36\">",
"      Skinner M, Anderson J, Simms R, et al. Treatment of 100 patients with primary amyloidosis: a randomized trial of melphalan, prednisone, and colchicine versus colchicine only. Am J Med 1996; 100:290.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/9/35994/abstract/37\">",
"      Sanchorawala V, Wright DG, Seldin DC, et al. Low-dose continuous oral melphalan for the treatment of primary systemic (AL) amyloidosis. Br J Haematol 2002; 117:886.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/9/35994/abstract/38\">",
"      Kyle RA, Wagoner RD, Holley KE. Primary systemic amyloidosis: resolution of the nephrotic syndrome with melphalan and prednisone. Arch Intern Med 1982; 142:1445.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/9/35994/abstract/39\">",
"      Gertz MA, Kyle RA. Acute leukemia and cytogenetic abnormalities complicating melphalan treatment of primary systemic amyloidosis. Arch Intern Med 1990; 150:629.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/9/35994/abstract/40\">",
"      Palladini G, Perfetti V, Obici L, et al. Association of melphalan and high-dose dexamethasone is effective and well tolerated in patients with AL (primary) amyloidosis who are ineligible for stem cell transplantation. Blood 2004; 103:2936.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/9/35994/abstract/41\">",
"      Palladini G, Russo P, Nuvolone M, et al. Treatment with oral melphalan plus dexamethasone produces long-term remissions in AL amyloidosis. Blood 2007; 110:787.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/9/35994/abstract/42\">",
"      Lebovic D, Hoffman J, Levine BM, et al. Predictors of survival in patients with systemic light-chain amyloidosis and cardiac involvement initially ineligible for stem cell transplantation and treated with oral melphalan and dexamethasone. Br J Haematol 2008; 143:369.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/9/35994/abstract/43\">",
"      Dietrich S, Sch&ouml;nland SO, Benner A, et al. Treatment with intravenous melphalan and dexamethasone is not able to overcome the poor prognosis of patients with newly diagnosed systemic light chain amyloidosis and severe cardiac involvement. Blood 2010; 116:522.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/9/35994/abstract/44\">",
"      Reece DE, Hegenbart U, Sanchorawala V, et al. Efficacy and safety of once-weekly and twice-weekly bortezomib in patients with relapsed systemic AL amyloidosis: results of a phase 1/2 study. Blood 2011; 118:865.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/9/35994/abstract/45\">",
"      Reece DE, Sanchorawala V, Hegenbart U, et al. Weekly and twice-weekly bortezomib in patients with systemic AL amyloidosis: results of a phase 1 dose-escalation study. Blood 2009; 114:1489.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/9/35994/abstract/46\">",
"      Venner CP, Lane T, Foard D, et al. Cyclophosphamide, bortezomib, and dexamethasone therapy in AL amyloidosis is associated with high clonal response rates and prolonged progression-free survival. Blood 2012; 119:4387.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/9/35994/abstract/47\">",
"      Mikhael JR, Schuster SR, Jimenez-Zepeda VH, et al. Cyclophosphamide-bortezomib-dexamethasone (CyBorD) produces rapid and complete hematologic response in patients with AL amyloidosis. Blood 2012; 119:4391.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/9/35994/abstract/48\">",
"      Comenzo RL, Reece D, Palladini G, et al. Consensus guidelines for the conduct and reporting of clinical trials in systemic light-chain amyloidosis. Leukemia 2012; 26:2317.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/9/35994/abstract/49\">",
"      Palladini G, Dispenzieri A, Gertz MA, et al. New criteria for response to treatment in immunoglobulin light chain amyloidosis based on free light chain measurement and cardiac biomarkers: impact on survival outcomes. J Clin Oncol 2012; 30:4541.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/9/35994/abstract/50\">",
"      Kumar SK, Dispenzieri A, Lacy MQ, et al. Changes in serum-free light chain rather than intact monoclonal immunoglobulin levels predicts outcome following therapy in primary amyloidosis. Am J Hematol 2011; 86:251.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/9/35994/abstract/51\">",
"      Kastritis E, Wechalekar AD, Dimopoulos MA, et al. Bortezomib with or without dexamethasone in primary systemic (light chain) amyloidosis. J Clin Oncol 2010; 28:1031.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/9/35994/abstract/52\">",
"      Wechalekar AD, Lachmann HJ, Offer M, et al. Efficacy of bortezomib in systemic AL amyloidosis with relapsed/refractory clonal disease. Haematologica 2008; 93:295.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/9/35994/abstract/53\">",
"      Landau HJ, Hassoun H, Elizabeth H, et al. Adjuvant bortezomib and dexamethasone following risk-adapted melphalan and stem cell transplant in patients with light-chain amyloidosis (abstract). J Clin Oncol 2009; 27:443S(abstract 8540).",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/9/35994/abstract/54\">",
"      Lamm W, Willenbacher W, Lang A, et al. Efficacy of the combination of bortezomib and dexamethasone in systemic AL amyloidosis. Ann Hematol 2011; 90:201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/9/35994/abstract/55\">",
"      Sanchorawala V, Finn KT, Fennessey S, et al. Durable hematologic complete responses can be achieved with lenalidomide in AL amyloidosis. Blood 2010; 116:1990.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/9/35994/abstract/56\">",
"      Dispenzieri A, Lacy MQ, Zeldenrust SR, et al. The activity of lenalidomide with or without dexamethasone in patients with primary systemic amyloidosis. Blood 2007; 109:465.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/9/35994/abstract/57\">",
"      Sanchorawala V, Wright DG, Rosenzweig M, et al. Lenalidomide and dexamethasone in the treatment of AL amyloidosis: results of a phase 2 trial. Blood 2007; 109:492.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/9/35994/abstract/58\">",
"      Moreau P, Jaccard A, Benboubker L, et al. Lenalidomide in combination with melphalan and dexamethasone in patients with newly diagnosed AL amyloidosis: a multicenter phase 1/2 dose-escalation study. Blood 2010; 116:4777.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/9/35994/abstract/59\">",
"      Kastritis E, Terpos E, Roussou M, et al. A phase 1/2 study of lenalidomide with low-dose oral cyclophosphamide and low-dose dexamethasone (RdC) in AL amyloidosis. Blood 2012; 119:5384.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/9/35994/abstract/60\">",
"      Kumar SK, Hayman SR, Buadi FK, et al. Lenalidomide, cyclophosphamide, and dexamethasone (CRd) for light-chain amyloidosis: long-term results from a phase 2 trial. Blood 2012; 119:4860.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/9/35994/abstract/61\">",
"      Seldin DC, Choufani EB, Dember LM, et al. Tolerability and efficacy of thalidomide for the treatment of patients with light chain-associated (AL) amyloidosis. Clin Lymphoma 2003; 3:241.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/9/35994/abstract/62\">",
"      Dispenzieri A, Lacy MQ, Rajkumar SV, et al. Poor tolerance to high doses of thalidomide in patients with primary systemic amyloidosis. Amyloid 2003; 10:257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/9/35994/abstract/63\">",
"      Palladini G, Perfetti V, Perlini S, et al. The combination of thalidomide and intermediate-dose dexamethasone is an effective but toxic treatment for patients with primary amyloidosis (AL). Blood 2005; 105:2949.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/9/35994/abstract/64\">",
"      Wechalekar AD, Goodman HJ, Lachmann HJ, et al. Safety and efficacy of risk-adapted cyclophosphamide, thalidomide, and dexamethasone in systemic AL amyloidosis. Blood 2007; 109:457.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/9/35994/abstract/65\">",
"      Cohen AS, Rubinow A, Anderson JJ, et al. Survival of patients with primary (AL) amyloidosis. Colchicine-treated cases from 1976 to 1983 compared with cases seen in previous years (1961 to 1973). Am J Med 1987; 82:1182.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/9/35994/abstract/66\">",
"      Kyle RA, Greipp PR. Amyloidosis (AL). Clinical and laboratory features in 229 cases. Mayo Clin Proc 1983; 58:665.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/9/35994/abstract/67\">",
"      Palladini G, Campana C, Klersy C, et al. Serum N-terminal pro-brain natriuretic peptide is a sensitive marker of myocardial dysfunction in AL amyloidosis. Circulation 2003; 107:2440.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/9/35994/abstract/68\">",
"      Dispenzieri A, Kyle RA, Gertz MA, et al. Survival in patients with primary systemic amyloidosis and raised serum cardiac troponins. Lancet 2003; 361:1787.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/9/35994/abstract/69\">",
"      Pardanani A, Witzig TE, Schroeder G, et al. Circulating peripheral blood plasma cells as a prognostic indicator in patients with primary systemic amyloidosis. Blood 2003; 101:827.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/9/35994/abstract/70\">",
"      Dispenzieri A, Gertz MA, Kyle RA, et al. Serum cardiac troponins and N-terminal pro-brain natriuretic peptide: a staging system for primary systemic amyloidosis. J Clin Oncol 2004; 22:3751.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/9/35994/abstract/71\">",
"      Dispenzieri A, Gertz MA, Kyle RA, et al. Prognostication of survival using cardiac troponins and N-terminal pro-brain natriuretic peptide in patients with primary systemic amyloidosis undergoing peripheral blood stem cell transplantation. Blood 2004; 104:1881.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/9/35994/abstract/72\">",
"      Kumar S, Dispenzieri A, Lacy MQ, et al. Serum uric acid: novel prognostic factor in primary systemic amyloidosis. Mayo Clin Proc 2008; 83:297.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/9/35994/abstract/73\">",
"      Kumar SK, Gertz MA, Lacy MQ, et al. Recent improvements in survival in primary systemic amyloidosis and the importance of an early mortality risk score. Mayo Clin Proc 2011; 86:12.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/9/35994/abstract/74\">",
"      Kumar S, Dispenzieri A, Lacy MQ, et al. Revised prognostic staging system for light chain amyloidosis incorporating cardiac biomarkers and serum free light chain measurements. J Clin Oncol 2012; 30:989.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/9/35994/abstract/75\">",
"      Dispenzieri A, Buadi F, Laumann K, et al. Activity of pomalidomide in patients with immunoglobulin light-chain amyloidosis. Blood 2012; 119:5397.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/9/35994/abstract/76\">",
"      Lorenz EC, Gertz MA, Fervenza FC, et al. Long-term outcome of autologous stem cell transplantation in light chain deposition disease. Nephrol Dial Transplant 2008; 23:2052.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/9/35994/abstract/77\">",
"      Nasr SH, Valeri AM, Cornell LD, et al. Renal monoclonal immunoglobulin deposition disease: a report of 64 patients from a single institution. Clin J Am Soc Nephrol 2012; 7:231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/9/35994/abstract/78\">",
"      Sanders PW. Management of paraproteinemic renal disease. Curr Opin Nephrol Hypertens 2005; 14:97.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/9/35994/abstract/79\">",
"      Royer B, Arnulf B, Martinez F, et al. High dose chemotherapy in light chain or light and heavy chain deposition disease. Kidney Int 2004; 65:642.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/9/35994/abstract/80\">",
"      Soma J, Sato K, Sakuma T, et al. Immunoglobulin gamma3-heavy-chain deposition disease: report of a case and relationship with hypocomplementemia. Am J Kidney Dis 2004; 43:E10.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/9/35994/abstract/81\">",
"      Lin J, Markowitz GS, Valeri AM, et al. Renal monoclonal immunoglobulin deposition disease: the disease spectrum. J Am Soc Nephrol 2001; 12:1482.",
"     </a>",
"    </li>",
"    <li>",
"     Light chain deposition disease. In: Serum free light chain analysis, 3rd ed, Bradwell AR, Mead GP, Carr-Smith HD (Eds), The Binding Site, Birmingham 2005. p.149.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/9/35994/abstract/83\">",
"      Ganeval D, No&euml;l LH, Preud'homme JL, et al. Light-chain deposition disease: its relation with AL-type amyloidosis. Kidney Int 1984; 26:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/9/35994/abstract/84\">",
"      Heilman RL, Velosa JA, Holley KE, et al. Long-term follow-up and response to chemotherapy in patients with light-chain deposition disease. Am J Kidney Dis 1992; 20:34.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/9/35994/abstract/85\">",
"      Leung N, Lager DJ, Gertz MA, et al. Long-term outcome of renal transplantation in light-chain deposition disease. Am J Kidney Dis 2004; 43:147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/9/35994/abstract/86\">",
"      Pozzi C, D'Amico M, Fogazzi GB, et al. Light chain deposition disease with renal involvement: clinical characteristics and prognostic factors. Am J Kidney Dis 2003; 42:1154.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6666 Version 22.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0605-61.234.146.186-0B2EC3AACF-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_9_35994=[""].join("\n");
var outline_f35_9_35994=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H20880512\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15768474\">",
"      PRE-TREATMENT EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15770357\">",
"      Assessment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15770364\">",
"      Organ involvement defined",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      TREATMENT OF PRIMARY AMYLOIDOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15768563\">",
"      INITIAL TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15768578\">",
"      Determining transplant eligibility",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15768806\">",
"      Patients eligible for transplant",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15770082\">",
"      - Choice of therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15769190\">",
"      - Hematopoietic cell transplantation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15769212\">",
"      - Melphalan dosing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15767052\">",
"      Patients not eligible for transplant",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Melphalan and dexamethasone",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H865232\">",
"      - Bortezomib-based regimens",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15770350\">",
"      RESPONSE ASSESSMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23381668\">",
"      Measuring response",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H95727747\">",
"      Modification of therapy based on degree of initial response",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23381716\">",
"      Monitoring disease status over time",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      RELAPSED OR REFRACTORY DISEASE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H863020\">",
"      Bortezomib-based regimens",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H862793\">",
"      Immunomodulatory derivatives",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H865576\">",
"      - Lenalidomide-based regimens",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H865651\">",
"      - Thalidomide-based regimens",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H863317\">",
"      PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H863345\">",
"      Prognostic models",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H864230\">",
"      Coexisting myeloma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10605386\">",
"      CLINICAL TRIALS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      TREATMENT OF LCDD OR HCDD",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20880512\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"HEME/6666\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/6666|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"mobipreview.htm?42/10/43181\" title=\"algorithm 1\">",
"      Treatment AL amyloidosis transplant eligible",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"mobipreview.htm?11/29/11742\" title=\"algorithm 2\">",
"      Treatment AL amyloidosis transplant ineligible",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/6666|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?43/44/44750\" title=\"figure 1\">",
"      Light chain amyloidosis survival by hematologic response",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?34/49/35614\" title=\"figure 2\">",
"      Light chain amyloidosis survival by NT-proBNP response",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/6666|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?9/15/9467\" title=\"table 1\">",
"      ECOG performance scale",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?3/2/3117\" title=\"table 2\">",
"      Methods to assess cardiovascular disability",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?22/57/23451\" title=\"table 3\">",
"      Amyloidosis early mortality score",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?5/35/5693\" title=\"table 4\">",
"      Amyloidosis prognostic staging systems",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/47/31482?source=related_link\">",
"      Autologous hematopoietic cell transplantation in multiple myeloma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/13/35034?source=related_link\">",
"      Clinical features, laboratory manifestations, and diagnosis of multiple myeloma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/10/23722?source=related_link\">",
"      Clinical manifestations and diagnosis of amyloid cardiomyopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/15/7418?source=related_link\">",
"      Clinical presentation, laboratory manifestations, and diagnosis of immunoglobulin light chain (AL) amyloidosis (primary amyloidosis)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?8/29/8666?source=related_link\">",
"      Determination of initial therapy in patients with multiple myeloma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/50/19241?source=related_link\">",
"      Determining eligibility for autologous hematopoietic cell transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/12/43209?source=related_link\">",
"      Etiology and diagnosis of delayed gastric emptying",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/7/38010?source=related_link\">",
"      Fertility preservation in patients undergoing gonadotoxic treatment or gonadal resection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?11/63/12280?source=related_link\">",
"      Gastrointestinal amyloidosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?11/22/11623?source=related_link\">",
"      Musculoskeletal manifestations of amyloidosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/51/14137?source=related_link\">",
"      Myopathies of systemic disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/62/35815?source=related_link\">",
"      Pathogenesis of immunoglobulin light chain (AL) amyloidosis and light and heavy chain deposition diseases",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/29/13784?source=related_link\">",
"      Renal amyloidosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/23/10618?source=related_link\">",
"      Staging and prognostic studies in multiple myeloma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/57/29594?source=related_link\">",
"      Thrombotic complications following treatment of multiple myeloma with thalidomide and its analogues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/53/23383?source=related_link\">",
"      Treatment of secondary (AA) amyloidosis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f35_9_35995="Esophageal foreign bodies";
var content_f35_9_35995=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F66623&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F66623&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Location of, and predisposing factors for, foreign bodies in the esophagus",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Location",
"       </td>",
"       <td class=\"subtitle1\">",
"        Frequency",
"       </td>",
"       <td class=\"subtitle1\">",
"        Predisposing condition",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"3\">",
"        Proximal one-third",
"       </td>",
"       <td rowspan=\"3\">",
"        Rare",
"       </td>",
"       <td>",
"        Central nervous system lesions",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Zenker's diverticulum",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cervical web",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"5\">",
"        Middle one-third",
"       </td>",
"       <td rowspan=\"5\">",
"        Frequent",
"       </td>",
"       <td>",
"        Cancer (primary or extrinsic)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Eosinophilic esophagitis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Radiation stricture",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Traction esophageal diverticula",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Spastic dysmotility",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"7\">",
"        Distal one-third",
"       </td>",
"       <td rowspan=\"7\">",
"        Common",
"       </td>",
"       <td>",
"        Peptic stricture",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Eosinophilic esophagitis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Esophageal mucosal ring",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cancer",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Achalasia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pulsion esophageal diverticula",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Spastic dysmotility",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_9_35995=[""].join("\n");
var outline_f35_9_35995=null;
var title_f35_9_35996="Entecavir versus lamivudine II";
var content_f35_9_35996=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F70763&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F70763&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Histologic improvement and change in Ishak Fibrosis Score at week 48, nucleoside-naive patients",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup span=\"5\" width=\"20%\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\" rowspan=\"2\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"2\">",
"        (HBeAg-positive)",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"2\">",
"        (HBeAg-negative)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\">",
"        Entecavir 0.5 mg",
"        <br/>",
"        (n = 314)*",
"       </td>",
"       <td class=\"subtitle2\">",
"        Lamivudine 100 mg",
"        <br/>",
"        (n = 314)*",
"       </td>",
"       <td class=\"subtitle2\">",
"        Entecavir 0.5 mg",
"        <br/>",
"        (n = 296)*",
"       </td>",
"       <td class=\"subtitle2\">",
"        Lamivudine 100 mg",
"        <br/>",
"        (n = 287)*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\" colspan=\"5\">",
"        Histologic improvement (Knodell scores)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Improvement",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"       <td class=\"sublist_other\">",
"        72%",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"       <td class=\"sublist_other\">",
"        62%",
"       </td>",
"       <td class=\"sublist_other\">",
"        70%",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"       <td class=\"sublist_other\">",
"        61%",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        No improvement",
"       </td>",
"       <td class=\"sublist_other\">",
"        21%",
"       </td>",
"       <td class=\"sublist_other\">",
"        24%",
"       </td>",
"       <td class=\"sublist_other\">",
"        19%",
"       </td>",
"       <td class=\"sublist_other\">",
"        26%",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\" colspan=\"5\">",
"        Ishak Fibrosis Score",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Improvement",
"        <sup>",
"         &loz;",
"        </sup>",
"       </td>",
"       <td class=\"sublist_other\">",
"        39%",
"       </td>",
"       <td class=\"sublist_other\">",
"        35%",
"       </td>",
"       <td class=\"sublist_other\">",
"        36%",
"       </td>",
"       <td class=\"sublist_other\">",
"        38%",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        No change",
"       </td>",
"       <td class=\"sublist_other\">",
"        46%",
"       </td>",
"       <td class=\"sublist_other\">",
"        40%",
"       </td>",
"       <td class=\"sublist_other\">",
"        41%",
"       </td>",
"       <td class=\"sublist_other\">",
"        34%",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Worsening",
"        <sup>",
"         &loz;",
"        </sup>",
"       </td>",
"       <td class=\"sublist_other\">",
"        8%",
"       </td>",
"       <td class=\"sublist_other\">",
"        10%",
"       </td>",
"       <td class=\"sublist_other\">",
"        12%",
"       </td>",
"       <td class=\"sublist_other\">",
"        15%",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Missing week 48 biopsy",
"       </td>",
"       <td>",
"        7%",
"       </td>",
"       <td>",
"        14%",
"       </td>",
"       <td>",
"        10%",
"       </td>",
"       <td>",
"        13%",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     %: percent.",
"     <br/>",
"     * Patients with evaluable baseline histology (baseline Knodell Necroinflammatory Score &ge;2).",
"     <br/>",
"     <span class=\"bullet\">",
"      &bull;",
"     </span>",
"     &ge;2-point decrease in Knodell Necroinflammatory Score from baseline with no worsening of the Knodell Fibrosis Score.",
"     <br/>",
"     &Delta; p&lt;0.05.",
"     <br/>",
"     <span class=\"lozenge\">",
"      &loz;",
"     </span>",
"     For Ishak Fibrosis Score, improvement = &ge;1-point decrease from baseline and worsening = &ge;1-point increase from baseline.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_9_35996=[""].join("\n");
var outline_f35_9_35996=null;
var title_f35_9_35997="Carvedilol death class IV HF";
var content_f35_9_35997=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F75953&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F75953&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 506px\">",
"   <div class=\"ttl\">",
"    Carvedilol improves outcome in patients with class IV heart failure",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 486px; height: 364px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    In the COPERNICUS trial of 2289 patients with class IV heart failure and a left ventricular ejection fraction carvedilol significantly reduced the risk of death by 38 percent compared to placebo (p = 0.0001). The drug also reduced the combined end point of death and hospitalization by 24 percent (p &lt;0.001).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from Packer M, Coats AJ, Fowler MB, et al. N Engl J Med 2001; 344:1651.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_9_35997=[""].join("\n");
var outline_f35_9_35997=null;
var title_f35_9_35998="Neurologic complications CA Rx";
var content_f35_9_35998=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F55758&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F55758&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Neurologic complications of chemotherapy, hormones, and biological response modifiers",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\" class=\"container\">",
"     <tbody>",
"      <tr>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tbody>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Acute encephalopathy",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Asparaginase",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            5-Azacytidine",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            BCNU (IA or HD)",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Cisplatin",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Corticosteroids",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Cytarabine (HD)",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Etoposide",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Fludarabine",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            5-Fluorouracil (5-FU)",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Glucocorticoids",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Hexamethylmelamine",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Ifosfamide",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Interferons",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Interleukin-1 and -2",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Methotrexate",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Mitomycin C",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Nelarabine",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Nitrogen mustard",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Pentostatin",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Procarbazine",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Sunitinib",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Tamoxifen",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Thiotepa (HD)",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Tumor necrosis factor",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Vinca alkaloids",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Headaches",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Asparaginase",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Cytarabine (IT)",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Corticosteroids",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Etoposide",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Fludarabine",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Hexamethylmelamine",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Interferons",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Interleukins 1, 2, and 4",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Mechlorethamine",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Methotrexate (IT)",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Nelarabine",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Retinoic acid",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Tamoxifen",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Temozolomide",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Thiotepa (IT)",
"           </td>",
"          </tr>",
"         </tbody>",
"        </table>",
"       </td>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tbody>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Vasculopathies and \"Strokes\"",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Asparaginase",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            BCNU (IA)",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Bevacizumab",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Cisplatin (IA)",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Doxorubicin",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Estramustine",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Methotrexate",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Seizures",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Asparaginase",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            BCNU",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Busulfan (HD)",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Cisplatin",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Cytarabine (HD)",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Dacarbazine",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Etoposide",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            5-FU",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Gemcitabine",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Ifosfamide",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Interferon",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Interleukin-2",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Methotrexate",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Nelarabine",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Nitrogen mustard",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Pentostatin",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Vinca alkaloids",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Teniposide",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Visual loss",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            BCNU (IA)",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Cisplatin",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Fludarabine",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Tamoxifen",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Aseptic meningitis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Cytarabine (IT)",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Methotrexate (IT)",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Dementia",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            BCNU (IA and HD)",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Cytarabine",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Interferon-alpha",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Fludarabine",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Methotrexate",
"           </td>",
"          </tr>",
"         </tbody>",
"        </table>",
"       </td>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tbody>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Myelopathy",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Methotrexate (IT)",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Cytarabine (IT)",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Thiotepa (IT)",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Cranial neuropathy",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            BCNU (IA) (ototoxicity)",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Bevacizumab (optic neuropathy)",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Cisplatin (ototoxicity)",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Vincristine (extraocular palsies)",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Neuropathy",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            5-Azacytidine",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Bortezomib",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Carboplatin",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Cisplatin",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Cytarabine",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Eribulin",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Etoposide",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            5-FU",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Gemcitabine",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Hexamethylmelamine",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Ifosfamide",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Interferon-alpha",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Ipilimumab",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Ixabepilone",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Lenalidomide",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Paclitaxel",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Procarbazine",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Purine analogs (fludarabine, cladribine, nelarabine, pentostatin)",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Suramin",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Teniposide (VM-26)",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Thalidomide",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Tumor necrosis factor",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Vinca alkaloids",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Acute cerebellar syndrome",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Capecitabine",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Cytarabine (HD)",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            5-FU",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Hexamethylmelamine",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Procarbazine",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Vinca alkaloids",
"           </td>",
"          </tr>",
"         </tbody>",
"        </table>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     HD: high dose; IT: intrathecal; IA intraarterial.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_9_35998=[""].join("\n");
var outline_f35_9_35998=null;
var title_f35_9_35999="Pyriform sinus fistula";
var content_f35_9_35999=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F76834&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F76834&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Pyriform sinus fistula",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 400px; height: 341px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Esophagography showing a fistula (lower arrow) extending from the apex of the left pyriform sinus (upper arrow) downward to the perithyroidal area.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Chi H, Lee YJ, Chiu NC, et al. Acute suppurative thyroiditis in children. Pediatr Infect Dis J 2002; 21:384. Copyright &copy; 2002 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_9_35999=[""].join("\n");
var outline_f35_9_35999=null;
